Targeting the reperfusion injury salvage kinase pathway in the clinical setting by Ludman, A.J.
Page 1 of 236 
 
Targeting the Reperfusion Injury Salvage 
 Kinase Pathway in the Clinical Setting 
 
 
Dr Andrew James Ludman MB BCh MRCP (UK) 
 
 
The Hatter Cardiovascular Institute 
University College London 
 
 
 
Doctor of Medicine (Research) 
Page 2 of 236 
 
Declaration: 
 
I declare that the work presented within this thesis is entirely my own. Where elements of the 
work have been aided this is clearly stated. The thesis presented is the one on which I expect 
to be examined. 
 
Signed: 
Printed Name: 
Date: 
Page 3 of 236 
 
Abstract 
 
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide. 
Ischaemic heart disease contributes the largest burden and despite advances in 
revascularisation therapy significant morbidity and mortality exist in both the elective and 
emergency treatment setting.  
Short episodes of sub-lethal ischaemia and reperfusion applied before a period of prolonged 
ischaemia (preconditioning) and reperfusion stuttered with short episodes of ischaemia 
(postconditioning) are powerful, endogenous, cardioprotective phenomena which offer the 
potential to reduce myocardial injury and infarction by as much as 50%. Despite many years 
of research these mechanical, invasive techniques have not been adopted to routine practice. 
A pharmacological mimetic, targeting the same protective pathways as pre- and post- 
conditioning would have great potential in reducing myocardial injury in a number of clinical 
settings and could be easily administered and adopted to the clinical arena.  
Chapter 1 of this thesis summarises the research to date in this rapidly evolving field 
concentrating on two pharmacological conditioning mimetics, atorvastatin and erythropoietin 
and the clinical assessment of cardioprotection and myocardial salvage. Chapter 2 details the 
hypotheses to be investigated. Chapter 3 describes two studies undertaken in coronary artery 
bypass surgery with high dose atorvastatin as a potential cardioprotective agent. Chapter 4 
describes a study testing the use of erythropoietin in patients presenting with acute 
myocardial infarction requiring emergency angioplasty and using cardiac magnetic resonance 
outcome measures. Chapter 5 highlights the difficulties in translating pre-clinical animal 
studies to the human clinical setting and discusses potential methods to improve this.  
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In summary, this thesis examines the pre-existing research regarding atorvastatin and 
erythropoietin as cardioprotective agents. Novel clinical studies testing the use of these 
agents in the settings of coronary artery bypass surgery and acute myocardial infarction are 
presented. The findings are discussed and reviewed in the context of ongoing advances in the 
field of cardioprotection. 
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CHAPTER 1 
 
Introduction 
 
Ischaemic Heart Disease 
 
Ischaemic heart disease (IHD) is the leading cause of mortality worldwide and some predict 
that this will remain the case at least as far ahead as 2020
1
. Similarly in the United Kingdom 
(UK) cardiovascular disease is the leading cause of death accounting for almost 198,000 
deaths each year, with 94,000 directly attributable to IHD
2
. Importantly IHD is one of the 
leading causes of premature mortality causing almost 31,000 premature deaths in the UK in 
2006. IHD is estimated to cost the UK economy approximately £9 billion per annum in direct 
health care costs, loss of productivity and informal care
3
. 
It is the formation of atheroma, lipid rich deposits, within the epidcardial coronary arteries 
that causes IHD. The reduction in arterial diameter may lead to a slow but progressive 
increase in symptoms or an atheromatous plaque may rupture suddenly leading to thrombotic 
occlusion of the coronary artery and the most notable manifestation of IHD, acute myocardial 
infarction (AMI)
4
. There are approximately 146,000 AMIs in the UK each year
5
 and without 
urgent treatment AMI may either lead to death from cardiac arrhythmia/failure/rupture or 
more often will result in substantial morbidity through the development of chronic cardiac 
failure. Current treatments for cardiovascular disease are directed at primary prevention of 
ischaemic events, elective procedures (percutaneous coronary intervention [PCI] or coronary 
artery bypass graft [CABG] surgery) to ensure adequate myocardial blood supply, emergency 
treatments to re-establish blood flow in occluded coronary arteries (thrombolytic agents, 
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primary PCI or emergency CABG surgery) and following this secondary prevention of 
further ischaemic episodes
6
.  
Despite advances in current treatments the ongoing mortality figures above suggest that 
improvements are still urgently needed in all areas. In this regard the field of 
‗cardioprotection‘ and in particular ‗myocardial conditioning‘ may be able to offer benefits in 
a wide range of clinical scenarios. 
Myocardial Ischaemia and Reperfusion Injury 
 
Cessation of blood supplying oxygen and nutrients to the myocardium (ischaemia) results in 
a cascade of metabolic changes with resultant implications for cellular processes. If the blood 
supply is not re-established within a matter of minutes irreversible cell death may occur. 
However, following prolonged ischaemia the process of re-establishing the blood supply 
(reperfusion) with attempted rapid resolution of the normal biochemical and metabolic state, 
may itself initiate cell signalling pathways responsible for further myocyte death
7
. The 
relative contributions to myocardial injury of ischaemia or reperfusion are difficult to 
quantify. However, in the majority of clinical settings where myocardial injury is evident, 
that injury arises from a combination of both ischaemia and reperfusion
8
.   
Ischaemic injury 
 
During ischaemia, hypoxia develops resulting in anaerobic metabolism which in turn 
contributes to a rising intracellular acidosis. In response to the acidosis, hydrogen ions are 
pumped out of the cell by the H
+
/Na
+
 exchanger leading to an excess intracellular Na
+
. The 
raised Na
+
 is dealt with by the Na
+
/Ca
2+
 exchanger which leads to a progressive rise in 
intracellular Ca
2+
.
9
 Cellular ATP is progressively depleted, ion pumps cannot function 
resulting in further intracellular calcium rise and ATP is further reduced. There may be 
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additional Ca
2+
 release from the sarcoplasmic reticulum. Progressive drop in cell pH and 
cytosolic swelling threaten to cause plasma membrane rupture.  Plasma membrane rupture is 
further threatened by caspase mediated cleavage of structural proteins in the cytosolic 
membrane. Plasma membrane rupture commits the cells to necrotic death and the 
accompanying destructive inflammatory response, however caspase mediated cleavage of 
essential proteins can also trigger apoptotic cell death
8
. 
Lethal myocardial reperfusion injury 
 
At reperfusion, oxygen is reintroduced and an attempt is made to re-establish normal 
physiologic parameters. However the abrupt biochemical and metabolic changes which occur 
are detrimental to the myocardium and compound the damage which has commenced during 
the ischaemic period.  
Reactive Oxygen Species (ROS) are produced from the re-energised mitochondria, from 
endothelial xanthine oxidase and later in the reperfusion period from neutrophilic NADPH 
oxidase. ROS contribute to myocardial injury by acting as neutrophil chemoattractants, 
causing sarcoplasmic reticulum dysfunction, exacerbating intracellular calcium overload, 
damaging the cell membrane by lipid peroxidation, inducing enzyme denaturation, via 
oxidative damage to DNA and by inducing the opening of a conformational transmembrane 
mitochondrial pore, termed the mitochondrial permeability transition pore (mPTP). The 
already calcium overloaded cardiomyocyte is subject to further calcium loading at 
reperfusion due to a damaged sarcolemmal membrane, dysfunctional sarcoplasmic reticulum 
and reverse function of the sodium-calcium exchanger. Resumed ATP generation in the 
presence of calcium overload causes hypercontracture which may induce cell death.  The 
rapid normalisation of pH facilitates mPTP opening and contributes to cardiomyocyte 
hypercontracture. The restoration of the mitochondrial membrane potential forces calcium in 
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to the mitochondria which in conjunction with ROS and the restoration of normal pH act to 
open the mPTP. This opening uncouples oxidative phosphorylation and induces 
mitochondrial swelling which if mitochondrial integrity is disrupted may cause the release of 
substances such as cytochrome C and cell death is likely to be inevitable
10
.  Later in the 
reperfusion process neutrophils accumulate in the myocardium in response to 
chemoattractants - they may promote cell death by further ROS generation, the release of 
degradative enzymes and vascular plugging
7 11 
. 
Mechanisms of myocyte cell death 
 
It appears that necrosis plays the major role in myocyte cell death during ischaemia-
reperfusion injury (IRI) but that apoptosis or ‗programmed cell death‘ also makes a 
contribution. The more newly described cellular function of autophagy may also play a part 
but its precise contribution is not clear. Necrosis is characterised by cell swelling with 
membrane rupture leading to a release of cytosolic components and an inflammatory 
reaction. Although classically thought of as an unregulated process, it is now becoming 
apparent that in fact necrosis does have a predictable course and is probably triggered and 
regulated by the cell in response to local changes
12
. Apoptosis, as originally described by 
Kerr et al.
13
, results in chromatin condensation and fragmentation, cell shrinkage and plasma 
membrane budding with the release of apoptotic bodies which contain cellular components. 
These in turn are phagocytosed with little or no inflammatory response. Autophagy degrades 
and recycles cytoplasmic components and selectively removes damaged mitochondria as a 
cytoprotective mechanism. It does play a role in IRI although it is not yet established whether 
cells may die ‗with autophagy‘ or ‗by autophagy‘14 or in fact whether autophagy as an 
adaptive response may in some part play a protective role from IRI.
15
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Cell death during ischaemia, at, and following reperfusion is probably a combination of 
necrosis, apoptosis and autophagy. The three mechanisms have been reported to be inter-
related and as such one can use the encompassing term ‗cell death‘ to more easily describe 
these processes. Importantly all three mechanisms are now thought to be heavily regulated 
and as such can be targeted in order to attempt to increase cell survival. By inhibiting or 
promoting key elements in the pathways leading to ‗cell death‘, interventions probably 
impact on all three mechanisms but with the same overall aim of reducing cell death and 
promoting cell survival.
12
 
Myocardial conditioning 
 
Cardioprotection has been defined as, ―all mechanisms and means that contribute to the 
preservation of the heart by reducing or even preventing myocardial damage‖16. The term 
‗myocardial conditioning‘ is encompassed within cardioprotection and is a broad description 
of agents or techniques which act to ‗condition‘ and subsequently protect the myocardium by 
activating endogenous cardioprotective mechanisms. The concept of being able to reduce 
damage to the myocardium evolved from a number of investigators in the 1960‘s, but initial 
disparate findings were summarised by Braunwald in 1974
17
, who suggested that the time for 
prospective trials in this new area had arrived. 
Ischaemic preconditioning 
 
Ischaemic preconditioning (IPC) is a powerful endogenous cardioprotective stimulus which 
has the ability to reduce myocardial infarct size. First described in a canine model of 
infarction by Murry et al.
18
 in 1986, IPC is a physical cardioprotective technique in which 
short sub-lethal bursts of myocardial ischaemia and reperfusion provide protection against a 
subsequent, potentially lethal, episode of myocardial ischaemia and reperfusion. This seminal 
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study paved the way for an explosion of research investigating the mechanism of protection 
and trying to replicate the protective effect at different time points using pharmacological 
agents (termed pharmacological preconditioning). IPC was shown to be protective in a 
variety of species such as pigs
19
, rabbits
20
, rats
21
 and mice
22
 and was subsequently reported to 
be protective in humans as well
23
. The protection afforded by IPC appears to be biphasic in 
nature with an early phase (classical or acute IPC) providing protection for approximately 2-3 
hours and a delayed phase (Second Window of Protection-SWOP) providing protection 
(albeit less potent) after approximately 12-24 hours and for up to 72 hours
24 25 
. The 
application of IPC in humans has been limited however due to its interventional nature and 
by the fact that the protective stimulus should be applied prior to the potential myocardial 
injury, which in the case of acute myocardial infarction is difficult to predict. In this case an 
intervention that could be applied after the onset of ischaemia would be more practicable.  
Ischaemic postconditioning 
 
Ischaemic postconditioning (IPost) is a technique whereby the restoration of reperfusion is 
stuttered by repeat transient episodes of ischaemia following a period of lethal ischaemia. 
Interestingly in 1994, a human case report describing the cessation of reperfusion arrhythmia 
in acute MI by re-occlusion of the coronary artery was published
26
 although the mechanisms 
behind this phenonmenon were the subject of discussion only. The first study to coin the term 
‗postconditioning‘ was reported by Na et al. in 199627. Using a feline model of ischaemia and 
ventricular premature beat driven interrupted reperfusion they demonstrated a significant 
reduction in the incidence of reperfusion associated ventricular fibrillation. Subsequently 
hypoxic post-conditioning was reported to reduce injury to rat cardiomyocytes subjected to 
hypoxia and reoxygenation
28
, however the now more widely accepted method of ischaemic 
postconditioning (IPost) was described in 2003 in a canine model by Zhao et al.
29
 The 
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investigators occluded the LAD for 60 minutes and then prior to 3 hours of continued 
reperfusion, the artery was unclamped and reclamped for 3 cycles of 30 seconds, therefore 
stuttering the reperfusion phase. It was demonstrated that postconditioning was able to reduce 
infarct size to the same extent as ischaemic preconditioning.  Applied at the onset of or just 
after reperfusion, this technique activates very similar cell survival pathways to IPC (see 
later) and produced the exciting possibility of being able to intervene in humans after the 
onset of ischaemia and realise large myocardium saving potential. This has been tested in the 
human setting of acute MI by a number of investigators. In the first study, Ovize‘s group took 
30 patients with ongoing acute myocardial infarction who were due to be reperfused by 
primary coronary angioplasty. Following direct stenting, in the intervention group, 
reperfusion was immediately interrupted by 4 cycles of 1 minute balloon inflation and 
deflation to impede flow in the coronary artery; the control group underwent reperfusion 
only
30
. Using total creatine kinase (CK) over 72 hours following the myocardial infarction as 
a surrogate marker of myocardial infarct size, the authors reported a 36% reduction in infarct 
size in the intervention group. In another study Laskey used two 90 second balloon inflations 
as the conditioning protocol in 10 patients undergoing emergency angioplasty for acute MI, 
the control group (7 patients) had only one balloon inflation of 90 seconds. Despite the 
unusual protocol, it was demonstrated that the postconditioned group experienced improved 
ST segment resolution and coronary blood flow
31
. Ma et al. used 3 cycles of 30 seconds 
ischaemia and reperfusion as the post-conditioning protocol in a study of 94 patients with 
acute MI. They demonstrated that IPost improved coronary arterial flow, improved 
endothelial function and reduced cardiac enzyme release
32
. Following these initial proof of 
concept studies, Ovize‘s group went on to recruit a new cohort of 38 patients and using the 
same postconditioning protocol demonstrated that postconditioning significantly reduced 
myocardial enzyme release using nuclear imaging they showed a reduction in mean infarct 
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size from 19.5% to 11.8%. At 1 year of follow-up echocardiography demonstrated a 7% 
improvement in left ventricular ejection fraction in the intervention group, proving the 
longevity of the postconditioning benefits
33
. Recently 118 patients randomised to usual care 
or who underwent post-conditioning (4 cycles of 30 seconds of balloon inflation/deflation) 
following reperfusion with PPCI for STEMI were evaluated with cardiac MRI and the 
postconditioning group had a 19% relative reduction of infarct size (51+/-16% of total area at 
risk versus 63+/-17%, P<0.01), corresponding to a 31% increase in salvage ratio
34
. 
Disappointingly these impressive findings have not yet been validated in a large multi-centre 
study and there has been a reluctance to adopt the technique due to its interventional nature 
and concerns at prolonging the patients‘ procedure. Thus the ability to give a 
pharmacological agent to a patient, prior to, during or following ischaemia, capable of 
replicating the protective effects of pre- or post-conditioning would be a huge leap forward 
not only in demonstrating a cardioprotective effect, but a safe pharmacological agent is much 
more likely to be adopted in to the clinical arena and would have widespread potential for use 
wherever myocardial injury is anticipated or ongoing.  
Pharmacological Conditioning 
 
Since the realisation that it was possible to intervene and reduce myocardial infarction size, 
many different pharmacological agents have been experimented with in order to try and 
increase myocyte survival. Careful experimental elucidation of the cell signalling pathways 
involved in pre and post conditioning has identified targets for pharmacological agents to act 
as mimetics of the conditioning stimulus. Unfortunately, despite more than 20 years of 
research, no pharmacological agent has shown consistent benefits and been adopted to 
routine clinical practice. There are many reasons for this ‗failure of translation‘ and these 
shall be described in more detail later (chapter 5), however it is only through continued 
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rigorous laboratory research using clinically-relevant experimental models to elucidate the 
underlying cardioprotective mechanisms, followed by carefully designed and targeted clinical 
studies, that a successful cardioprotective agent will be found. 
Improving our understanding of the cardioprotective cell signalling pathways implicated will 
assist in improving the chance of successful translation from laboratory to the clinical setting. 
The actual pathways underlying IPC and IPost remain unclear although the current paradigm 
is summarised below. 
Potential mechanistic pathway underlying ischaemic preconditioning 
 
As described above the physical cardioprotective stimulus of IPC reduces eventual infarct 
size in the face of ischaemia – reperfusion.  
IPC acts to increase circulating serum levels of endogenous mediators which are either able 
to act via cell surface receptors or act independently. Acting via G protein coupled receptors 
on the cell surface the main triggers of IPC are adenosine
35
, bradykinin
36
 and opioids
37
. 
Receptor-independent triggers are thought to include nitric oxide as its blockade decreases 
IPC in rats
38
, free radicals as although harmful to a certain degree are able to activate G-
proteins, protein kinases and KATP channels
39
 and the calcium L-type channel which when 
blocked prevents IPC
40
. The signalling cascade appears to converge on PKC as a pivotal 
point
41
 although the role of differing isoforms is still being investigated
42
. The upstream 
signalling from PKC is thought at present to be via phosphatidylinositol-3-OH kinase (PI3K)-
AKT, endothelial nitric oxide synthase (eNOS), cGMP and PKG which culminates in 
phosphorylation and opening of the mitochondrial KATP channel
43
. Via the mitochondrial 
electron transport chain a burst of reactive oxygen species are produced which serves to 
further activate a number of pro-survival kinases including p38, JNK, extracellular signal-
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related kinase (ERK), PKC, AKT and other mitogen activated protein kinase (MAPK)
44
 
resulting in cardioprotection. Many of these survival kinases activate nuclear transcription 
factors and mediators of delayed preconditioning. 
The Reperfusion Injury Salvage Kinase (RISK) pathway 
 
Given that the anti-apoptotic survival kinases PI3K-AKT and ERK were shown to have such 
a pivotal role in IPC and that apoptosis contributes to myocardial infarct size, Yellon and 
Baxter
45
 first formulated and tested the hypothesis that pharmacological activation of these 
kinases may protect the myocardium against reperfusion injury. In fact, it was subsequently 
shown that both necrosis and apoptosis were limited by activation of this pathway resulting in 
a reduction in infarct size
46
. Following this it was demonstrated that IPC resulted in 
phosphorylation and activation of the PI3K-AKT and ERK signalling pathways not only at 
the time of the initial IPC stimulus but at the time of reperfusion as well
47
. Blockade of PI3K-
AKT and ERK signalling pathways abrogated the protection afforded by IPC and confirmed 
them as crucial to the infarct size reduction
46
. These pathways were subsequently termed the 
Reperfusion Injury Salvage Kinase (RISK) pathway
48
. 
The method in which IPC actually activates the RISK pathway at reperfusion is still under 
investigation. It is postulated that the initial IPC stimulus may either prime the kinases or 
enable their cellular redistribution. Alternatively there may be an intermediary which acts at 
reperfusion after the delay. The intermediary may well be PKC which is able to act up to 3 
hours following the IPC stimulus
49
.  
End effectors of the RISK pathway and the mPTP 
 
The RISK pathway is thought to act downstream by inhibiting pro-apoptotic factors, 
inhibiting GSK3-β, activating eNOS, and via the mitochondrial translocation of PKCε50. Pro-
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survival pathways appear to converge on a common target for cell survival, the mitochondrial 
permeability transition pore (mPTP). Inhibition of the mPTP in the time following 
reperfusion enables the mitochondria to retain stability, promoting cell survival and limiting 
reperfusion injury
51
. 
Importantly for translation to the acute clinical setting it is also possible to harness the 
protective effects of the RISK pathway with pharmacological or physical interventions 
applied at the time of reperfusion (IPost) without the need to have applied a pre-ischaemic 
stimulus.  
Cell signalling pathways activated by postconditioning 
 
As described above the technique of postconditioning
29
, which is a modified form of 
reperfusion, is also able to reduce the eventual infarct size resulting from ischaemia-
reperfusion injury. 
It appears that postconditioning is able to recruit the RISK pathway at reperfusion to exert its 
cardioprotective effect
52
. The postconditioning stimulus is able to activate both PI3K-AKT 
and ERK1/2 via a diverse range of receptors including GPCRs and those for growth factors
46
. 
Levels of nitric oxide (NO) are increased via eNOS and act on PKG, and probably via PKC 
in order to activate the mitochondrial KATP channel which in turn inhibits the opening of the 
mPTP. Increased levels of NO as well as glycogen synthase 3β (GSK 3β) are thought to be 
able to inhibit the mPTP directly
53
. In this way both the cardioprotective phenomena of IPC 
and IPost are postulated to converge on the mPTP as a crucial unifying mediator of the cell 
survival signal
54
. 
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Potential targets for pharmacological cardioprotective agents 
 
Elucidation of the survival mechanisms described above has allowed the identification of a 
number of pharmacological agents that, by activating parts of the described pathway, are 
hypothesised to be able to limit infarct size (figure 1). Two such agents are the HMG-CoA 
reductase inhibitors (henceforth referred to as ‗statins‘) and erythropoietin; which are thought 
to act via the RISK pathway to a common end point of inhibiting the mPTP and reducing 
myocardial cell death. The next sections shall review the use of these two agents to date. 
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Figure 1: Acting at reperfusion via the RISK pathway, erythropoietin and atorvastatin are 
two examples of pharmacological mimetics of ischaemic pre/post conditioning. Below is a 
simplified schematic of the potential protective effect of atorvastatin and erythropoietin. 
Thought to act via GPCR on the cell membrane, at reperfusion the RISK pathway is 
triggered. Increased intracellular NO along with a small burst of ROS is proposed to inhibit 
the kATP ion pump and subsequently inhibit mPTP opening. By inhibiting mPTP opening 
mitochondrial stability is maintained, cardiomyocyte survival promoted and resultant 
myocardial infarction size is reduced.  [RISK: Reperfusion Injury Salvage Kinase pathway, 
GPCR: G-protein coupled receptor, mPTP: mitochondrial permeability transition pore, NO: 
nitric oxide, ROS: reactive oxygen species]. 
 
 
Page 29 of 236 
 
‘Statins’ as a myocardial conditioning mimetic 
 
HMG-CoA reductase inhibitors have become standard medical therapy in the armamentarium 
available for the prevention and treatment of cardiovascular disease. Large randomised 
controlled clinical trials have established their role as effective medical therapy for the 
primary
55 56 
 and secondary
57 58
 prevention of cardiovascular events. HMG-CoA reductase 
inhibitors competitively inhibit the conversion of acetyl coenzyme A and acetoacetyl 
coenzyme A to mevalonate in the formation of cholesterol and prevent the formation of the 
isoprenoids
59
 (see figure 2). Statins were first developed in order to lower total serum 
cholesterol and improve the lipid profile but have subsequently been shown to exert a variety 
of beneficial, ‗pleiotropic‘ effects, particularly relevant to cardiovascular disease, including 
improved endothelial function, reduced oxidative stress, less platelet adhesion, and 
atherosclerotic plaque stabilisation
60
.  
It is well-established that statin therapy offers widespread beneficial effects on the 
cardiovascular system through both its lipid lowering and non-lipid lowering effects 
described above. However, there is a less appreciated non-lipid lowering effect of statin 
therapy, namely its potential to directly protect the myocardium from the detrimental effects 
of acute ischaemia-reperfusion injury, a feature which has been widely documented in the 
experimental literature.  
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Figure 2: The HMG-CoA reductase inhibitors or Statins prevent the formation of mevalonate 
and the isoprenoids. 
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Experimental cardioprotection using statin therapy 
 
In the late 1990s, the finding that statin therapy was beneficial in terms of improving 
cardiovascular outcomes resulted in a search for the mechanisms underlying this 
cardioprotective effect. Using experimental animal models of acute myocardial ischaemia-
reperfusion injury, it is possible to examine the effects of statin therapy at different time-
points in the course of the acute ischaemia-reperfusion insult. Clearly, the time-point at which 
the statin treatment is administered has a direct bearing on its potential for clinical 
application. For example, pre-ischaemic statin treatment would be limited to the clinical 
settings of planned cardiac surgery and elective PCI procedures in which the timing of the 
ischaemic can be readily anticipated. 
Statin therapy administered prior to myocardial ischaemia 
 
Initial studies in 1998 suggested that statin therapy may be able to exert direct cytoprotective 
effects through the upregulation of endothelial nitric oxide synthase (eNOS), a critical non-
lipid lowering effect of statin therapy
61
. On this background, in 1999, the first experimental 
animal studies were published demonstrating direct cardioprotective effects elicited by statin 
treatment. Ueda and colleagues
62
 investigated the effects of pravastatin pre-treatment on the 
response of the hypercholesterolaemic rabbit heart to the endogenous cardioprotective effects 
of ischemic preconditioning (IPC). Crucially this important study found that the presence of 
hypercholesterolaemia blunted the cardioprotective benefits of IPC. These authors were able 
to demonstrate that pravastatin could restore the infarct-limiting effects of IPC in 
hypercholesterolaemic hearts, and the mechanism underlying this effect was not associated 
with lipid-lowering and was attributed to the activation of ecto-5‘-nucleotidase, an adenosine 
producing enzyme. Interestingly, in this study, pravastatin given alone without the added 
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stimulus of IPC did not reduce infarct size, suggesting perhaps that a sub-threshold dose of 
pravastatin had been used particularly as a later study has demonstrated cardioprotection with 
pravastatin alone
63
. Lefer and colleagues
64
 demonstrated that pre-treatment with simvastatin 
was able to protect isolated perfused normocholesterolaemic rat hearts against acute 
ischemia-reperfusion injury. The authors reported that the cardioprotective effect was 
dependent on the presence of neutrophils and resulted from the reduction of the inflammatory 
response provoked by acute ischaemia-reperfusion injury (see table 1 for a summary of the 
experimental studies demonstrating pre-ischaemic cardioprotection with statin therapy).  
Table 1: Experimental cardioprotection with Statin therapy given prior to myocardial 
ischaemia. 
Study Experimental Model Treatment regime  Key results Novel 
mechanistic 
insight 
Pre-ischaemic cardioprotection elicited by Statin therapy 
Ueda et al 1999
62
 Hypercholesterolaemic 
perfused rabbit hearts 
Pre-treatment for 8 
weeks with Pravastatin 
5 mg/kg/day (orally). 
Restoration of IPC 
protection in 
hypercholesterolaemic 
hearts but not in normal 
ones, associated with 
ecto-5‘-nucleotidase 
activity. 
Synergistic 
cardioprotective 
effect with IPC. 
Lefer et al 1999
64
 Perfused rat hearts. Pre-treatment with 
25µg Simvastatin or 
Pravastatin 18 hours 
prior IRI.                     
Hearts perfused with 
PMNs. 
↑LV developed 
pressure ↓PMN 
infiltration             
↓CD18 upregulation in 
PMN. ↓PMN adherence 
to rat vascular 
endothelium. ↓P-
selectin expression.  
Anti-inflammatory 
effect dependent 
on NO. 
Scalia et al 
2001
65
 
APO E-/- mice fed a 
high cholesterol diet 
subjected to in situ 
IRI. 
Pre-treatment with a 
subcutaneous injection 
of 1 mg/kg 
Simvastatin 18 hours 
prior to IRI. 
Reduced myocardial 
infarct size.                                     
No effect on 
cholesterol. 
Simvastatin able to 
cardioprotect an 
atherosclerotic 
animal heart 
model.                       
Anti-inflammatory 
effect dependent 
on NO 
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Study Experimental Model Treatment regime  Key results Novel 
mechanistic 
insight 
Lefer et al 2001
66
 In situ Db/Db murine 
heart 
Pre-treatment for 5 
days with 
intraperitoneal 
simvastatin (0.5mg/kg 
daily). 
  
Reduced myocardial 
infarct size.                                
↓PMN infiltration                 
↓PMN adherence to rat 
vascular endothelium              
Simvastatin able to 
cardioprotect a 
type II diabetic 
animal heart 
model.                         
Anti-inflammatory 
effect dependent 
on NO. 
Kawabata et al 
2001
67
 
Isolated rabbit hearts. Pre-treatment with 
intravenous 
Pravastatin 
(0.025mg/kg) 60 
minutes prior to IRI. 
Preserved ATP levels 
and maintained pH 
(MRI spectroscopy). 
These effects abolished 
by glibenclamide and 
L-NAME. 
Pravastatin-
induced 
cardioprotection of 
rabbit heart via 
KATP channel and 
NO. 
Di Napoli et al 
2001
68
 
Perfused rat hearts Simvastatin acutely 
before and during IRI 
at 10, 25, 50 and 100 
µM. 15mins I, 22-
180mins R. 
Optimal results seen 
with 25µM simvastatin. 
↓CK in effluent. 
↓vascular permeability. 
↑eNOS mRNA and 
protein. ↓iNOS mRNA 
and protein. 
Simvastatin 
provides 
cardioprotection 
via an eNOS 
dependent 
pathway. 
Ikeda et al 2003
69
 Perfused rat hearts Pre-treatment 
Rosuvastatin (0.25 or 
1.25 mg/kg) given 18 
hours prior to IRI. 
↑LV developed 
pressure ↓PMN 
infiltration             
↓PMN adherence to rat 
vascular endothelium              
Rosuvastatin able 
to cardioprotect rat 
hearts.                         
Anti-inflammatory 
effect dependent 
on NO. 
Lazar et al 
2003
70
 
In situ pig heart Pre-treatment with 
atorvastatin 40 mg 
daily given orally for 
21 days 
Less arrhythmias         
Improved wall-motion 
scores Smaller infarct 
size.  No effect on 
cholesterol 
Atorvastatin able 
to cardioprotect 
the pig heart when 
administered for 3 
weeks. 
Wolfrum et al 
2003
71
 
In situ rat heart Pre-treatment with 
Cerivastatin (0.3 
mg/kg/d) for one 
week. 
Smaller infarct.                     
Increased eNOS and 
cardioprotection 
blocked by L-NAME.                             
Cerivastatin able 
to cardioprotect 
the rat heart.                     
Protection 
dependent on 
eNOS.                         
Tiefenbacher et 
al 2003
72
 
In situ rat heart Pre-treatment of 
Fluvastatin IV bolus 
(2mg/kg) given 20 
minutes prior to IRI. 
followed by IV 
infusion of 1mg/kg/hr. 
↑Regional wall 
thickening ↑myocardial 
blood flow and ↓Infarct 
size               Protection 
abolished by L-NAME                          
↓myocardial MPO. 
Fluvastatin able to 
acutely 
cardioprotect the 
rat heart.                     
Anti-inflammatory 
effect dependent 
on NO. 
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Study Experimental Model Treatment regime  Key results Novel 
mechanistic 
insight 
Tavackoli et al 
2004
73
 
In situ rat heart Pre-treatment 
Simvastatin (20 mg/kg 
per day) for 3 days. 
Smaller infarct size, 
protection blocked by 
glyburide.                             
Simvastatin-
induced 
cardioprotection of 
rat heart via KATP 
channel                 
Sanada et al 
2004
74
 
In situ dog heart Pre-treatment of IV 
bolus of Pravastatin 
(0.2, 2, or 10 mg/kg), 
Pitavastatin (0.01, 0.1, 
or 0.5 mg/kg), or 
Cerivastatin (0.5, 5, or 
50µg/kg) given 
immediately prior to 
IRI. 
Smaller infarct size 
with protection blocked 
by wortmannin or 8-
SPT given at 
reperfusion. 
Cardioprotection 
of the canine heart 
requires activation 
of PI3K-Akt and 
ecto-5‘-
nucleotidase 
activity at 
reperfusion. 
Verma et al 
2004
75
 
Cultured human 
ventricular 
cardiomyocytes 
subjected to simulated 
IRI. 
Pravastatin (1, 10, and 
100 µM) added to the 
hypoxic/reoxygenation 
buffers. 
Reduced cardiomyocyte 
death. Protection 
blocked by bosentan, L-
NAME and was 
associated with 
production of NO and 
Akt phosphorylation.                              
Pravastatin able to 
cardioprotect 
isolated human 
ventricular 
cardiomyocytes 
through ET-1, Akt 
and NO.
Birnbaum et al 
2005
76
 
In situ rat heart Pre-treatment with 
atorvastatin 10 
mg/kg/day (oral 
gavage) prior to IRI. 
Smaller infarct size 
with protection blocked 
by COX-2 inhibitor.                        
Protection associated 
eNOS and iNOS 
phosphorylation as well 
as prostaglandin 
production. 
Cardioprotection 
of the rat heart 
requires COX-2 
activation and 
prostaglandin 
release. 
Di Napoli et al 
2005
77
 
Isolated rat hearts Oral treatment with 
Rosuvastatin (0.2-
20mg/kg) for 3 weeks. 
Less myocardial 
dysfunction, endothelial 
dysfunction and 
mitochondrial damage. 
NO dependent 
effects on vascular 
endothelium and 
myocardium. 
Mensah et al 
2005
78
 
Isolated rat heart Oral gavage for 1, 3 
days and 1 or 2 weeks 
with oral 20mg/kg 
atorvastatin. 
Supplemental dose of 
40mg/kg given prior to 
IRI. 
Reduced infarct size 
with 1 or 3 days 
treatment but not 1 or 2 
weeks treatment. 
Protection recaptured if 
acute atorvastatin 40mg 
given prior to IRI 
Cardioprotective 
effect of 
atorvastatin wanes 
with chronic 
dosing possibly 
due to down-
regulation of 
PI3K-Akt pathway 
by PTEN. Possible 
to recapture 
protection with 
acute high dose of 
atorvastatin. 
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Study Experimental Model Treatment regime  Key results Novel 
mechanistic 
insight 
Atar et al  2006
79
 In vivo rat Oral gavage with 3 
days atorvastatin 
10mg/kg/d  
Reduce infarct size- 
protection blocked by 
COX-2 and iNOS 
inhibitors. 
Atorvastatin 
cardioprotection 
requires iNOS and 
COX-2. 
Matsuki et al  
2006
80
 
In vivo rat Fluvastatin given at 
10mg/kg orally for 2 
weeks before I/R or 
given IV just prior to 
ischaemia or 
reperfusion. 
Reduce infarct size with 
only fluvastatin chronic 
treatment. Protection 
blocked by L-NAME. 
Fluvastatin only 
protects when 
given chronically. 
Penumathsa et al 
2007
81
 
In vivo 
hypercholesterolaemic 
rat 
Oral gavage with 3 
days atorvastatin 
1mg/kg/d and 
resveratrol 20mg/kg/d 
Synergistic protection 
associated with Akt and 
eNOS phosphorylation. 
Synergistic 
protection 
associated with 
Akt eNOS 
phosphorylation. 
Ye et al 2007
82
 Isolated rat heart Oral gavage with 3 
days subthreshold 
atorvastatin 2mg/kg/d 
and dipyridamole 
6mg/kg/d 
Synergistic protection 
associated with eNOS 
phosphorylation. 
Synergistic 
protection 
associated with 
eNOS 
phosphorylation. 
Manickavasagam 
et al 2007
83
 
Isolated rat heart Oral gavage with 3 
days subthreshold 
atorvastatin 2mg/kg/d 
and cilostazol 
20mg/kg/d 
Synergistic protection 
associated with eNOS 
phosphorylation. 
Synergistic 
protection 
associated with 
eNOS 
phosphorylation. 
Bulhak et al 
2007
84
 
In vivo rat heart Intraperitoneal 
injection of 
rosuvastatin 
(10mg/kg) for 2 days. 
Reduced infarct size. 
  
Rosuvastatin 
cardioprotection 
associated with 
inhibition of 
geranylgeranyl 
pyrophosphate and 
altered RhoA 
membrane 
translocation. 
Birnbaum et al 
2008
85
 
Isolated rat heart Oral gavage for 3 days 
with atorvastatin 
10mg/kg/d, 
simvastatin 
10mg/kg/d, 
simvastatin 2mg/kg/d, 
simvastatin 2mg/kg/d, 
+ ezetimibe 1mg/kg/d. 
Reduced infarct size 
with atorvastatin and 
high dose simvastatin 
but not low dose 
simvastatin or 
ezetimibe. Protection 
associated with 
upregulation of NOS. 
  
Lipid-lowering 
drug ezetimibe is 
not 
cardioprotective. 
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Study Experimental Model Treatment regime  Key results Novel 
mechanistic 
insight 
Kocsis et al. 
2008
86
 
Isolated rat hearts Oral gavage for 12 
days with lovastatin 
15mg/kg/d or 
lovastatin 50 µmol/l 
perfused acutely 
during IR. 
Acute lovastatin 
abolished myocardial 
protection from IPC 
and failed to protect in 
its own right but did not 
affect protection from 
IPost. Chronic 
lovastatin ↓ infarct size, 
abolished protection 
from IPost but IPC 
remained protective. 
↓ Myocardial coenzyme 
Q9 
Chronic lovastatin 
is cardioprotective. 
Lovastatin may 
interfere with 
myocardial 
adaptation to 
ischaemic stress. 
Szarszoi, 2008
87
 Isolated rat hearts Oral chronic dosing 
with simvastatin 
10mg/kg for 2 weeks 
prior to ischaemia or 
acutely 10 µmol/l at 
reperfusion. 
Acute simvastatin 
preserved contractile 
force following IRI but 
chronic simvastatin 
showed no protection. 
Chronic 
simvastatin does 
not protect against 
IRI but acute 
dosing does. 
Thuc, 2010
63
 Cultured rat 
cardiomyocytes and 
isolated rat hearts 
Cells cultured with 
pravastatin 10mins 
prior to injury with 
H2O2. Pravastatin 
administered 10 mins 
prior to ischaemia or at 
reperfusion in isolated 
hearts. 
Pravastatin limited 
mitochondrial injury 
and cell death. Prior to 
ischaemia and at 
reperfusion infarct size 
was reduced. ERK1/2 
upregulated, ROS, 
mitoKATP and PKC 
implicated. 
Pravastatin 
appeared to limit 
cell injury through 
ROS but 
protection is 
mediated via a 
ROS burst and 
RISK pathway. 
 
Subsequent experimental studies have demonstrated pre-ischaemic cardioprotection in the 
absence of cholesterol-lowering using other statins including rosuvastatin
69
, atorvastatin
70
, 
pitavastatin and cerivastatin
74
 and lovastatin
86
. Interestingly, lovastatin has been reported as 
being protective when given chronically but not when perfused acutely in isolated rat hearts. 
The acute regime abolished protection from IPC but IPost remained protective, whilst with 
chronic use lovastatin abolished protection from IPost but IPC was unaffected
86
. The authors 
postulate that in these scenarios lovastatin reduces coenzyme Q9 and reduces the ability of 
the myocardium to adapt to ischaemic stress. Simvastatin-induced cardioprotection has been 
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reported in other clinically relevant animal models of disease including atherosclerosis (using 
the ApoE -/- mice)
64
 and type II diabetes (using the Db/Db mice)
65
. Many of these studies 
have also investigated the effect of pre-ischaemic statin therapy when administered in vivo 
for 1-21 days, exploring a number of different types of cardioprotective mechanisms, and 
therefore a direct protective effect on the myocardium or at the level of the cardiomyocyte 
could not be inferred. In this respect, experimental studies have made progress by 
demonstrating acute cardioprotective effects with statin therapy when administered 20-60 
minutes before or immediately prior to acute myocardial ischaemia-reperfusion injury insult
67 
72 74
. However, other experimental studies have demonstrated cardioprotection in the absence 
of endothelial cells and systemic factors such as neutrophils in the isolated buffer-perfused 
heart as well as in cultured human ventricular cardiomyocytes subjected to simulated 
ischaemia-reperfusion injury
75
, confirming that statin therapy is able to exert direct 
cardioprotective effects on the heart at the level of the cardiomyocyte.  
An interesting finding by our research group concerning the pre-ischaemic cardioprotective 
effect elicited by atorvastatin pre-treatment in the rat heart was that chronic treatment with 2 
weeks therapy failed to limit-infarct size, although the cardioprotective effect could be re-
captured by administering an acute high-dose of atorvastatin immediately prior to IRI
78
. This 
finding was attributed to the down-regulation of the PI3K-Akt signal transduction pathway, a 
critical cellular protective pathway (see later section). This important finding has clinical 
implications for CHD patients most of whom are already on chronic statin therapy- the 
implication being that their current statin treatment regime may not confer cardioprotection 
against an episode of acute myocardial ischaemia-reperfusion injury, although the beneficial 
cardioprotective effect may be recaptured by administering an additional high-dose of statin 
immediately prior to IRI (see later section). One other study has replicated the loss of 
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cardioprotection with chronic dosing
87
 however, it must be appreciated that other 
experimental studies have failed to observe a similar loss, which may be due to the use of 
different animal models and experimental technique (see table 1 for details)
70 71 77 80 86
. 
Although the above studies provide evidence that statin therapy can protect the myocardium 
against acute ischaemia-reperfusion injury when administered either chronically or acutely 
prior to IRI, there is an additional target for statin therapy which also needs to be considered. 
In this regard, it has been shown that statin therapy can also confer cardioprotection when 
administered after the onset of myocardial ischaemia and at the onset of myocardial 
reperfusion (see table 2).   
Statin therapy administered at the onset of myocardial reperfusion 
 
Experimental studies have demonstrated that acute statin therapy has the ability to confer 
cardioprotection even when administered after the onset of myocardial ischaemia and at the 
onset of reperfusion. Isolated working rat hearts subjected to IRI were significantly protected 
by the administration of simvastatin given after the onset of myocardial ischaemia and 
throughout the IR period
68
-see table 1. However, the first experimental study to report 
infarct-limitation with statin therapy administered at the onset of myocardial reperfusion was 
by Yellon‘s group in 200388. In that study it was reported that atorvastatin reduced 
myocardial infarct size, when administered to isolated perfused murine hearts at the onset of 
myocardial reperfusion, demonstrating that the direct cardioprotective effects of statin 
therapy could be extended into the reperfusion phase. Subsequent studies have reported 
similar findings using simvastatin
89
, mevastatin and pravastatin
63 75 90
 but interestingly not 
with fluvastatin
80
, although as the authors suggest, the optimal acute dose of fluvastatin may 
not have been used in their study. These experimental findings have important clinical 
implications for patients presenting with an acute myocardial infarction in which the 
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administration of statin therapy at the time of reperfusion may confer cardioprotection. The 
mechanistic pathway underlying this direct cardioprotective effect elicited by statin therapy is 
the subject of ongoing investigation and is reviewed in the next section. 
 
 
 
Table 2: Experimental cardioprotection with Statin therapy given prior to myocardial 
reperfusion. 
Study Experimental 
Model 
Treatment regime  Key results Novel mechanistic 
insight 
Post-ischaemic cardioprotection elicited by Statin therapy 
Bell et al 
2003
88
 
Perfused mouse 
heart 
Atorvastatin given for 
the first 15 minutes of 
myocardial reperfusion. 
Smaller infarct size.     
Protection associated with 
Akt and eNOS 
phosphorylation and 
blocked by wortmannin.   
Cardioprotection with 
atorvastatin given at 
reperfusion through 
PI3K-Akt-eNOS 
pathway. 
Bergmann et 
al 2004
90
 
Isolated rat 
cardiomyocytes 
Mevastatin and 
pravastatin given prior 
to reoxygenation. 6 
hours hypoxia, 18 and 
24 hours 
reoxygenation. 
Inhibited apoptosis by 
both mevastatin and 
pravastatin. 
Cardioprotection by 
mevastatin and 
pravastatin via Akt, 
GSK3β and inhibition 
of Caspase 3. 
Wolfrum et 
al 2004
89
 
In vivo rat Activated simvastatin 
1mg/kg given 3 mins 
prior to reperfusion 
Reduced myocardial 
infarct size. Protection 
blocked by PI3K inhibitor 
and L-NAME.  
Cardioprotection at 
reperfusion mediated 
via PI3K-Akt 
pathway. Reduction in 
infarct size after 3 and 
24 hours reperfusion 
when simvastatin 
given at reperfusion 
via PI3k/Akt 
Efthymiou et 
al 2005
91
 
Perfused mouse 
heart 
Atorvastatin given for 
the first 15 minutes of 
myocardial reperfusion. 
Smaller infarct size.     
Protection blocked by 
pharmacological inhibition 
of PI3K, p38 MAPK. 
Cardioprotection with 
atorvastatin given at 
reperfusion through 
PI3K-Akt and 
p38MAPK-HSP27 
pathways. 
     
Study Experimental 
Model 
Treatment regime  Key results Novel mechanistic 
insight 
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Matsuki et al 
2006
80
 
In vivo rat heart Fluvastatin given iv at 
reperfusion. 
No protection at 
reperfusion. 
Fluvastatin does not 
protect when given at 
reperfusion. 
Shakkottai et 
al 2008
92
 
Isolated rat heart Atorvastatin given just 
prior to reperfusion. 
Reduced infarct size and 
protection not blocked by 
8-SPT. 
Cardioprotective 
action of atorvastatin 
at reperfusion not 
mediated through 
adenosine receptor. 
D'Annunzio 
et al 2009
93
 
Isolated rabbit heart Rosuvastatin given at 
reperfusion (30mins I, 
120mins R) 
Reduced infarct size in 
normal and 
hypercholesterolaemic 
rabbits. Attenuated MMP-
2 action. 
Rosuvastatin is 
cardioprotective with 
MMP-2 implicated in 
the mechanism. 
 
Potential mechanisms underlying statin-induced cardioprotection 
 
Nitric oxide has been implicated as a crucial signalling molecule in the mechanism of 
cardioprotection and the other pleiotropic effects of statin therapy (figure 3). Experimental 
studies have demonstrated that statins stabilise eNOS mRNA, upregulate and activate eNOS 
and increase NO production
61 65 94
. The mechanism through which statins actually activate the 
nitric oxide signalling pathway is still the subject of investigation but it may be through the 
PI3K-Akt-eNOS pathway
88
 (see later). 
By inhibiting the formation of mevalonate and thus the isoprenoids
59
, critical proteins in the 
inflammatory cascade are inhibited (in particular Ras, Rho and Rab) which act via nuclear 
factor-κB and, as such, statins exhibit a powerful anti-inflammatory effect95. By inhibiting 
isoprenylation and preventing the formation of geranylgeranyl pyrophosphate (see figure 2), 
rosuvastatin has been shown to prevent Rho A translocating to the plasma membrane, 
increasing the cytosol-to-membrane ratio in the myocardium and providing infarct size 
reduction. The addition of GGPP abrogates this protection
84
.  The inhibition of Rho also 
prevents its inhibitory action on NO and thus provides a further mechanism of NO 
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upregulation
96
. Furthermore, inhibition of Rho kinase activates PI3k/Akt, providing 
cardioprotection- see later
97 98 
.  
Alternatively, Giricz and colleagues
99
 have reported that in fact lovastatin, and by inference 
all statin medications, do not increase cardiac NO levels. In a hyperlipidaemic rat heart 
model, the authors postulate that increased reactive oxygen species production reduces NO 
availability. The authors attempted to restore cardiac NO availability by inhibiting the 
mevalonate pathway with lovastatin or by cholesterol rich diet but were unable. Giving 
farnesyl, a major metabolite in the mevalonate pathway, did not alter NO levels either. 
However the authors were unable to conclusively demonstrate that by using lovastatin or a 
cholesterol rich diet they had completely blocked the mevalonate pathway and the hearts 
were not subjected to any ischaemia or reperfusion stimulus. The authors have previously 
found that treatment with farnesyl restores pacing preconditioning in a permanent coronary 
occlusion hyperlipidaemic rat model although not by restoring cardiac NO synthesis
100
.  
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Figure 3: Summary of the important pleiotropic effects of Statins (please see text for detail 
and an explanation of the abbreviations). 
 
 
 
 
 
 
 
 
 
Inhibition of
mPTP
opening
Acute
administration
? Adenosine 
receptor 
Akt/PKB
Activated
eNOS
NO
PI-3K
PKG
PKC
Erk 1/2 PI-3K/Akt
RISK Pathway
PPAR-γ
?PTEN
Rho kinase
NFκβ
?eNOS
mRNA
Inhibition of 
Rho, Ras, Rab
-Anti-Inflammatory 
effects 
Direct cardioprotective 
effects
Inhibition of 
HMG CoA
Reductase
?Isoprenoids
?GGPP
?cytosolic / 
membrane Rho
Nitric Oxide
Potential 
protective 
pathways for 
statins given 
before ischaemia
Potential 
protective 
pathways for 
statins given at 
reperfusion
Chronic
administration
Potential 
protective 
pathways for 
statins given 
before ischaemia
Page 43 of 236 
 
Statins and the Reperfusion Injury Salvage Kinase (RISK) pathway  
 
Subsequent experimental studies from Yellon‘s group suggested that the direct 
cardioprotective effect elicited by Statin therapy was due to the activation of the Reperfusion 
Injury Salvage Kinase (RISK) pathway, the term given to a group of pro-survival kinases, the 
activation of which at the onset of myocardial reperfusion confers powerful cardioprotection 
in the animal heart
46 53
. In that study, it was demonstrated that atorvastatin administered at the 
onset of myocardial reperfusion reduced myocardial infarct size by 50% in isolated perfused 
murine hearts, and that this protective effect was mediated through the activation of the 
PI3K-Akt-eNOS signal transduction pathway, given that the infarct-limiting effects were 
abrogated in the presence of a PI3K inhibitor and were lost in mice lacking eNOS
88
. In 
addition, the p38MAPK-HSP27 signalling pathway has also been implicated in the 
cardioprotection elicited by atorvastatin if given at the onset of reperfusion
91
. Subsequent 
studies have also implicated the recruitment of the RISK pathway in cardioprotection 
obtained with statin pre-treatment of hearts
74
. The myocardial protective phenomena of pre- 
and postconditioning appear to activate the RISK pathway at reperfusion possibly via the 
adenosine receptor; preconditioning being mediated via the A1
101
, A2a
102
 and A3 forms
103
 
and post-conditioning mediated via the A2b form
104
. The mechanism through which elements 
of the RISK pathway are actually activated by statin therapy is however unclear, although it 
may be through the potentiation of myocardial adenosine by ecto-5‘-nucleotidase74. 
Interestingly the non-selective adenosine receptor blocker, 8-sulfophenyl theophylline, was 
reported to blunt the infarct-limitation conferred by statin pre-treatment in dogs
74
 and both 
theophylline and 8-SPT have been demonstrated to prevent atorvastatin-induced Akt, ERK 
1/2, and eNOS phosphorylation
105
. Recently the blockade of adenosine receptor binding by 
caffeine, in a rat model of IRI, has been reported to prevent the cardioprotection afforded by 
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atorvastatin
106
, although in a recent study from our group we were unable to abolish 
atorvastatin-induced infarct-limitation at the onset of reperfusion in the perfused rat heart 
using SPT as a pharmacological inhibitor of the adenosine receptor
92
. Our study was in an 
isolated rat heart model with atorvastatin given at the onset of reperfusion where as Ye et al. 
used an in-vivo rat model with 3 days of oral dosing of both atorvastatin and caffeine; this 
may explain the discrepancy between the results seen. Nonetheless the RISK pathway 
appears to be a core component of a common cardioprotective pathway which converges on 
and inhibits the opening of the mitochondrial permeability transition pore, thereby preventing 
cardiomyocyte death
51 54
. As mentioned earlier the waning of the cardioprotective effect of 
atorvastatin given chronically for 2 weeks observed by our group is thought to be related to 
the upregulation of phosphatase and tensin homolog deleted on chromosome ten (PTEN), a 
phosphatase which down-regulates the PI3K-Akt component of the RISK pathway
78 and 
prevents the detrimental effects of prolonged upregulation of this growth promoting pathway. 
The additional higher dose of atorvastatin is presumed to restore cardioprotection by re-
activating the PI3K-Akt pathway
78
.  
Clinical Cardioprotection using Statin Therapy 
 
The experimental animal studies suggest that statin therapy has the ability to protect the 
myocardium against the detrimental effects of acute ischaemia-reperfusion injury irrespective 
of whether it is administered prior to the index ischaemic event or at the onset of myocardial 
reperfusion. As such it could be argued that statin therapy may theoretically confer 
cardioprotection in a range of clinical settings including those in which the index ischaemic 
event can be readily anticipated such as planned cardiac surgery or elective percutaneous 
coronary intervention (PCI), and in those settings in which myocardial ischaemia has already 
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commenced such as in acute myocardial infarction patients undergoing myocardial 
reperfusion using thrombolytic therapy or primary PCI.  
Statin therapy and percutaneous coronary intervention  
 
Peri-operative myocardial necrosis following elective or urgent percutaneous coronary 
intervention (PCI) has been documented using serum cardiac enzymes and cardiac magnetic 
resonance imaging
107
 and its presence has been linked to clinical outcomes
108-110
. In recently 
published guidelines, the myocardial infarction associated with PCI (termed type 4a), has 
been defined as an increase in a biomarker (preferably Troponin) of more than three times the 
99th percentile upper reference limit
111
. The aetiology of myocardial injury during PCI is 
likely to be multi-factorial with individual patient‘s anatomy, complexity of procedure, and 
concurrent medications playing a role
112
. Clinical studies suggest that Statin therapy may be 
beneficial in the setting of PCI in terms of reducing peri-procedural myocardial injury and 
potentially improving clinical outcomes. 
With respect to elective PCI, initial studies were designed to investigate the potential 
protective endothelial effects of statin therapy in terms of coronary artery lumen diameter and 
restenosis rates following PCI, with the statin generally initiated following PCI. In a 
retrospective analysis of 5052 patients undergoing elective PCI, Chan and colleagues
113
 were 
the first to demonstrate an association between statin use prior to PCI with improved clinical 
outcomes in terms of fewer peri-procedural MI‘s (defined by CKMB 3x upper limit of 
normal, 5.7% versus 8.1%, P=0.038), and a mortality reduction at 30 days (0.8% versus 
1.5%; hazard ratio, 0.53; P=0.048) and at 6 months (2.4% versus 3.6%;hazard ratio, 0.67; 
P=0.046)
113 114
 (see table 3).                
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Table 3: Statin therapy and percutaneous coronary intervention 
Study Study design Number and 
type of 
patients  
Intervention Follow up Outcomes 
Elective PCI      
Bertrand, 
1997
115
 
Multi centre, 
randomised, 
placebo 
controlled 
695 patients 
having 
undergone 
successful 
balloon 
angioplasty (no 
stent) 
Pravastatin 
40mg/d or 
placebo started 
after coronary 
intervention 
6 months No difference in 
luminal diameter 
or rate of 
restenosis. No 
difference in 
clinical 
outcomes. 
Serruys, 
1999
116
 
Randomised, 
placebo 
controlled, 
double blind 
1054 patients 
undergoing 
elective 
coronary artery 
balloon 
angioplasty (no 
stent) 
40mg twice/d 
fluvastatin or 
placebo started 
2-3 weeks pre-
PTCA 
Angiographic 
restenosis at 26 
weeks and 
MACE 
outcomes at 40 
weeks. 
No effect on 
restenosis. Death 
and MI reduced 
from 4 to 1.4% 
(log rank 
P=0.025) 
Schartl, 
2001
117
 
Open label, 
randomised, 
multi centre 
131 patients 
following PCI 
Atorvastatin or 
usual care. 
Atorvastatin 
titrated to 
achieve LDL-C 
<100mg/dl. 
Plaque volume 
at 12 months 
A non-
significant 
reduction in 
plaque volume. 
No difference in 
MACE rates. 
Serruys, 
2002
118
 
Randomised, 
placebo 
controlled, 
double blind 
1677 patients 
who had 
undergone first 
successful PCI 
80mg/d 
fluvastatin or 
placebo started 
at hospital 
discharge 
Survival time 
free from 
MACE at a 
median follow 
up of 3.9 years. 
Significant 
reduction in 
MACE rates in 
fluvastatin 
group. RR 0.78 
(95% CI 0.64 to 
0.95, P=0.01) 
Pasceri, 
2004
119
 
Randomised, 
placebo 
controlled, 
double blind 
153 Statin naive 
patients 
undergoing 
elective PCI 
40mg/d 
atorvastatin or 
placebo started 
7 days prior to 
procedure. 
Post procedural 
peak levels of 
CK-MB, Trop-I 
and Myoglobin. 
Atorvastatin 
significantly ↓ 
myocardial 
enzyme release 
post elective 
PCI. 
Brigouri, 
2004
120
 
Randomised 451 patients 
due to undergo 
elective PCI 
Randomised to 
Statin (variable 
type) or no 
Statin 
Incidence of 
large peri-
procedural 
myocardial 
injury (CK-MB 
and Trop-I ↑ ≥5 
times ULN) at 6 
and 12 hours 
post PCI 
↓incidence of 
CK-MB release 
5x ULN, and ↓ 
incidence of 
Trop I 5x ULN 
(32 to 23.5%, 
p=0.043). 
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Study Study design Number and 
type of 
patients  
Intervention Follow up Outcomes 
Mood, 2007
121
 Meta-analysis 3941 patients 
undergoing 
elective PCI 
Randomised to 
Statin (variable 
type) started 
periprocedure 
Clinical 
outcomes from 
1 day to 45 
months 
↓ incidence of 
myocardial 
infarction post 
PCI (0.57, 
95%CI 0.42 to 
0.78, p=0.0001) 
Naples II, 
2009
122
 
Randomised, 
placebo 
controlled, 
double blind 
668 statin naive 
patients 
undergoing 
elective PCI 
Randomised to 
80mg 
atorvastatin 
loading 24hours 
prior to PCI or 
placebo 
Incidence of 
CK-MB and 
Trop-T >3 
times ULN at 6 
and 12 hours 
post-PCI 
↓ CK-MB (9.5% 
vs 15.8%, 95% 
CI 0.35-0.89, p = 
0.01). ↓ Trop T 
26.6% vs 39.1%, 
95% CI 0.40-
0.78, p < 0.001) 
Armyda-
Recapture, 
2009
123
 
Randomised, 
placebo 
controlled, 
double blind 
352 patients 
established on 
statins 
undergoing 
elective PCI 
Randomised to 
80mg ‗reload‘ 
12 hours pre-
PCI and 40mg 
immediately 
pre-PCI 
MACE at 30 
days. Peri-
procedural 
cardiac enzyme 
release. Peak 
post procedure 
CRP. 
↓ MACE 3.4% 
vs. 9.1%, p = 
0.04. ↓ incidence 
of CKMB and 
Trop-T >3xULN, 
13% vs. 23%, p 
= 0.02 and 36% 
vs. 47%, p = 
0.03. 
Veselka, 
2009
124
 
Randomised, 
controlled, open 
label 
200 statin naive 
patients 
undergoing 
elective PCI 
Randomised to 
80mg 
atorvastatin 
daily for 2 days 
prior to PCI or 
no statin 
Cardiac enzyme 
release between 
16 and 24hours 
post PCI 
No difference in 
CK-MB or TnI 
release. 
Cay, 2010
125
 Randomised, 
open label, 
controlled. 
299 statin naive 
patients 
undergoing 
elective PCI 
Randomised to 
40mg 
rosuvastatin 24 
hrs pre-PCI or 
no treatment. 
CK-MB and 
TnI at 12hrs 
post PCI 
↓CK-MB >3× 
ULN: 0.7% vs. 
11.0%. 
↓TnI >3× ULN 
10.5% vs 39.0%. 
Any CK-MB↑ 
>ULN 10.5% vs 
34.2%. Any 
cTnI↑ >ULN 
20.9% vs 61.6%, 
p<0.001 for all. 
      
Urgent PCI      
Chang, 2004
126
 Observational 119 patients 
undergoing 
urgent PCI 
following ACS 
Statins or no 
Statin therapy 
Myocardial 
injury measured 
by CK-MB or 
CK ≥ 3 times 
ULN. MACE 
over 6 months 
↓ Myocardial 
injury 10 to 2% 
(p=0.04). 
↓MACE 21 to 
17% (p=0.015)  
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Study Study design Number and 
type of 
patients  
Intervention Follow up Outcomes 
Chyrchel, 
2006
127
 
Randomised, 
open label 
140 patients 
undergoing 
urgent PCI 
following ACS 
80mg 
atorvastatin 
daily started 3 
days prior to 
PCI and then 
40mg daily or 
just 40mg daily 
started after PCI 
MACE rates 
over approx. 
600 days 
↓composite 
endpoint of 
death, MI & re-
PCI rates from 
25.9 to 8.1% 
(p=0.006) 
Patti, 2007
128
 Multi centre, 
randomised, 
placebo 
controlled, 
double blind 
171 patients 
undergoing 
urgent PCI 
following ACS 
80mg 
atorvastatin  12 
hours prior to 
PCI with 40mg 
just prior and 
continuing or 
placebo until 
after PCI and 
then 
atorvastatin 
40mg started 
30 day MACE 
rates. 
Peri-procedural 
myocardial 
injury defined 
by twice the 
ULN of CK-
MB, Trop I or a 
2 fold increase. 
↓MACE (OR 
0.12, 95%CI 
0.05 to 0.5, 
p=0.004). 
↓incidence of 
CK-MB release 
7% v 27% 
(p=0.001), ↓ 
incidence of 
Trop I release 
41% v 58% 
(p=0.039). 
Gibson, 
2009
129
 
Post hoc 
analysis of the 
PROVE-IT
130
 
study 
2868 patients 
who underwent 
urgent PCI for 
ACS 
80mg 
atorvastatin or 
40mg 
pravastatin 
2 year MACE 
rate 
↓MACE (21.5% 
 atorvastatin vs 
26.5% 
pravastatin, (HR: 
0.78, 95%CI: 
0.67 to 0.91, 
p=0.001). ↓target 
vessel 
revascularisation. 
Elective and 
urgent PCI 
     
Chan, 2002
113
 Observational 5052 patients 
undergoing 
elective and 
urgent PCI 
(recent MI 
excluded) 
26.5% of 
patients taking 
variable Statins 
pre-procedure. 
Mortality at 30 
days and 6 
months. 
↓unadjusted 30 
mortality from 
1.5 to 0.8% (HR 
0.53, log rank 
P=0.048). 
↓unadjusted 6 
months mortality 
from 3.6 to 2.4% 
(HR 0.67, log 
rank P=0.046) 
Chan, 2003
114
 Observational 1552 patients 
undergoing 
elective or 
urgent PCI 
39.6% of 
patients taking 
variable Statins 
pre-procedure. 
Level of hsCRP 
and peri-
procedural MI 
(defined as 
CKMB >3 
times ULN) 
Statin use 
associated with 
↓hsCRP (0.4 v 
0.5, p=0.012). 
Statins ↓ peri-
procedural MI 
(5.7 v 8.1% 
p=0.038) 
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Study Study design Number and 
type of 
patients  
Intervention Follow up Outcomes 
Merla, 2007
130
 Meta-analysis 4751 patients 
undergoing all 
types of PCI 
Observational 
and randomised 
studies 
(variable 
Statins) started 
periprocedure. 
Incidence of 
peri-procedural 
myonecrosis 
Incidence of 
myonecrosis 
reduced from 
17.5% to 9% in 
the Statin group. 
(OR 0.45, 95% 
CI 0.33 to 0.62, 
p<0.01) 
                                                            
The Atorvastatin for the Reduction of MYocardial Damage during Angioplasty (ARMYDA) 
study
119
 was one of the first prospective randomised studies to investigate whether acute 
statin therapy could limit peri-procedural myocardial injury in statin-naïve patients- 153 
patients undergoing elective PCI were randomised to receive either 40 mg/day atorvastatin or 
placebo for 7 days prior to the PCI. Its primary outcome measure was peri-procedural 
myocardial infarction, defined as a CK-MB> 2 times the upper limit of normal post-PCI. One 
week of atorvastatin treatment prior to PCI reduced the incidence of peri-procedural MI from 
18% to 5% (P=0.025). Brigouri and colleagues
120
 also examined the effect of statin therapy 
started prior to PCI on the incidence of peri-procedural myocardial infarction- 451 patients 
undergoing elective PCI were randomised to receive a statin or no treatment. The choice of 
statin was left to the discretion of the physician (atorvastatin 29%, pravastatin 29%, 
simvastatin 39% and fluvastatin 3%) and was started at least 3 days prior to the procedure. 
Statin therapy was reported to reduce peri-procedural MI (defined as 5 times the ULN of 
either CK-MB or Troponin I) when compared to no treatment with respect to CK-MB (8 with 
statin versus 15.6 in control, P=0.012) and Troponin-I (23.5 with statin versus 32 in control, 
P=0.043). Brigouri‘s group have recently followed this study with Naples II which 
randomised 668 statin naive patients to an 80mg loading dose of atorvastatin within 24 hours 
of elective PCI. The atorvastatin treated group were reported to have a significantly reduced 
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incidence of CK-MB and Troponin-T release greater than 3 times the ULN (CK-MB: 9.5% 
vs. 15.8%, 95% confidence interval 0.35-0.89, odds ratio 0.56, p = 0.01) (Trop T: 26.6% vs. 
39.1%, 95% CI 0.40-0.78, OR 0.56, p < 0.001).
122
 
A meta-analysis undertaken by Birnbaum‘s group130 demonstrated that statin therapy prior to 
elective PCI reduced the incidence of myocardial necrosis, but the number of studies 
analysed was small. Furthermore, a meta-analysis by Mood et al.
121
 of statin use prior to 
elective PCI and their effect on outcome, included studies totalling 3941 patients and showed 
a reduction of peri-procedural MI of 43% in those taking statin therapy. The reduction in 
cardiovascular events occurred early post-procedure and was sustained, with an average 
follow up of 22.4 months. There was however no significant reduction in all cause or 
cardiovascular mortality. The authors acknowledged that their analysis was limited in some 
measure due to variation in study design and the necessity of comparing sometimes 
heterogeneous treatment protocols. A large proportion of the positive effect observed in this 
meta-analysis was driven by the ARMYDA study
119
 which included peri-procedural 
myocardial infarction in the figures of longer-term adverse cardiac events. Based on the 
hypothesis put forward by our group, with respect to the fact that the cardioprotective 
benefits of statin therapy may wane over time but can be recaptured by a further acute dose
78
, 
the ARMYDA investigators have also performed ARMYDA-RECAPTURE to determine 
whether patients already on chronic standard statin therapy due to undergo PCI will incur 
further benefit from an acute dose of statin therapy prior to PCI. 383 patients already 
established on statin medication scheduled to undergo PCI were randomised to a ‗reload‘ of 
80mg atorvastatin 12 hours pre-procedure and 40mg immediately pre-PCI. This was a mixed 
group with 47% of patients having recently experienced an acute coronary syndrome. The 
incidence of 30 day MACE was significantly lower in patients treated with atorvastatin 
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reload prior to PCI (3.7% vs. 9.4%, p = 0.037), however this was entirely driven by a 
reduction in periprocedural myocardial infarction in the acute coronary syndrome patients
123
 
suggesting perhaps that patients undergoing low risk elective PCI may have little to gain. In 
this regard a further study in 200 patients has shown no benefit in elective PCI of 48hours 
pretreatment with 80mg atorvastatin and although this study is relatively small and unblinded 
it does mean that a conclusive benefit in elective PCI is yet to be demonstrated
124
. 
With respect to urgent PCI, a few studies have investigated statins as cardioprotective agents 
exclusively in patients presenting with an acute coronary syndrome undergoing PCI (see table 
3). An initial observational study of 119 patients by Chang et al
126
 suggested that patients 
who were undergoing PCI following an acute coronary syndrome and were already taking a 
statin medication had a reduced incidence of cardiac events compared to those without 
statins. The incidence of myonecrosis (defined by a peak CK-MB or CK 3 times the ULN 
was reduced from 10% to 2% (P=0.04) and adverse cardiac events over 6 months of follow 
up were reduced from 21% to 17% (P=0.015) in those taking statins. 
Two prospective clinical studies have investigated the effect of statin therapy in patients with 
non-ST elevation MI (NSTEMI) undergoing PCI. Chyrchel and colleagues
127
 randomised 
140 patients with NSTEMI who were undergoing an early invasive PCI strategy to receive 
either 80mg of atorvastatin starting 3 days prior to intervention and then 40mg daily or no 
treatment prior to PCI but 40mg of atorvastatin daily commencing after the PCI. The patients 
were followed over approximately 600 days with an analysis of MACE as the primary 
outcome. Strikingly, the early initiation of atorvastatin reduced the composite end point of 
death, MI or repeat PCI from 25.9% to 8.1% (P=0.006). The authors did not define on what 
criteria they diagnosed the end point of myocardial infarction and did not describe a 
distinction between procedure related myonecrosis and later cardiac events. However these 
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were very promising results suggesting that by starting statin therapy just 3 days earlier in 
these patients it is possible to make a significant impact on long term outcomes. 
In ARMYDA-ACS
128
, 171 NSTEMI patients were randomised to receive 80 mg of 
atorvastatin 12 hours prior to the procedure and an additional 40mg, 2 hours prior to the 
procedure or placebo (all patients received 40mg atorvastatin daily following intervention 
regardless of initial randomisation). They reported a reduction in 30 day MACE from 17% in 
the placebo group to 5% in the atorvastatin group (p=0.01), although this was due to a 
reduction in peri-procedural myocardial necrosis as there were no cardiac events in either 
group after day 2 post-PCI. A subsequent sub-group analysis has suggested that reduced 
levels of circulating adhesion molecules (ICAM1 and VCAM1) may be partly responsible
131
. 
A retrospective analysis of the PROVE-IT data was conducted to explore the effects of 
atorvastatin 80mg versus pravastatin 40mg in those patients with ACS who had just 
undergone PCI prior to recruitment
129
. 2848 patients fulfilled this criteria and follow up over 
a median of 2 years revealed a 22% relative risk reduction in MACE rate (26.5 vs 21.5%, 
p=0.001) in the atorvastatin group. This included a reduction in the composite outcome of 
death and MI and a reduction in target vessel revascularisation. This is of course a post-hoc 
analysis of a tightly controlled study population and with PCI conducted in the bare metal 
stent era and so results should be interpreted with some caution, however this may be a hint at 
improved longer term outcomes with intensive over moderate statin use in PCI following 
ACS. 
In summary, statin therapy appears to limit peri-procedural myocardial necrosis and 
subsequent non-fatal events when started a short duration before both elective and urgent PCI 
but at the present time it is not conclusive whether this impacts on longer term mortality. The 
majority of patients undergoing elective PCI would be expected to be on long-standing statin 
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therapy, although patients undergoing a diagnostic coronary angiogram query proceed to PCI 
or those with acute coronary syndromes undergoing urgent PCI, may not be. The weight of 
benefit at present would appear to be in those patients with an ACS undergoing PCI. 
Statin therapy in acute coronary syndromes  
 
The majority of clinical studies investigating the effects of statin therapy in patients 
presenting with an acute coronary syndrome have focused on the initiation of statin therapy 
1-2 days following admission. Large randomised placebo controlled studies have already 
established chronic statin use as effective medical therapy for the primary and secondary 
prevention of cardiovascular events. Subsequent studies have begun to investigate the effects 
of acute statin therapy on patients presenting with acute coronary syndromes, but in the 
majority of these studies statin therapy was initiated 24 hours after the ACS (see table 4). 
 
Table 4: Statin therapy in acute coronary syndromes 
Study  Study design Number and 
type of patients  
Intervention Follow up Outcomes 
Arntz, 2000
132
 Prospective, 
open label, 
randomised 
135 patients 
undergoing PCI 
following new 
Q wave 
infarction or 
ACS 
Pravastatin 
started at 
20mg/d and 
titrated for 
LDL-C 
<130mg/dl or 
standard care by 
family 
physician 
Angiographic 
minimal 
luminal 
diameter and 
MACE rates at 
6 and 24 
months 
↓rate of 
progression of 
coronary 
atherosclerosis. 
↓MACE rates, 
OR 3.6, 95%CI 
1.6 to 7.8, 
p=0.005) 
Kayikcioglu, 
2002
133
 
Randomised, 
placebo 
controlled 
164 patients 
having been 
thrombolysed 
for acute MI 
Pravastatin 
40mg or 
placebo 
Clinical 
outcomes at 6 
months 
↓rate of 
subsequent 
angina, 59.5% 
to 30% 
(p=0.018) , 
↓composite 
MACE, 75.6% 
to 32.5% 
(p=0.0001).   
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Study  Study design Number and 
type of patients  
Intervention Follow up Outcomes 
Okazaki, 
2004
134
 
Randomised, 
open label 
70 patients 
following an 
ACS and PCI 
20mg 
atorvastatin or 
control (lipid 
lowering diet 
and cholesterol 
absorption  
inhibitor) 
Atherosclerotic 
plaque volume 
at 6 months, 
MACE rates. 
Significant 
reduction in 
plaque volume. 
No difference in 
MACE rates 
initially but 
extended 
recruitment 
subsequently 
showed a 
benefit
136
. 
Cannon, 
2004
135
 
Multi-centre, 
randomised, 
double blind, 
placebo 
controlled 
4162 patients 
following ACS 
Atorvastatin 
80mg aiming 
LDL-
C<70mg/dl or 
pravastatin 
40mg aiming 
LDL-
C<100mg/dl 
MACE rates 
over average 2 
year follow up. 
Relative risk 
reduction in 
composite 
MACE of 16% 
(95% CI 5 to 
26%, p=0.005) 
in atorvastatin 
group 
De Lemos, 
2004
136
 
Multi-centre, 
randomised, 
double blind, 
placebo 
controlled 
4497 patients Simvastatin 
40mg and then 
80mg or 
placebo for one 
month and then 
simvastatin 
40mg 
MACE rates 
over 4 months 
and 2 years. 
No reduction in 
MACE at 4 
months. At 2 
years rate of 
cardiovascular 
death ↓from 5.4 
to 4.1% 
(p=0.05). 
Colivicchi, 
2002
137
 
Prospective, 
randomised 
81 patients 
following ACS 
not amenable to 
revascularisation 
Atorvastatin 
80mg or 
conventional 
treatment 
12 month 
MACE rates 
↓MACE from 
46 to 22% (OR 
0.33, 95%CI 
0.12 to 0.88, 
P=0.0025) 
Schwartz, 
2001
138
 
Multi-centre, 
randomised, 
double blind, 
placebo 
controlled 
3086 patients 
following an 
ACS 
Atorvastatin 
80mg or 
placebo to start 
24 to 96 hours 
after admission 
MACE rates 
over 16weeks 
↓recurrent 
ischaemia 
requiring 
hospitalisation 
from 8.4 to 
6.2% (P=0.02).  
No difference in 
other MACE 
outcomes. 
Liem, 2002
139
 Randomised, 
placebo 
controlled, 
double blind 
540 patients 
following an 
ACS 
Fluvastatin 
80mg daily 
started within 2 
weeks of event 
Observed 
ischaemia and 
MACE rates 
over 12 months 
No difference in 
observed 
ischaemia, no 
difference in 
MACE 
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Study  Study design Number and 
type of patients  
Intervention Follow up Outcomes 
Thompson, 
2004
140
 
Randomised, 
placebo 
controlled, 
double blind 
3408 patients 
following an 
ACS 
Pravastatin 20 
to 40mg or 
placebo 
MACE rates at 
30 days 
Non-significant 
trend to benefit 
of pravastatin. 
Lenderink, 
2006
141
 
Retrospective 
cohort 
10,484 patients 
following an 
ACS 
Statin naive 
survivors at 24 
hours receiving 
Statins versus 
those not. 
All cause 
mortality at 7 
and 30 days. 
↓7 day mortality 
(0.4%v2.6%, 
unadjusted HR 
0.16, 95% CI 
0.08 to 
0.37).Non-
significant 
↓mortality at 
30days. 
Briel, 2006
142
 Meta-analysis 
of randomised 
controlled trials 
13,024 patients 
following an 
ACS 
Variety of 
Statins and 
doses started 
within 14 days 
MACE 
outcomes at 1 
and 4 months 
No reduction in 
death, MI or 
CVA up to 4 
months. 
Aronson, 
2008
143
 
Prospective 
observational 
study 
1,563 patients 
following acute 
MI 
Statin started 
in-hospital pre-
discharge (type 
and dose not 
recorded) or not 
Admission with 
heart failure 
over median 
follow up of 17 
months. 
Pre-discharge 
statin therapy ↓ 
admission with 
heart failure 
from 14.8 to 
6.5% 
(p<0.0001). 
Kim, 2010
144
 Prospective, 
single blind, 
randomised 
controlled study 
171 patients 
with STEMI 
80mg or 10mg 
atorvastatin pre-
PPCI and then 
10mg long term 
30 day MACE 
rate 
No reduction in 
MACE rate. 
Improved TIMI 
frame count, 
MBG and ST 
segment 
resolution. 
 
Initial retrospective observational studies suggested that the early initiation of statin therapy 
may well provide a reduction in short term cardiovascular adverse event
145-148
 although not 
all studies supported these findings
149
. Accordingly, small randomised clinical studies were 
performed
132-134 150
 (often with mixed end-points), which overall suggested that the early 
initiation of a statin was beneficial. 
Larger clinical studies that were designed to investigate early statin therapy in the setting of 
ACS have been undertaken. In the PROVE-IT-TIMI 22 clinical study
135
 4162 patients within 
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10 days of presentation with an ACS were enrolled and randomised to receive either 80mg of 
atorvastatin/day or 40mg pravastatin/day. The higher-dose atorvastatin therapy was found to 
reduce the relative risk at 2 years of the composite endpoint (death, MI, ACS requiring 
hospitalisation, coronary revascularisation or stroke) by 16% (95% CI 5 to 26%, p=0.005). 
Following this the much awaited Z phase of the A to Z study
136
 did not live up to the 
expectation placed upon it by the positive findings from PROVE-IT. The investigators 
randomised 4497 patients who had presented with an ACS to one month of simvastatin 40mg 
followed by 80mg continuing or placebo for 4 months followed by continuing on 20mg. 
Results at 4 months surprisingly failed to show any difference in the primary end point of 
composite MACE. Over the total of 2 years follow up there was a benefit from the more 
intensive, earlier initiated regime with a modest non-significant reduction in all cause 
mortality and cardiovascular death from 6.7 to 5.5% (p=0.08) and from 5.4 to 4.1% (p=0.05) 
respectively. It appeared that PROVE-IT and A to Z had generated disparate results, and 
indeed A to Z not exhibiting earlier benefits appeared to contradict the growing body of 
evidence from the smaller studies described above
132-134 150
. 
A posthoc comparison
151
 of the studies suggests that the differences in outcome are explained 
by slightly different cohort characteristics (in terms of baseline inflammatory status, LDL-
cholesterol levels, intensity of statin therapy) and by a higher rate of pre-randomisation 
revascularisation in the PROVE-IT study. The overall conclusion of the comparison, however 
remains that early initiation of statin therapy with or without appropriate revascularisation 
following an admission with acute coronary syndrome brings a mortality benefit. Patients not 
amenable to any revascularisation procedure also benefit from the early use of statins
137
. 
The Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) 
study
138
 was designed specifically to look at even earlier treatment with intensive atorvastatin 
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therapy (80mg) following an acute coronary syndrome (unstable angina or non-Q wave MI) 
versus placebo with therapy initiated 24 to 96 hours following admission. 3086 patients were 
randomised and followed over 16 weeks. There were no significant differences between the 
groups of death, non-fatal MI or cardiac arrest but there was a significant reduction in repeat 
admissions for ischaemic events in the 16 weeks of follow up (8.4% to 6.2%, p=0.02). This 
study showed that the beneficial effects of statins are seen very early on and as such are 
unlikely to be completely related to LDL-cholesterol concentration and the pleiotropic effects 
exert actions very soon following initiation. The FLuvastatin On Risk Diminishment 
following Acute myocardial infarction (FLORIDA) group undertook a randomised placebo 
controlled study to look at the incidence of ischaemia following the initiation of fluvastatin 
within 14 days following an ACS
139
 in 540 patients. It did not corroborate the findings of 
MIRACL and no significant difference was seen between the fluvastatin and placebo groups 
in terms of MACE or recorded ischaemia (on ambulatory ECG). However, the outcome 
measures were not standard and the overall power of the study was significantly less than the 
initial calculations due to the loss of un-interpretable ECG‘s. Overall this study did not 
strengthen the argument for the use of statins post ACS although perhaps the difference 
between FLORIDA and MIRACL is that the earlier the statin can be initiated the greater the 
potential for benefit can be.  
Further studies to clarify these issues have become more difficult as justifying placebo 
control is ethically difficult. The PACT study
140
 attempted to explore whether pravastatin 
given within 24 hours of presenting with an ACS would improve 30 day outcomes. The trial 
was halted having recruited 3408 patients (having aimed for ten thousand) as the population 
of patients being screened were increasingly already on statin therapy. They showed a non-
significant but favourable trend in the pravastatin group towards a 6.4% relative risk 
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reduction of death, recurrence of MI or readmission to hospital with unstable angina. 
Lenderink and colleagues
141
 reported from the Euro Heart Survey (10,484 patients) on the use 
of statins in the very early period following presentation with an acute coronary syndrome in 
statin-naive patients. Those patients surviving to 24 hours who received statins had an 
absolute reduction in mortality at 7 days of 2.2% (unadjusted HR 0.16, 95%CI 0.08-0.37) 
which was maintained at 30 days but was no longer statistically significant. When separated 
by presentation, with ST elevation MI (STEMI) versus non-ST elevation MI (NSTEMI), 
statistical significance was seen in those presenting with STEMI (HR 0.17, 95% CI 0.04 to 
0.7) but not NSTEMI. Although observational data, these results suggested that very early 
statin use, even in the setting of acute ST-elevation MI, could make a significant difference. 
Accordingly, Kim et al.
144
 conducted the Statin STEMI study which recruited 171 patients 
and randomised to 80mg or 10mg atorvastatin prior to PPCI for STEMI and then 10mg 
atorvastatin following this. There was no difference in the primary end-point of 30 day 
MACE rate but they demonstrated an improvement in secondary end-points of myocardial 
blush grade (2.2 +/- 0.8 vs. 1.9 +/- 0.8, p = 0.02), TIMI frame count (26.9 +/- 12.3 vs. 34.1 
+/- 19.0, p = 0.01) and ST segment resolution (61.8 +/- 26.2 vs. 50.6 +/- 25.8%, p = 0.01). 
A thorough meta-analysis in this area concluded that on current evidence early initiation of 
statin therapy following an ACS is not associated with a relevant reduction in death, MI or 
stroke in the first 4 months following an ACS
142
. The authors did conclude, as others have 
done
151
, that early initiation is unlikely to be harmful, may reduce the recurrence of unstable 
angina requiring hospitalisation in the first 4 months, may reduce the incidence of heart 
failure
143
 and is likely to increase patient adherence to statin therapy in the longer term
152
.  
Current guidelines do not yet advocate the use of ‗acute statins‘ but both the ESC and the 
AHA/ACC guidelines on the management of patients with NSTEMI or unstable angina 
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recommend starting a statin medication in all patients in the absence of contraindications and 
that this should be started prior to hospital discharge
153 154
. We would argue that statins 
should be given as early as possible in the treatment of patients with ACS on the basis that 
the likelihood for harm is low and that studies appear to show benefits with early 
administration. The overall risk of a statin related adverse event and particularly severe 
myotoxicity, even with intensive therapy, is low but is significantly increased above lower 
doses of statins
155
 and therefore the ‗optimal‘ medical therapy is likely to vary as to the risk 
stratification of the patient. 
 There is certainly a need for further studies examining the acute administration of statins in 
the treatment of a suspected acute coronary syndrome which would help clarify further the 
optimal dosing regimen and timing. In this regard, there are clinical studies underway 
examining the effects of Atorvastatin therapy administered in STEMI patients undergoing 
primary PCI (ARMYDA-MI)
156
.  
Statin therapy and cardiac surgery  
 
Cardiac surgery requiring cardiopulmonary bypass subjects the myocardium to significant 
global ischaemia-reperfusion injury, which can be detected as myocardial necrosis and a rise 
in serum cardiac enzymes, a finding which has been associated with short, medium and long-
term clinical outcomes
157-159
. The mean 30 day mortality for elective CABG surgery in the 
UK is 1.8% but as surgery is performed in increasingly high risk groups mortality estimates 
can reach 10-20%
160
. The nature of the myocardial injury is not entirely clear and is likely to 
be multi-factorial and significantly influenced by the length of cardioplegic arrest, the 
composition of cardioplegic solutions, the number of grafts, the time required for each 
anastomosis, atheroembolisation, direct injury due to handling and retraction of the heart, 
systemic inflammation and the use of intracoronary shunts
161 162
. Ischaemia-reperfusion 
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injury is probably the most important mode of injury, related to the global ischaemia induced 
by aortic cross-clamping during the performance of the distal coronary anastomoses. The 
importance of myocardial injury during CABG surgery has been recognised and is classified 
as a Type 5 Myocardial Infarction when there is evidence of increased biomarkers greater 
than 5 times the 99
th
 percentile of the upper reference limit plus either new pathological Q 
waves or new left bundle branch block on ECG, angiographically documented new graft or 
native coronary artery occlusion, or imaging evidence of new loss of viable myocardium
111
. 
Clinical outcomes in this group are clearly worsened, and so the prior application of a 
cardioprotective strategy may limit the myocardial damage incurred by the PMI. The use of 
statins has been explored in order to try and reduce myocardial injury and improve outcomes 
(see table 5). 
Table 5: Statin therapy and cardiac surgery 
Study Design Type of patients 
(No) 
Intervention Follow 
up 
Outcome 
Pan, 2004
163
 Retrospective 
cohort 
1663 patients 
undergoing 
primary CABG 
Pre-operative 
Statin or not. 
30 days ↓ all cause mortality from 
3.75% to 1.8% (p<0.05). ↓ 
all cause mortality and 
stroke from 7.1% to 4.6% 
(p<0.05). 
Ali, 2005
164
 Retrospective 
cohort (with 
matched 
propensity 
model analysis) 
5469 patients 
undergoing 
primary CABG 
Pre-operative 
Statin or not. 
In-
hospital 
outcome 
No significant difference 
between matched groups in 
mortality or other 
measures. 
Collard, 
2006
165
 
Pre-specified 
subset analysis 
of a prospective 
longitudinal 
study 
2666 patients 
undergoing 
primary elective 
CABG 
Pre-operative 
Statin or not. 
Hospital 
stay 
↓cardiac mortality in first 3 
post-operative days (0.3% v 
1.4%, p=0.03). No 
reduction of in-hospital MI. 
Chello, 
2007
166
 
Randomised, 
placebo 
controlled 
30 patients 
undergoing on-
pump CABG 
Simvastatin 
40mg or placebo 
started 3 weeks 
pre-op  
N/A ↓ IL-6 and IL-8. 
↑ neutrophil apoptosis 
Study Design Type of patients 
(No) 
Intervention Follow 
up 
Outcome 
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Fedoruk, 
2008
167
 
Retrospective 
cohort 
447 patients 
undergoing 
isolated cardiac 
valve surgery 
Pre-operative 
Statin or not 
30 days Adjusting for risk factors-  
composite outcome of 
30day 
mortality/stroke/renal 
failure  ↓with OR 2.7  (95% 
CI 1.24-5.66, P=0.012) 
Liakopoulos, 
2008
168
  
Meta-analysis 30,000+ patients 
undergoing 
cardiac surgery. 
Variable types of 
preoperative 
Statin or not. 
Variable A 1.5% absolute reduction 
in early all cause mortality. 
Reduced peri-operative 
stroke and AF. No 
reduction in peri-operative 
MI or renal failure. 
Mannacio, 
2008
169
 
Randomised, 
placebo 
controlled 
200 patients 
undergoing 
elective CABG 
surgery 
7 days of 20mg 
rosuvastatin or 
placebo pre-op. 
8 days ↓ Trop I (peak 0.16 ± 0.15 
vs 0.32 ± 0.26 ng/ml, 
P=0.0008), Myoglobin, 
CK-MB and hsCRP in 
postoperative period. 
 
Initially, a retrospective study by Pan and colleagues
163
 comprising 1663 patients undergoing 
elective CABG surgery compared those taking regular statin therapy (943 patients) against 
those not (720 patients) and showed a significant reduction in the 30 day post-operative all 
cause mortality from 3.75% to 1.8% (p=0.01) but did not show any difference in post-
operative myocardial infarction, incidence of arrhythmia, occurrence of stroke or renal 
dysfunction. A further retrospective study by Ali and Buth
164
 comprising 5469 patients 
undergoing CABG surgery did not report any significant benefit in those taking statins pre-
operatively. Collard and colleagues
165
 undertook the Multicenter Study of Peri-operative 
Ischemia (McSPI) Epidemiology II Study, a prospective longitudinal study of 5436 patients 
undergoing primary elective CABG surgery in order to determine the incidence of death in 
the first three post-operative days. A subset of 2666 patients was divided into two groups; 
those receiving preoperative statins and those not. A significant improvement in all cause 
mortality and cardiac mortality (all deaths in the early period were cardiac in nature) was 
demonstrated in the statin group in the first three post-operative days from 1.4% to 0.3% 
(p<0.01) however over the total hospital stay, no difference in mortality was seen. Again, 
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although a difference in early mortality was seen, there was no difference in peri-operative 
myocardial enzyme release. Interestingly, a multivariate analysis controlling for 
postoperative discontinuation of medications found that discontinuation of statins was 
independently associated with an increased risk of late postoperative cardiac mortality 
compared with those continuing with statin therapy (1.91% v 0.45%, p<0.01). This may 
correlate to observations in the laboratory setting where withdrawal of statins results in a 
rapid reduction in NO due to previously inhibited Rho Kinase becoming translocated to the 
plasma membrane and activated
170
. 
Recently a randomised study of rosuvastatin versus placebo in a selected population of 
patients undergoing CABG was performed. In contrast to previous studies patients treated for 
7 days prior to CABG surgery with rosuvastatin showed significantly less myocardial injury 
perioperatively
169
. However, in that particular study, patients already taking a statin were 
required to stop treatment 30 days prior to the study protocol and all patients were only 
treated for 7 days pre-operatively and for an unstated post-operative period; this therefore 
does not reflect common clinical practice. 
The mechanism of protection which statins appear to be affording in this case is not clear. 
Whether statins are having a direct myocardial protective effect in this setting is difficult to 
conclude from one study. A recent study looking at patients undergoing CABG on 
cardiopulmonary bypass randomised 30 patients to either simvastatin 40mg for 3 weeks prior 
to surgery or placebo and examined cytokine release as a measure of inflammation and the 
rate of neutrophil apoptosis. They found a reduction in IL-6 and IL-8 and an increased rate of 
neutrophil apoptosis. Their hypothesis being that the inflammatory effect of the CPB 
increases neutrophil functional activity, preventing their normal rate of turnover and causing 
a prolonged inflammatory effect. Statins acting to reduce this prolonged neutrophil activity 
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and hence reducing the inflammatory state, may explain the differences in mortality seen in 
those taking statins or not
166
. 
However, as discussed earlier it has been shown in animal based ischaemia/reperfusion injury 
studies that the direct myocardial protective effect of statins wanes over time
78
 and this may 
explain the lack of difference in cardiac enzyme release. Crucially, in these animal studies it 
was possible to recapture the protective effect and this is an avenue which I have investigated 
in the setting of CABG surgery and the findings will be discussed later. 
One study has been undertaken in cardiac valve surgery; a retrospective analysis of 447 
patients undergoing a variety of cardiac valve operations compared 30 day outcomes of those 
taking or not taking a statin medication prior to the operation. Although the statin group had 
more risk factors for peri-operative complications, they had better outcomes, with the 
unadjusted odds ratio for the composite outcome of death, stroke and renal failure being 1.9 
with a 95% CI of 0.95 to 3.76 (p=0.068). The authors acknowledge that this retrospective 
analysis requires validation by a randomised study but if confirmed this would extend the 
domain of the potential protection provided by statins
167
. 
A recent meta-analysis of preoperative statin use in cardiac surgery comparing data from 
30,000 patients has shown significant benefits from preoperative statin use in early post-
operative all-cause mortality, atrial fibrillation and stroke but conferred no benefit on 
postoperative myocardial infarction or renal failure
168
. There was a 1.5% absolute reduction 
in early postoperative death; however 95% of this effect was contributed to by the 16 
observational studies compared against only 3 prospective studies. The overall mortality 
reported in the control groups was 3.7%, twice the current mortality in the United Kingdom 
(1.8%)
160
 and so a further mortality reduction of 1.5% may be difficult to realise; although of 
course statin use may already be playing a role in UK‘s lower mortality figure. 
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At the present time, unless absolutely contraindicated, patients should be taking a statin 
medication prior to and following CABG and probably valve surgery and it should be 
continued during the operative period as much as is possible. 
Statin therapy and non-cardiac surgery  
 
Cardiac complications during and following non-cardiac surgery are common. In a group of 
6237 unselected patients over 40 years old, undergoing a variety of major non-cardiac types 
of surgery, the average rate of myocardial infarction or cardiac death was 2.5% (range 2-3.7) 
and in patients with known vascular disease this increased to 6.6% (range 2.2- 19)
171
. Even 
when patients are known to have cardiac disease it is difficult to predict who will have a 
problem. Patients may not be symptomatic under normal circumstances but intra-operative or 
postoperative factors which change the ratio of myocardial supply and demand such as 
hypotension, hypertension, anaemia, vasoactive medications and the general inflammatory 
state of surgery may reveal previous quiescent coronary disease. Of postoperative deaths 
reported to the National Confidential Enquiry into Peri-operative Deaths (NCEPOD) in the 
United Kingdom that underwent a post-mortem examination in 1999, 36% died from 
cardiovascular causes
172
. There is once again an obvious need for interventions to reduce 
cardiac events and statins have been implicated as having a role to play (table 6). 
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Table 6: Statin therapy and non-cardiac surgery 
Study Study design Number and 
type of patients  
Intervention Follow up Outcomes 
Poldermans, 
2003
173
 
Retrospective 
case 
controlled  
2816 patients 
undergoing major 
vascular surgery. 
160 cases 
matched with 
320 controls 
Analysis of 
Statin use. 
30 day 
mortality 
Significantly 
↓mortality rate in Statin 
uses against controls 
(OR 0.22, 95 CI 0.1 to 
0.47) 
Kertai, 
2004
174
 
Retrospective 
cohort 
570 patients 
undergoing 
elective AAA 
repair 
Analysis of pre-
op Statin and β-
blocker use or 
not. 
In hospital and 
30 day 
mortality and 
MI 
Statin use 
independently 
associated with 
↓mortality or post-op 
MI (OR 0.24, 95% CI 
0.1 to 0.7, p=0.01) 
Lindenauer, 
2004
175
 
Retrospective 
cohort 
780,591 patients 
undergoing major 
non-cardiac 
surgery. 
70,159 Statin 
users with 
matched 
propensity 
analysis 
In hospital 
mortality 
Statin use assoc. with 
↓crude mortality from 
3.05 to 2.13% 
(p=0.001).  
Durazzo, 
2004
176
 
Prospective, 
randomised, 
placebo 
controlled, 
double blind 
100 patients 
undergoing major 
vascular surgery. 
20mg 
atorvastatin for 
a mean of 30 
days pre-op or 
placebo. 
6 months  ↓ adverse cardiac 
events from 26 to 8% 
(p=0.031). 
O’Neil 
Callahan, 
2005
177
 
Retrospective 
cohort 
1163 patients 
who had 
undergone major 
vascular surgery 
Pre-operative 
Statin or not 
In hospital ↓peri-op cardiac events 
from 16.5 to 9.9% 
(p=0.001). Mainly 
↓myocardial ischaemia. 
Feringa, 
2007
178
 
Prospective 
non-
randomised. 
359 patients 
undergoing 
elective major 
vascular surgery. 
Pre-operative 
Statin therapy 
or not. Variety 
of types and 
doses 
30 days and 
longer (mean 
2.3 years) 
Higher Statin doses 
significantly ↓post-op 
Troponin T release. 
Statins significantly ↓ 
30 day and late post-
operative cardiac 
events. 
Schouten, 
2009
179
 
Prospective, 
randomised, 
placebo 
controlled, 
double blind 
497 patients 
scheduled to 
undergo vascular 
surgery 
80mg 
fluvastatin 
extended release 
or placebo 
started pre-
operatively 
30 days ↓ myocardial ischaemia 
from 18.9% to 10.9% 
(OR 0.53; 95%CI 0.32-
0.88). ↓ cardiovascular 
death or non-fatal MI 
from 10.1% to 4.8% 
(OR 0.48; 95% CI 
0.24-0.95) 
Dunkelgrun, 
2009
180
 
Prospective, 
randomised, 
open label 
1066 patients 
scheduled to 
undergo non-
cardiovascular 
surgery 
Patients 
allocated to 
bisoprolol, 
80mg 
fluvastatin, 
combination 
therapy or 
30 days Bisoprolol ↓ cardiac 
death or MI (2.1% vs. 
6.0% events; 95%CI: 
0.17–0.67; P=0.002). 
Fluvastatin non-
significantly ↓ cardiac 
death or MI (3.2% vs. 
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neither (control) 4.9% events;95%CI: 
0.35–1.10; P= 0.17) 
 
An initial case control study suggested a large reduction in peri-operative cardiac 
complications in patients taking statins prior to non-cardiac vascular surgery with an adjusted 
odds ratio of 0.22 (95% confidence interval 0.1-0.47) between statin users and non-users
173
. 
Following this, the same group went on to show that statin use prior to elective aortic 
aneurysm repair, even after adjusting for covariates, was associated with a reduction in the 
combined end-point of peri-operative mortality and MI at 30 days follow-up (OR 0.31, 95% 
CI 0.13 to 0.74, p=0.01)
174
. A large retrospective cohort study of 780,591 patients undergoing 
non-cardiac surgery showed a reduction in crude mortality from 3.05% to 2.13% (p<0.01) in 
those taking regular statin medication and this difference persisted in the propensity matched 
cohort as well. This study was limited in drawing conclusions because they defined a patient 
to have received regular statin treatment if they received it on post-operative day 1 or 2 and 
so were not able to comment on duration of preoperative use definitively
175
.  In the 
retrospective StaRRS study of 1,163 patients, regular statin use prior to non-cardiac vascular 
surgery reduced peri-operative cardiac complications from 16.5% to 9.9% (p=0.001) but the 
reduction was driven by a reduced incidence of myocardial ischaemia and congestive heart 
failure rather than total mortality
177
.   
Poldermans‘ group went on to demonstrate in a non-randomised prospective observational 
study of 359 patients that the intensity of statin therapy is also important when considering 
reductions in cardiac events during major non-cardiac vascular surgery. In patients 
undergoing elective abdominal aneurysm repair, peripheral arterial bypass surgery and 
carotid artery surgery, myocardial injury was measured by Troponin-T release and ischaemic 
episodes were recorded using continuous 12 lead ECG recording. Cardiac events were 
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recorded at 30 days and later (mean 2.3 years). Both, higher statin doses (regardless of LDL 
cholesterol concentration) and lower serum LDL cholesterol concentrations were associated 
with reduced myocardial ischaemia. In fact for each reduction in LDL cholesterol of 10mg/dl 
there was a 13% reduction in ischaemic events.  They also reported a significant reduction in 
the rate of cardiac events (albeit small numbers) at 30 days with an odds ratio of 0.32 (95% 
CI 0.1-0.96) and in late cardiac events with a hazard ratio of 0.41 (95% CI 0.21- 0.75)
178
.  
A randomised double blind study by Durrazo et al.
176
 allocated 100 patients about to undergo 
vascular surgery to 20mg of atorvastatin or placebo at least 30 days prior to their operation. 
The primary endpoint was of composite cardiac death, non-fatal myocardial infarction, 
unstable angina and stroke. Atorvastatin significantly reduced cardiac events over 6 months 
post-operatively from 26% to 8% (p=0.031). Although very promising, the total number of 
events was small (17) and as such further validation was needed.  
DECREASE III was designed to fulfil this role. 497 statin-naive patients scheduled to 
undergo vascular surgery were randomised to placebo or 80mg fluvastatin extended release. 
At 30 days post-operatively myocardial ischaemia was detected in 74 patients and was 
reduced from 18.9% in the placebo arm to 10.9% in the fluvastatin group (OR 0.53; 95% CI 
0.32-0.88) with a 52% relative risk reduction in the combined end-point of cardiovascular 
death or non-fatal MI (OR 0.48; 95% CI 0.24-0.95)
179
. This study suggests that there is a 
large benefit to be gained from fluvastatin XL in patients undergoing non-cardiac vascular 
surgery. This is unlikely to be an effect confined to fluvastatin and the majority of patients 
undergoing vascular surgery are likely to benefit from a statin in terms of their systemic 
atherosclerotic disease and placebo controlled trials may no longer be justifiable. Creative 
study design may certainly allow us to clarify the optimum timing and dosing of preoperative 
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statin therapy and whether or not the use of statins acutely prior to the operation could bring 
further benefit would be a very interesting basis for study. 
Although major society guidelines are yet to be updated some general recommendations 
regarding statin use prior to non-cardiac surgery can be made. All patients prescribed statins 
for established primary or secondary prevention prior to any type of surgery should continue 
them perioperatively and these should be stopped for the shortest possible time peri-
operatively. All patients with known atheromatous vascular disease undergoing vascular 
surgery should, if not already on a statin, be seriously considered for one and this should be 
commenced as early as possible prior to surgery and again should be continued peri and post 
operatively. At present we cannot advocate a statin prior to all surgical types however 
because the DECREASE IV study, designed to evaluate bisoprolol and fluvastatin in patients 
at intermediate risk of post-operative cardiovascular events, demonstrated a benefit of 
bisoprolol but only a non-significant trend to benefit with fluvastatin. It is likely that in this 
lower risk group, there is less to gain from statin medications in terms of atherosclerotic 
plaque stabilisation etc.
180 181
 .  
Conclusion 
 
Statins are established as playing a major role in cardiovascular disease in almost all 
categories of patient risk. The ‗pleiotropic‘ effects of statins continue to reveal further 
potential benefits in a diverse range of interventional settings. The benefit of using statins 
acutely prior to scenarios where myocardial injury may be expected and in emergent 
situations is slowly being realised. The potential benefits of limiting myocardial injury in 
these settings are evident and further work is needed to clarify the optimum statin regime in 
different settings and the mechanisms behind the cardioprotective actions. Whether or not 
further cardioprotective effects can be gained by additional acute doses of statins has exciting 
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potential and merits further study. Specifically, whether high-dose atorvastatin is beneficial in 
the setting of cardiac surgery has not been established (see chapter 3). 
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Erythropoietin as a myocardial conditioning mimetic 
 
Erythropoietin (Epo) is a haematopoietic cytokine which acts via membrane bound receptors 
on erythroid progenitor cells to regulate red cell mass
182
. Recombinant versions (rhEpo) are 
well established in humans as a treatment for anaemia but fairly recently Epo has also been 
demonstrated to have cardioprotective potential. The different types of rhEpo are the α and β 
forms and a long acting analogue, darbepoietin α (DA). The different types have almost 
identical clinical haematopoietic effects although DA acts over a longer time period. The α 
and β forms have been reported as having some variation in biochemical response and that 
there may be some inter-batch variation in glycosylation within the same type. This does not 
appear to affect the haematopoietic characteristics but it is not known how interaction with 
the Epo receptor complex may vary to produce any cardioprotective effects
183
. Epo is 
reported as being able to reduce inflammation, inhibit myocyte apoptosis and stimulate 
vasculogenesis in order to limit infarct size and reduce detrimental myocardial remodelling in 
laboratory models of ischaemia and reperfusion injury. It appears that activation of the RISK 
pathway (figure 3), as described above, is again crucial to these beneficial effects. In the 
following section, the laboratory and clinical evidence for cardioprotection by Epo shall be 
reviewed with particular emphasis on its role in acute reperfusion injury. 
The emerging cardioprotective effect of Epo 
 
Beyond its role in haematopoeisis, Epo and its receptor have been demonstrated in a number 
of other cell types including all types of muscle cell, insulin producing cells, endothelial cells 
and neurons
184
. The identification of these alternative sites sparked renewed investigation into 
the abilities of Epo and particularly whether it could afford cellular protection in the nervous 
and cardiovascular systems. Epo was found to protect neurons and the brain against 
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ischaemic injury in 1998
185
 but it was later in 2003 that a number of different groups 
demonstrated that Epo had cardioprotective effects (see below). 
The time point that Epo is administered relative to the experimental I/R injury allows 
elucidation of the potential mechanism of protection but also, this time point can be 
correlated to the clinical setting where the cardioprotective effect may eventually be 
harnessed; for example, prior to an elective procedure where myocardial injury is anticipated, 
such as elective CABG surgery, or after the onset of ischaemia in an unexpected acute 
myocardial infarction. In the section below the evidence for cardioprotection at the different 
experimental time points is reviewed (see Table 7 for a summary of studies). 
Epo administered 24 hours prior to ischaemia 
 
Initially, investigators established the presence of the Epo receptor (EpoR) in isolated 
neonatal rat ventricular myocytes and then, when co-incubated with Epo, apoptosis induced 
by hypoxia was found to be significantly reduced
186
. Epo treatment 24 hours previously was 
found to significantly reduce apoptosis by 50% in isolated neonatal rat cardiomyocytes 
subjected to either oxidative stress or when subjected to 12 hours anoxia from  56.8% ±6.7% 
to 37.7% ±3.9% (p<0.01)
187
. Similarly, a study in isolated adult rat cardiomyocytes showed 
that Epo reduced apoptosis by approximately 50%
188
. Cai et al.
189
 first demonstrated in 2003 
that rats treated with 5000 U/kg of Epo 24 hours prior to I/R injury on an isolated 
Langendorrf rig showed improved functional recovery and a reduction in myocyte apoptosis. 
Yellon‘s group showed in an isolated rat heart model that hearts treated by Epo, ‗3 times a 
week‘ for 3 weeks were protected but not when treated only once,  a week before I/R, 
although the same dose (5000 U/kg) administered just once, 24 hours prior to I/R was 
protective
190
. The infarct limiting effect of Epo administered 24 hours prior to I/R has also 
been demonstrated in a rat in-vivo recovery model
191 192
 but not by all
193
. Burger et al. have 
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used a mouse in vitro
194
 and in vivo model
195
 in order to demonstrate that Epo significantly 
reduces apoptosis and therefore subsequent infarct size at this time point, and that p-38 
MAPK mediated heme oxygenase-1 (HO-1) expression is important in this effect
195
. 
Epo administered at the onset or just after ischaemia 
 
Initial studies with Epo administered at this time point looked at the effects of permanent 
coronary artery occlusion without reperfusion. In the rat
186 196 197 
and the rabbit
187
 Epo was 
shown to reduce apoptosis and improve functional recovery, although repeated doses 
achieved no further benefit than just the first dose
197
. Although benefit in a permanent 
ligation model was an exciting development, models exploring the effects of Epo with 
reperfusion more closely mirror the human clinical setting. Epo given at or just after the onset 
of ischaemia in infarct models with reperfusion has shown reduced apoptosis and infarct size 
in rat in-vitro
198-202
 and in-vivo models
188 203-207 
. One large mammal study has been 
conducted by Kristensen et al.
208
 using a catheter based porcine coronary occlusion model 
where 35,000U rhEpo was administered intravenously either 90mins or 24 hours 
(intramuscularly) and 90 mins before (intracardiac) 45 mins I and 150 mins R. Although in 
the latter group there was an improvement in LV functional parameters (dp/dtmax), there was 
no difference shown in infarct size between the control and treated groups, which appears to 
contradict the findings in the smaller animals.  
Epo administered at reperfusion 
 
Cardioprotective effects of Epo at reperfusion would have the potential to be translated to a 
number of elective and emergency settings of myocardial reperfusion injury in humans. The 
first study at this time point in a rat in-vivo model gave rhEpo (5000 U/kg) following 30 mins 
I and just before 4 hrs reperfusion and then daily doses for 7 days. Interestingly at the 4 hour 
Page 73 of 236 
 
time point no difference in infarct size was shown, although at 7 days the treated group had 
improved LV function as demonstrated by a reduced LVEDP, suggesting that beneficial 
remodelling had taken place despite no difference in initial infarct size. However following 
this study, treatment with Epo at reperfusion has shown significant reductions in infarct size, 
apoptosis and improvements in haemodynamic measurements in rat in-vitro models
202 209 210
, 
in-vivo models
205-207 209
, rabbit in-vitro
211
 and in-vivo
204
 models. Of the larger mammals 
studied canine, porcine and ovine models have been used. In the canine model
212
 100 U/kg 
and 1000 U/kg doses of rhEpo were given just before reperfusion and both showed a 
significant reduction in infarct size, incidence of lethal arrhythmias and in myocyte apoptosis 
(although a greater effect was seen with the higher dose). However, in the porcine and ovine 
models such impressive results were not seen. Toma et al.
213
 used a porcine catheter based 
model to occlude the LCx coronary artery for 60mins and administered darbepoietin 
(30µg/kg) intravenously at reperfusion. Following 2 weeks of reperfusion there was no 
difference in infarct size seen using histology but they did demonstrate moderate beneficial 
remodelling in the peri-infarct zone, with decreased fibrosis, increased capillary density and 
increased regional wall motion. Olea et al.
214
 used an ovine catheter based coronary occlusion 
model and 3000 U/kg of rhEpo was administered at reperfusion and 24 and 48 hrs later. No 
difference in infarct size was seen as assessed by morphometry or hydroxyproline methods 
and using echocardiography and LV catheterisation, no difference in EF was found. In fact in 
the treated group there was an increased LVESV and LVEDP, suggesting LV dilatation and 
adverse remodelling at 10 weeks post infarction. A further step towards the human setting has 
been taken by Yellon‘s group who have investigated rhEpo given at reoxygenation in a 
human atrial trabeculae model of I/R. The atrial appendage from patients undergoing cardiac 
surgery on cardiopulmonary bypass was harvested and atrial trabeculae isolated and 
suspended in a superfused organ bath and the developed contractile force measured. In this 
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way the trabeculae were subjected to hypoxia and reoxygenation with rhEpo (50ng/ml) 
perfused at reoxygenation and it was reported that the treated group had a significantly 
improved recovery of contractile force than controls and this coincided with decreased 
caspase 3 (as a measure of apoptosis) in the treated group which was mediated via PI3k and 
ERK 1/2
215
. 
Delayed Epo administration 
 
A number of investigators have explored the protective effects of rhEpo given after the initial 
reperfusion with further doses at delayed time points, or in permanent ligation models where 
there may be no reperfusion and Epo is administered quite sometime after ischaemia. Van der 
Meer et al.
216
 found that although darbepoietin (40µ/kg) administered at the onset of 
permanent coronary artery ligation reduced infarct size at 9 weeks, this was not the case with 
delayed administration 3 weeks following the index ischaemia. However at both time points 
of dosing, significant improvements were seen in haemodynamic measures of LV function 
and increased capillary density noted. Westenbrink et al.
217
 confirmed these findings, where 
in a similar model, dosing at 3 weeks post coronary artery ligation did not reduce infarct size 
but significantly improved the haemodynamic measurements. However, at time points closer 
to reperfusion than 3 weeks, substantial benefits in infarct size have been realised as well. In 
a rat permanent ligation model a significant reduction in infarct size at 4 weeks was 
demonstrated with rhEpo up to 12 hours after ischaemia as well as improved LVEF. Epo 
given at 24 hours, did not reduce infarct size but did reduce apoptosis
218
. However in a canine 
permanent ligation model a reduction in infarct size was only seen when rhEpo was given at 
the onset of I, although dosing at 6 hours post I did produce significant haemodynamic 
benefits, increased circulating endothelial progenitor cells and improved capillary density; 
treatment at 7 days post ligation produced no benefit at the 4 week assessment
219
. Although in 
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reperfused rat models a reduction in infarct size and beneficial remodelling has been reported 
with DA administered 24 hrs
220
 and 7 days
221
 after infarction.  
Table 7: Overview of all animal or human tissue studies investigating the effect of Epo on 
infarct size or apoptosis following ischaemia-reperfusion or permanent coronary artery 
occlusion.  
First 
author  
Date Model Treatment regime Key results Mechanistic insight 
Administration of Epo  24 hours before ischaemiaa 
Cai 
189
 2003 Rat in 
vitro, 30 
min global 
I
b
 / 45 min 
R
c
 
rhEpo (5000 U/kg) 
ip 24 h before I 
 LVDPd,  apoptosis  caspase 3 activation 
Bullar
d
190
 
2005 Rat in 
vitro, 35 
min I / 120 
min R 
rhEpo (5000 U/kg) 
sc three times a 
week for three 
weeks before I 
 ISe   IS dependent on NOS, 
but not PI3K 
Hale
193
 2005 Rat in 
vivo, 
permanent 
ligation, 6 
weeks 
rhEpo (5000 U/kg) 
sc 5 days and just 
before I and daily 
for 5 days after I 
= IS,  EFh  
Liu
191
 2006 Rat in 
vivo, 30 
min I / 3 h 
R 
rhEpo (5000 U/kg) 
ip 24 h before I 
 IS  myocardial 
proinflammatory 
cytokines,  neutrophils 
Liu
192
 2006 Rat in 
vivo, 30 
min I / 3 h 
R 
rhEpo (5000 U/kg) 
ip 24 h before I 
 IS  COX-2 mRNA and 
PGE2 and 6-keto-PGF1α  
 IS dependent on COX-2 
Burger
194
 
2006 Mouse in 
vivo, 45 
min I / 3 h 
R 
rhEpo (2500 U/kg) 
iv 24 h and 30 min 
before I 
 IS,  apoptosis  myocardial eNOS 
expression.  
No  IS in eNOS -/- mice 
Burger
195
 
2009 Mouse in 
vitro 
90min I/ 
90min R;  
in vivo, 45 
min I/ 3h 
R 
in vivo 45 
min I/ 6h 
rhEpo (20 U/ml) 
for 24hours prior to 
I/R 
rhEpo (2500 U/Kg) 
iv 24h and 30 min 
before I. 
rhEpo (2500 U/Kg) 
iv 5 mins after I 
HO-1, CO,   apoptosis. 
 
HO-1 in WT mice and 
eNOS
-/-
 mice. =apoptosis 
and IS in HO-1-/- mice. 
↓IS in WT 
Anti-apoptotic effect 
mediated via HO-1 and 
CO. HO-1 expression 
mediated via p-38 MAPK 
and Akt but not Erk. 
HO-1 independent of 
eNOS. 
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R 
First 
author  
Date Model Treatment regime Key results Mechanistic insight 
 
Administration of Epo immediately before or after start of ischaemia 
Tramo
ntano 
186
 
2003 Rat, in 
vivo, 60 
min of I, 
no R 
rhEpo (5000 U/kg) 
ip at time of I 
 apoptosis Akt dependent 
Moon 
196
 
2003 Rat, 
permanent 
ligation 8 
weeks  
rhEpo (3000 U/kg) 
ip immediately 
after start of I 
 IS,  apoptosis (at 24 h), 
 fLVEDD,  gLVESD,  
thinning LV wall,  EF, = 
mortality 
No change in haematocrit 
Parsa 
187
 
2003 Rabbit, in 
vivo, 
permanent 
ligation 4 
days 
rhEpo (5000 U/kg) 
iv at time of I 
 peak LVDP,  dP/dtmax in 
response to isoproterenol,  
 apoptosis (at 6 h) 
 phosphorylation of Akt 
and ERK 
No change in haematocrit 
Cai
198
 2004 Rat in 
vitro, 30 
min global 
I / 45 min 
R 
Perfusion with 
rhEpo (100 U/kg) 
for 15 min before I 
 LVDP,  iLVEDP,  
apoptosis 
 phosphorylation of Akt.  
Effects mediated by PI3K 
Van 
der 
Meer 
199
 
2004 Rat in 
vitro, 40 
min global 
ischaemia 
/ 2 h R 
Perfusion with 
rhEpo (10 U/ml) 
starting before I 
until end of R. 
 LVDP,  apoptosis  phosphorylation of 
ERK1/2, but not of 
STAT5 
Kriste
nsen
208
 
 
2005 Pig in 
vivo, 45 
min I / 150 
min R 
rhEpo (35000 U) iv 
90 min before I or 
24 h (im) and 90 
min before I (ic) 
= IS,  dP/dtmax (in latter 
group) 
 
Moon
1
97
  
2006 Rat, 
permanent 
ligation 4 
weeks 
rhEpo (3000 U/kg) 
iv immediately 
after ligation as 
single dose, or 
daily for 6 days 
afterwards 
 IS (only significant in 
single dose group),  
LVEDP,  EF, = mortality 
No benefit with repeated 
dosing. 
Miki
200
 2006 Rat in 
vitro, 25 
min global 
I / 2 h R 
rhEpo (5 U/ml) for 
15 min before I 
 IS   phosphorylation of 
JAK2 and Akt;  IS 
dependent on PI3K, 
guanylyl cyclase, and 
mitoKATP 
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First 
author  
Date Model Treatment regime Key results Mechanistic insight 
Nishih
ara
203
 
2006 Rat in 
vivo, 20 
min I / 120 
min R  
rhEpo (5000 U/kg) 
iv 15 min before I 
 IS   phosphorylation of Akt, 
STAT 3, GSK-3β;  IS 
dependent on PI3K and 
PKC (NS);  
Miki
201
 2007 Rat in 
vitro, 25 
min global 
I / 2 h R 
rhEpo (5 U/ml) for 
15 min before I 
 IS  phosphorylation of Akt 
and ERK1/2;  IS not 
dependent on ERK1/2. 
Ohori
2
22
 
2008 Rat in 
vitro, 2, 6 
or 24hrs of 
oxidative 
stress. 
rhEpo (10 U/ml) 
1hr prior to 
oxidative stress. 
↓apoptosis 
↑ Ser9 phosphorylation of 
GSK-3β in the 
mitochondria. 
↓BAX translocation to 
mitochondria 
EpoR and β subunit 
present in H9c2 cells. 
Protection mediated via 
PI3k/Akt to 
phosphorylate mito GSK-
3β and prevent BAX 
translocation. 
 
Administration of Epo at reperfusion 
Calvillo
1
88
 
2003 Rat in vivo, 
30 min I / 
4 h R or 7 
days R 
rhEpo ip, 24 h 
and 0.5 h before 
I (2500 U/kg) or 
at R (5000 
U/kg), and daily 
for 7 days 
= IS (at 4 h),  LVEDP (at 7 
days) 
 
Parsa
187
 2003 Rabbit, in 
vivo, 30 
min I / 3 
days R 
rhEpo (5000 
U/kg) iv at time 
of R 
 IS  Akt dependent 
Parsa
204
 
 
2004 Rabbit in 
vivo, 30 
min I / 3 
days R 
rhEpo (1000 
U/kg) iv 12 h 
before I or 
imme-diately 
before I or R 
 IS (both groups),  
LVEDP,  + dP/dtmax, (only 
when given before I),  
apoptosis 
 phosphorylation of 
JAK2, STAT3/5, ERK, 
and Akt 
Lipsic
205
 2004 Rat in vivo, 
45 min I / 
24 h R 
rhEpo (5000 
U/kg) ip, 2 h 
before I, at time 
of I, or at R 
 IS (all groups),  
apoptosis,  LVEDP  
 caspase 3 
Bullard
2
09
 
2005 Rat in 
vitro, 35 
min I / 120 
min R; in 
vivo, 40 
min I / 24 
h R 
rhEpo (50 ng/ml) 
for 20 min 5 min 
before R (in 
vitro); rhEpo 
(5000 U/kg) ip at 
R (in vivo) 
 IS   phosphorylation eNOS, 
Akt (NS), and ERK1/2 
(NS). 
 IS dependent on PI3K 
and ERK 1/2  
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First 
author  
Date Model Treatment 
regime 
Key results Mechanistic insight 
Hirata
21
2
  
2005 Dog in 
vivo, 90 
min I / 6 h 
R 
rhEpo (100 or 
1000 U/kg) iv 
before R 
 IS,  incidence of 
ventricular fibrillation,  
apoptosis 
 phosphorylation of Akt. 
 IS dependent on PI3K 
Hanlon
2
02
 
2005 Rat in 
vitro, 20 
min I / 40 
min R 
(LVDP), 
30 min I / 
120 min 
(IS) 
Perfusion with 
rhEpo (10 U/ml) 
for 10 min before 
I or at R 
 IS,  LVDP    phosphorylation of Akt, 
ERK1/2, and 
translocation of PKC-ε;  
IS dependent on PKC 
(during I), and PI3K 
(during R) 
Olea
214
 
 
2006 Sheep in 
vivo, 90 
min I / 10 
weeks R 
rhEpo (3000 
U/kg) iv at time 
of R, and 24 and 
48 h later. 
= IS, = EF,  LVESV,  
LVEDP 
 
Chan
210
 2007 Rat in 
vitro, 40 
min global 
I / 120 min 
R. 
Perfusion with 
rhEpo (5 U/ml) 
at 5 min before R 
until end of R. 
 IS,  LVDP  phosphorylation of 
JAK2, ERK,  expression 
of MMP-2 and 9.  IS 
dependent on ERK.  
Toma 
213
 
2007 Pig in vivo, 
60 min I / 
2 weeks R 
j
DA (30 g/kg) 
iv at R 
= IS,  peri-infarct fibrosis, 
 capillary density,  wall 
motion  
 
Baker
206
  2007 Rat in vivo, 
30 min I / 
2 h R 
DA (0.25-25 
g/kg) iv 15 min 
before I, 15 min 
before R, and 10 
s after R (optimal 
dose 2.5 g/kg) 
 IS for all time points of 
administration  
 phosphorylation of 
ERK1 and p38 MAPK, 
but not Akt 
 IS (given before I) 
dependent on ERK1/2 
and p38 MAPK, mito- 
and sarcKATP channels, 
but not PI3K 
Doue
207
 2008 Rat in vivo, 
20 min I/ 
90min R 
rhEpo (200U/kg) 
iv at reperfusion. 
rhEpo (200U/kg) 
iv just before 20 
mins I, 30mins 
R. 
apoptosis 
 
LVEDD and FS at 2 and 
4 weeks.  
 
Mudala
giri
215
 
2008 Human 
atrial 
trabeculae 
rhEpo (25, 50 
and 150 ng/ml). 
90 mins I, 
120mins R. 
Optimal dose of 
50 ng/ml at 
reoxygenation. 
contractile force 
 
caspase 3 activation 
Dependent on PI3K and 
ERK 1/2. 
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First 
author  
Date Model Treatment 
regime 
Key results Mechanistic insight 
Kobaya
shi
211
 
2008 Rabbit in 
vitro, 
30min 
I/120 min 
R 
Perfusion with 
rhEpo (1 U/ml) 
for 20mins until I 
 
 rhEpo (10 U/ml) 
25mins after I for 
65mins. 
IS, p-Akt in 
mitochondrial fraction. 
 
 
=IS 
Epo induces translocation 
of Akt to the 
mitochondria and protects 
when given pre-ischaemia 
 
Epo failed to protect at 
reperfusion 
 
Delayed administration of Epo after reperfusion 
Van 
der 
Meer
21
6
 
2005 Rat, 
permanent 
ligation 9 
weeks 
DA (40 g/kg) ip 
once at time of I 
(early), or every 3 
weeks, starting 3 
weeks after I (late) 
 IS (early), = mortality,  
LVDP (late),  LVEDP 
(both),  capillary density 
(both),   dP/dtmax (late) 
 
Moon
2
18
  
2005 Rat, 
permanent 
ligation 4 
weeks  
rhEpo (150 or 3000 
U/kg) iv 
immediately after 
start of I or 4, 8, 
12, and 24 h after 
onset of I 
 IS, = mortality,  
LVEDV,  LVESV,  EF, 
 apoptosis (at 24 h). 150 
and 3000 U/kg equally 
protective. 
3000 U/kg equally 
effective when given 4 ,8, 
or 12, but not 24 h after 
onset of I 
Hirata
219
 
2006 Dog, 
permanent 
ligation 4 
weeks 
rhEpo (1000 U/kg) 
iv at time of 
ligation (early) or 
after 6 h or 1 week 
(late) 
 IS (only early EPO),  
LVEF (early and 6 h),  
LVEDP (early and 6 h),  in 
circulating EPC‘s (early and 
6 h),  capillary density 
(early and 6 h) 
=VEGF 
Prunie
r
221
 
2007 Rat in 
vivo, 40 
min I / 8 
weeks R 
DA (1.5 μg/kg) ip 
once a week, 
starting 7 days after 
IR 
 IS, = mortality,  thinning 
of anterior wall,  dP/dtmax, 
 capillary density,  
circulating EPC‘s 
No increase in circulating 
EPC‘s by 0.75 μg/kg DA 
and no protective effects 
by this dose 
Gao
220
 
 
2007 Rat in 
vivo, 30 
min I / 72 
h R 
DA (30 μg/kg) at 
start of I, start of R, 
1 or 24 h after R 
 IS for all groups,  +/- 
dP/dtmax on isoproterenol,  
apoptosis (at 48 h)  
Significant for all time-
points of administration 
Weste
nbrink
217
  
2007 Rat, 
permanent 
ligation 9 
weeks 
DA (40 μg/kg) ip 
every 3 weeks, 
starting 3 weeks 
after LAD ligation 
= IS,  EF,  LVEDD,  
 LVEDP,  LVDP,  
dP/dtmax,  capillary density, 
 circulating EPC‘s. 
Homing of EPC‘s to LV 
wall  
 myocardial VEGF 
expression 
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First 
author  
Date Model Treatment 
regime 
Key results Mechanistic insight 
Kobay
ashi
223
 
2008 Rabbit in 
vivo, 30 
mins I, 2 
days, 14 
days and 2 
mths R. 
rhEpo (1,500 
U/Kg) sc given at 
reperfusion and 
daily for 5 days. 
 
Epo DDS
k
 applied 
to heart just after 
reperfusion 
=IS between systemic Epo 
and control. =EF/FS 
 
 
=IS at day 2, IS, ↑EF/FS at 
14 days and 2mths 
EpoDDS had no systemic 
effects on haematocrit. 
Day 2:↑EpoR, pAkt, 
pGSK-3β, pStat3, pErk, 
ProMMP-1, VEGF, Bcl-
2, =Bcl-XL. 
Day 14: ↑EpoR, pAkt, 
pErk,ProMMP-1, 
=VEGF, Bcl-2, Bcl-XL, 
pStat3, pGSK-3β. 
Prunie
r
224
 
2009 Rat in vivo, 
40mins I 
and 8 
weeks R 
DA 5000 U/kg ip 
at reperfusion 
DA 5000U/kg ip at 
reperfusion then 
300U/kg ip once 
per week 
↓IS 
 
↓IS, =incidence of thrombus 
No increased 
thrombogenicity of 
chronic Epo in this 
setting. 
a
When EPO was given before ischaemia as well as at reperfusion, the study is classified 
under ―Administration of EPO at reperfusion‖; when EPO was given before reperfusion as 
well as delayed after reperfusion, the study is classified under ―Delayed administration of 
EPO after reperfusion‖. bischaemia; creperfusion; dLV developed pressure; einfarct size; fLV 
end diastolic dimension;
 g
LV end systolic dimension; 
h
ejection fraction; 
i
LV end diastolic 
pressure;
 j
darbepoetin, 
k
drug delivery system 
 
Summary 
 
As demonstrated above, there is a wealth of evidence in small animal models (and one human 
tissue model
215
) of I/R that Epo can provide significant cardioprotection when administered at 
a number of time points either prior to ischaemia, after the onset of ischaemia, at reperfusion 
and at delayed time points often several days after reperfusion. This has produced a great 
expectation that this cardioprotection may be realised in the clinical setting. Tempering this 
hope however are the results from the experiments performed in larger mammals; these tend 
to be closed chest, catheter based, coronary artery occlusion techniques which appear to 
represent the clinical environment of either elective or emergency coronary artery 
intervention more closely than the external compression/ligation used in smaller animals. 
Page 81 of 236 
 
Although the number of studies is small (3), a benefit in infarct size reduction has not yet 
been seen and there are mixed results regarding the later myocardial remodelling effects. The 
reason behind the failure to protect in larger mammals is not known. The incidence of 
arrhythmia during these experiments is quite high, but equal between the groups and thus is 
unlikely to introduce bias. The anti-arrhythmic medications used have been suggested as 
interfering with the protection, or perhaps a difference in the collateral circulation in these 
species is present, but no definite reason has been established and if these reasons are correct 
then it would make the translation of rhEpo as a cardioprotective agent to the human clinical 
setting rather challenging
208 214 
. 
Despite mixed sentiments in terms of the potential translation to the clinical arena, all the 
studies described above have provided important insights in to the potential mechanisms of 
protection of Epo and these shall be described in the next section. 
 
Potential mechanisms of cardioprotection by Epo 
 
Epo has been reported to have a number of different beneficial actions which together 
contribute to its overall cardioprotection. These are its ability to reduce the inflammatory 
reaction, the formation of new myocardial blood supply, improved myocardial remodelling 
and a potent anti-apoptotic effect.  
Anti-inflammatory effects 
 
Myocardial ischaemia and infarction are potent inductors of inflammatory conditions within 
the affected area
225
 particularly due to cellular necrosis, and as such, a reduction in 
inflammation has been suggested as a possible means of reducing injury and deleterious 
remodelling. However, it is not well established whether reduction in markers of 
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inflammation causes a reduction in cell death or is due to a reduction in cell death from an 
alternative protective mechanism. Epo does demonstrate an anti-inflammatory effect with a 
number of studies reporting cardioprotection by this mechanism
191 226
. This is unlikely to be 
the predominant cause of cardioprotection as studies performed in isolated cell lines and 
isolated heart models are removed from any immune interaction and yet cardioprotection is 
still demonstrated. It has been argued however that Epo may prevent the myocyte adopting 
‗an inflammatory phenotype‘ which can occur despite removal from the immune system and 
be cardioprotective, with this effect being mediated via PI3K
226 227
. 
Neovascularisation and the prevention of adverse myocardial remodelling 
 
Following a myocardial infarction, neoangiogenesis is an integral part of the remodelling 
process but the capillary network is unable to support the greater demands of the myocardium 
resulting in progressive loss of tissue, infarct extension and fibrous replacement. The ability 
to directly induce new blood vessel formation in the infarct bed (vasculogenesis) and 
proliferation of existing vasculature (angiogenesis) has been shown to decrease myocyte 
apoptosis, increase viable myocardium and produce a sustained functional recovery
228
. In this 
regard, Epo has demonstrated that it can induce significant increase in vascular endothelial 
growth factor (VEGF)
217 223 
, mobilise and improve the homing of endothelial progenitor 
cells
217 219
, reduce peri infarct fibrosis
213
 and result in an increased capillary density seen at 
varying time points post infarction
216 217
. 
Anti-apoptotic actions 
 
As previously described, the myocyte death caused from I/R injury is a combination of 
necrosis and apoptosis with a significant contribution coming from apoptosis
229
 and with 
apoptosis continuing to occur late in to reperfusion (72hrs) whereas necrosis has peaked by 
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24 hours
230
. This would suggest that interventions, including Epo, directed at inhibiting 
apoptosis would be expected to have an effect some hours after I/R, which has indeed been 
demonstrated by the studies discussed above. Epo in its haemopoeitic role increases red cell 
mass by preventing apoptosis in erythroid progenitor cells
182
, it also prevents neuronal 
apoptosis
231
, and thus this action could be suggested to account for much of its 
cardioprotective effect as well. 
Cell survival signalling and Epo 
 
Epo is able to act directly at the level of the cardiomyocyte as demonstrated by a number of 
experiments in isolated cell lines
186-188 232 
. The majority of its haematopoietic actions are 
mediated via the classical EpoR which has been demonstrated in the human heart
233
, but the 
existence of a common β subunit heteroreceptor has also been demonstrated and is thought to 
mediate the direct cellular protective effects
234
 (although protective effects not requiring the β 
subunit have been demonstrated with darbepoietin
235
) . This is evidenced by the fact that 
engineered analogues of Epo which do not activate the classical Epo R and demonstrate no 
haematopoietic effects are still able to activate tissue protection from I/R through their action 
at the β subunit232 236 237 .  
Following interaction with its membrane bound receptor, Epo activates a number of 
intracellular survival pathways.  
Epo and the Reperfusion Injury Salvage Kinase (RISK) Pathway 
 
As described previously the RISK pathway (figure 1) appears pivotal to cardioprotection 
induced particularly at reperfusion
46
. Epo activates this pathway with phosphorylation of 
MEK1/2- PI3k-Akt-Erk1/2 demonstrated in isolated cells
186 187
, ex-vivo
189
 and in-vivo
187 237 
 
models although protection is thought to rely more heavily on Akt as targeted blockade 
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abrogates protection whereas blockade of Erk does not
195
. The end result is an inhibition of 
the opening of the mPTP via activation of eNOS, GC and PKC-ε and opening of 
mitochondrial KATP channels
200 202 203
. An increase in the threshold of mPTP by Epo has been 
shown to limit apoptosis
238
. 
The JAK-Stat pathway 
 
Once JAK1/2 are activated
200 239
, these in turn activate STAT-3
203
 and STAT-5
204
 (but not 
STAT-1α or STAT-5b239) which will eventually increase transcription of eNOS and COX-2, 
both of which have infarct limiting roles
192 194
. 
Alternative Akt mediated effects 
 
Epo can induce translocation of Akt to the mitochondria and phosphorylate GSK-3β211 
(which is thought to occur at the serine 9 position
222
) and directly inhibit mPTP opening. 
pGSK -3β may also prevent cell death via inhibiting access of Bcl-2 associated X protein 
(BAX) to the mitochondria and inhibiting its pro-apoptotic effects
222
. 
The application of Epo as a human cardioprotective agent 
 
Steps in this direction were stimulated following the demonstration that Epo may provide 
neuroprotection following acute stroke
240
. In the efficacy arm of this study 40 patients were 
randomised to rhEpo-β (33,000U) administered within 5 hours of symptom onset and for 2 
days following this or placebo. Functional outcome was significantly improved at 1 month 
and there was a non significant trend to infarct size reduction as measured by MRI. As a 
translational step Yellon‘s group have used a unique human atrial trabeculae model to 
demonstrate that Epo is cardioprotective against I/R when infused at reperfusion
215
. 
Increasing evidence was added by Namiuchi et al.
241
 who demonstrated that in 101 patients 
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with STEMI presenting for PPCI, those with higher endogenous serum Epo levels were likely 
to have smaller myocardial infarct sizes as measured by peak and total CK release, although 
the Epo level was not an independent predictor of infarct size. Serum Epo levels have also 
been examined in 67 patients undergoing cardiac surgery using cardiopulmonary bypass. 
Serum Epo levels were measured preoperatively and cardiac Troponin I measured over the 3 
post-operative days was used as a correlate of myocardial injury but no relationship was 
found
242
. 
Epo as an adjunctive treatment to current management of acute coronary syndromes 
 
In 2006 Lipsic et al.
243
 published a small safety and efficacy study examining the potential 
cardioprotective effect of darbepoietin in STEMI. 22 patients were randomised to 300U of 
darbepoietin plus standard care or standard care alone prior to undergoing primary 
percutaneous coronary angioplasty. There was no difference in adverse events between the 
groups and no difference in EF at 4 months. There was a significant increase in endothelial 
progenitor cells in the treated group. Interestingly there was a non-significant trend to harm in 
the Epo group in the measured peak CK (1077 vs 487 U/L, p=0.22) and CK-MB (101 vs 47 
U/L, p= 0.09). 
In the setting of NSTEMI the cardioprotective effects of Epo have also been investigated. 51 
patients were randomised to 40,000 U of rhEpo-α or placebo within 8 hours of a positive 
Troponin I result (>0.2 µg/l). No significant difference was shown in any cardiac enzyme and 
over the 18mths follow up there was no difference in major adverse cardiac events. The 
authors did note a significant increase in BP 2-4 hours following Epo administration but it 
was not reported whether this was transient or a longstanding phenomenon
244
. The timing of 
the Epo administration in this study is difficult to gauge. Patients must already have had 
significant myocardial injury in order to be included in the study and inclusion was timed 
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from the knowledge of the Troponin result rather than from symptom onset. Although Epo in 
experimental models can afford protection late in to reperfusion, protection was more reliable 
and larger with administration time points up to and including reperfusion (see table 7), 
suggesting that future studies would be advised to study Epo before or at reperfusion. 
Following this a paper presented at the 2009 ACC has investigated the role of Epo in patients 
with STEMI undergoing PPCI. The Regeneration of Vital Myocardium in ST-Segment 
Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) randomised 138 patients to 
33,000units rhEpo-β just after the first balloon inflation and then at 24 and 48 hours 
following this or placebo. The study failed to show any difference in the primary endpoint 
which was MRI assessed LVEF at 6 months or in the main secondary end point of infarct 
size. The authors did highlight a non-significant trend to harm in the Epo group in the MACE 
rate at 6 months although as yet there is no further explanation (Ott, 2009 Unpublished). 
Subsequently, four small studies have examined EPO as an adjunct to reperfusion therapy in 
STEMI. Binbrek et al.
245
 administered 30,000units of rhEpo-β to 236 patients prior to 
thrombolysis for STEMI and were unable to show any difference in myocardial infarct size as 
measured by CK-MB release. Ozawa et al.
246
 administered 12,000units of rhEpo-β to 41 
patients within 24 hours of successful PPCI and demonstrated an improved LVEF within the 
EPO group over 6 months (from 51.0±19.6% to 58.5± 15.0%, P=0.0238), but not in the 
control group (from 47.2± 16.2% to 51.3±18.2%, P=0.2292) but this was not significant 
between EPO and placebo and there was no difference in infarct size (SPECT) or MACE.  
Suh et al.
247
 administered 50U/kg of rh-Epo-α to 57 patients just prior to PPCI for LAD 
territory STEMI. The low Epo dose was chosen in an attempt to prevent side effects from 
Epo use. Suh et al. were unable to demonstrate any difference in enzymatic infarct size, CMR 
parameters or MACE rates over 6 months, potentially due to the low dose Epo used which is 
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substantially lower than that used in pre-clinical studies.  Ferrario et al.
248
 recruited 30 
patients with STEMI undergoing PPCI and randomised to 33,000units of rhEpo-β just prior 
to reperfusion and at 24 and 48 hours or placebo. The Epo group had increased numbers of 
CD34+ endothelial progenitor cells and gene expression was shifted towards anti-apoptotic, 
anti-inflammatory and anti-atherosclerotic up regulation. There was reduced CK-MB (AUC) 
over 120 hours but no difference in infarct size by CMR acutely and at 6 months. There was a 
reduced LVESV in the Epo group and improved regional wall thickening in the infarct 
territory, which has been suggested as improved LV remodelling in this group. 
In summary, a number of studies have examined Epo use in STEMI with a variety of 
protocols varying in Epo dose, timing of administration, patient type and end-points assessed. 
Results have not been consistent. The animal data would suggest that higher acute dosing 
prior to reperfusion is more likely to be beneficial and there is a need for studies with this in 
mind to further clarify the effects of Epo in STEMI. 
Table 8: Overview of all clinical studies investigating the cardioprotective effect of EPO in 
patients with acute coronary syndromes or myocardial ischaemia-reperfusion injury 
First author, 
year of 
publication 
Design Type of patients 
(n) 
Intervention Follow 
up 
Outcome 
      
Lipsic
243
, 
2006 
Randomised, 
open-label 
a
STEMI, referred 
for PCI (n=20) 
DA (300 μg) iv 
before PCI 
4 mo = peak 
b
CK, = LVEF at 
4 mo,  circulating 
EPC‘s at 72 h. 
Liem
244
, 2007 Randomised, 
placebo-
controlled  
nonSTEMI 
(n=51) 
rhEpo-α (40,000 
U) iv within 8 h 
of presentation  
18 mths = peak CK/peak 
troponin I, = 
cumulative CK, = 
event rate at 18mths 
Note: increase in 
c
SBP 
2-4 h after 
administration 
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First author, 
year of 
publication 
Design Type of patients 
(n) 
Intervention Follow 
up 
Outcome 
Mocini
242
, 
2008 
Randomised, 
open-label 
CABG
d
 and 
CVS
e
 (n=67) 
 
CABG (n=40) 
Measurement of 
Epo 
 
rhEpo-α (40,000 
U)iv immediately 
pre-op 
3 days No correlation between 
serum Epo levels and 
post-op Trop-I or CK-
MB. 
=Trop-I and CK-MB 
post-op. 
Ott, 2009 
(unpublished)  
Randomised, 
double blind, 
placebo 
controlled 
STEMI treated 
by PPCI (n=138) 
rhEpo-β 
(33,000U) iv at 
first balloon 
inflation and 24 
and 48 hours 
following. 
6 
months. 
No difference in MRI 
measured EF or infarct 
size. 
Binbrek, 
2009
245
 
Randomised, 
open label 
STEMI treated 
with 
thrombolysis 
(n=236) 
rhEpo-β 
(33,000U) iv just 
prior to 
thrombolysis. 
30 days No difference in 
enzymatic infarct size 
(CK-MB), 
echocardiographic 
measures or MACE. 
Ferrario, 
2009
248
 
Randomised, 
placebo 
controlled, 
double blind. 
STEMI treated 
with PPCI 
(n=30). 
rhEpo-β 
(33,000U) prior 
to reperfusion, 24 
and 48 hours. 
12 
months. 
CD34+ cells at 72hrs, 
NFkB, VEGFR-2, 
EPO-R and AKT gene 
genes from 24 to 72 h. 
 TP53, CASP3, IL12a 
genes. CK-MB 
(AUC). LVESV. 
infarct regional wall 
thickening. 
Suh, 2010
247
 Randomised, 
open label, 
placebo 
controlled 
STEMI (LAD 
only) treated with 
PPCI (n=57) 
rhEpo-α 
(50U/kg) just 
prior to 
reperfusion 
6 
months 
No difference in CK-
MB, MRI parameters 
or MACE. 
Ozawa, 
2010
246
 
Randomised, 
single blind, 
placebo 
controlled 
STEMI treated 
with PPCI (n=41) 
rhEpo-β 
(12,000U) within 
24hours after 
reperfusion 
6 
months 
No difference in 
CD34+ cells, infarct 
size (SPECT) or 
coronary artery luminal 
diameter. EF in EPO 
group. 
a
ST elevation myocardial infarction, 
b
creatine kinase, 
c
systolic blood pressure, 
d
coronary 
artery bypass surgery, 
e
cardiac valve surgery 
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Epo and cardiac surgery  
 
As previously discussed, cardiac surgery using cardiopulmonary bypass represents another 
clinical setting where the heart is injured through ischaemia and reperfusion. Epo was 
initially used in this setting for its haematopoietic effects, generally with relatively long term 
dosing regimes in order try and limit peri-operative blood transfusion
249
. Although markers of 
cardiac injury were not routinely measured, adverse events were recorded and no significant 
difference in any type of event was reported. There was an increase in post-operative death in 
the Epo treated group but on review this was felt not to be treatment related. Further 
mechanistic studies in humans post-cardiac surgery have not found an increase in clotting 
risk with repeated dosing and so has been reported as safe in this setting
250
. Recently Mocini 
et al. have investigated whether 40,000 U rhEpo or placebo administered in the immediate 
pre-operative period can protect against the I/R injury sustained. 40 patients undergoing 
elective CABG were randomised and Troponin I and CK-MB were measured over the 3 post-
operative days as the primary outcome. No difference was found in peak cardiac enzyme 
levels (Trop-I 1.7±1.8 vs 2.6±3.4, p>0.05 and CK-MB 19.6±13.2 vs 17.1±12.6) although it 
was not stated exactly when the peak level occurred and the authors did not have enough data 
at day 3 in order to plot a summary time course measure such as the area under the curve
242
.  
Epo during resuscitation 
 
Cardiac arrest and subsequent resuscitation can be seen as another situation where the heart 
(as well as the whole body) is subjected to first ischaemia and then reperfusion. An 
interesting experiment in a rat model has shown improved cardiac function in rats 
resuscitated from ventricular fibrillation with concomitant administration of 5000 U/kg of 
rhEpo
251
. Although this has been tested from a neurological stand point in humans with 
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benefit
252
, the potential cardioprotective role has not been established and would be a further 
avenue of study. 
 
Potential barriers to the translation of Epo as a cardioprotective agent in humans 
 
The use of rhEpo to treat anaemia (mainly in the setting of renal failure) is well established 
but the extent to which Hb is normalised appears to correlate to increased mortality, 
particularly in those with IHD and CCF
253
. Meta-analysis of studies in this population has 
raised the prospect of increased risk of uncontrolled hypertension and thrombotic 
complications
254
. Therefore care must be taken prior to using Epo as a therapeutic agent in 
cardiovascular I/R injury because both hypertension and thrombosis would have the potential 
to cause particular harm in this group.   There are however strategies which can mitigate this 
risk in order to allow the safer use of Epo. 
As shown in Table 7 a significant number of animal experiments have demonstrated that 
cardioprotection can be achieved in most species with a single dose of Epo, which is unlikely 
to have significant effects on haematocrit or other long term actions. In dogs, 
cardioprotection was achieved with a dose as low as 100 U/kg
212
 and as such, finding a dose 
response effect for cardioprotection in humans would assist in keeping the exposure to rhEpo 
as low as possible. One could envisage the use of 1-3 doses around the time of I/R injury for 
cardioprotective effects without extended dosing. Concomitant use of prophylactic heparin in 
a cohort of patients receiving Epo and undergoing cardiac surgery was safe and ensured no 
difference in complications between groups and no difference in platelet reactivity
250
. A 
recent study in rats treated with DA in a model of I/R and subsequently subjected to a 
thrombogenic stimulus found no increase in venous thrombosis
224
. 
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Particularly of concern to interventional cardiologists is the interaction of Epo with the 
antiplatelet effects of aspirin and clopidogrel which are so crucial for maintaining coronary 
artery stent patency. Tang et al.
255
 investigated the effects of differing rhEpo doses on the 
individual anti-platelet effects of aspirin and clopidogrel. With doses up to 200 U/kg no effect 
was found. With the 400 U/kg dose the post aspirin prolongation in bleeding time was 
significantly blunted although there was no effect on clopidogrel. Unfortunately the effect on 
the combination of aspirin and clopidogrel or in addition to other antiplatelet agents such as 
the glycoprotein IIb/IIIa inhibitors was not explored. Therefore although these results should 
be borne in mind when considering studies of rhEpo in cardiology patients taking aspirin and 
clopidogrel, it is likely that the combination of antiplatelet agents and anticoagulants used 
would diminish any adverse effects. This does however warrant further study. 
Alternative possibilities to traditional rhEpo exist; carbamylated rhEpo does not interact with 
the classical EpoR and therefore does not have haematopoetic effects but is able to exert 
tissue protective effects via the common β subunit256 and has been shown to retain 
cardioprotective benefits with no change in haematocrit
238 257 
. 
Epo may also be able to exert beneficial actions if administered locally rather than 
systemically. A novel gelatin based drug delivery system applied to the epicardial surface of 
the infarcted myocardium which released rhEpo over time, was found to reduce infarct size 
and increase EF at 14 days in a rat model of I/R with no effects on haematocrit
223
. Although 
not tested in humans, this system could be envisaged to have a role in cardioprotection during 
cardiac surgery. 
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Conclusion 
 
The cardioprotective benefits of Epo have been extensively demonstrated in experimental 
models of I/R injury. The benefits have yet to be realised in the clinical setting although a 
number of studies appear to have been conducted safely in different patient groups. There are 
a number of ongoing studies around the world continuing to address this issue and it will be 
interesting to see how these results compare. 
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Evaluation of cardioprotection in the clinical setting 
 
In order to be able to measure cardioprotection one must first be able to detect cardiac 
ischaemia and injury. In the clinical setting myocardial injury is commonly assessed using 
biochemical tests, by assessing the electrical activity in the heart using an electrocardiogram 
(ECG) and by assessing LV or RV myocardial function using either non-invasive imaging 
(echocardiography or MRI) or with invasive angiography less commonly. Therefore the 
ability to limit the extent of abnormality in any measurement of cardiac injury can be used as 
a measure of cardioprotection.  
Biochemical markers of cardiac injury 
 
The measurement of cardiac injury in the clinical setting is routinely made using biochemical 
markers of myocyte injury. The most commonly used cardiac enzymes currently are 
Troponin-T/I and the myocardial band of creatine kinase (CK-MB). Elevation of these serum 
markers allows confirmation of the diagnosis of myocardial injury and enables judgements to 
be made as to optimal management. There is a proportionality to the cardiac enzyme rise in 
that the greater the rise the greater the myocardial damage
258
 and different cardiac enzymes 
will be elevated at different time points following ischaemia (figure 4), however cardiac 
enzyme rise alone is not usually enough evidence to make a diagnosis as sometimes non-
cardiac conditions may cause a rise. 
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Figure 4: Time course of the appearance of cardiac biomarkers in the blood after acute 
myocardial infarction (AMI). [CV: coefficient of variation]. (Adapted from
259
). 
 
 
 
Electrocardiography 
 
The electrocardiogram (ECG) is a common clinical tool. Abnormalities in the ECG trace are 
able to either hint at or give the diagnosis of myocardial ischaemia and the coronary artery or 
myocardial territory involved may be identified. Particularly in the case of ST segment shifts, 
where elevation suggests sudden acute ischaemia, the resolution of the ST segment shift can 
be used as a surrogate marker of cardioprotection. In that the protected myocardium subjected 
to ischaemia is less likely to cause such a rise in the ST segment
260
.  
Functional measures 
 
Imaging techniques (either invasive or non-invasive) are able to measure either regional or 
global myocardial wall function. Long term outcomes become progressively worse with 
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reducing global LV/ RV functions and as such cardioprotective interventions which prevent 
myocyte death can be assessed on their ability to preserve LV or RV function and if 
successful may be expected to then improve longer term outcomes. Therefore LV function is 
commonly used as a surrogate measure of cardioprotection in studies. 
Comparing cardioprotection between individuals 
 
All surrogate markers of myocardial injury and cardioprotection need to be assessed for each 
individual in a clinical study and then compared across the study groups. No individual is 
identical and there is a need to normalise the relative success of cardioprotection in order to 
be able to interpret the findings. As such the measurement of the myocardial Area At Risk is 
important and shall be described below. 
Clinical myocardial area at risk assessment 
 
What is the area at risk? 
 
The myocardial area at risk (AAR) is the proportion of the myocardium jeopardised when the 
artery or arteries supplying this area are occluded
261
. If no reperfusion were to occur then the 
AAR would represent the maximal area of myocardial damage. When first described by 
Lowe et al. it was shown that for a given ischaemic time the eventual myocardial necrosis 
correlates to the AAR in animal models of I/R
261
 and humans
262
.  
Why do we need to measure the AAR? 
 
Following coronary artery occlusion, whether in experimental animal models or acute 
myocardial infarction in humans, myocardial injury starts. The progression of this injury is 
described as the ‗wavefront phenomenon‘ as the cell death proceeds as a wave from 
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endocardial to epicardial sufaces
263
. Early on in the ischaemic time the lateral extents of 
myocardial necrosis are established on the endocardial border and do not extend. As the 
ischaemic time progresses the myocardial injury traverses towards the epicardium within the 
myocardial AAR
264. However, if prior to maximal ‗transmural‘ myocardial infarction 
reperfusion takes place (by whatever means) or other adjunctive therapies are initiated, then 
the wavefront progression of cell death may be halted and so ‗salvaging‘ myocardium from 
the initial AAR
265 266 
. The amount of myocardium salvaged is dependent on a number of 
factors but particularly the ischaemic time
267
, presence of collateral circulation
268
 and the 
adequacy of the restored perfusion
269
.   
When conducting studies on an intervention designed to limit myocardial injury it is possible 
to assess myocardial salvage in groups of patients via surrogate end points such as LV 
ejection fraction or cardiac enzyme release but by measuring the AAR in each individual and 
then comparing this to a more direct measure of eventual infarct size it is possible to gauge a 
much more accurate estimation of the effect of the trial intervention. In this way it is possible 
to control between individuals for variations in anatomy and the initial AAR, and assess 
confounding factors. Thus measurement of the eventual infarct size in relation to the AAR is 
a very attractive strategy for researchers and clinicians alike. 
Techniques to measure the myocardial area at risk in the clinical setting 
 
The measurement of the AAR has been continually evolving since its first description in 
1978
261
. In the majority of animal experiments this is fairly straightforward as the perfused 
heart can be stained or marked in a number of ways and sectioned to allow accurate 
quantification of viable and infarcted areas. Besides post-mortem examination techniques it is 
not possible to measure the AAR in humans in such a direct way and so a variety of 
techniques are used as surrogates. These are broadly divided by the imaging modality they 
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rely on and have different strengths and weaknesses. The main modalities used include 
coronary and LV angiography, metabolic imaging methods, echocardiography, nuclear 
imaging and magnetic resonance imaging (MRI). In the following section the different 
methods will be briefly described with greater emphasis on two very utile angiographic 
methods and the emerging role of cardiac MRI in this field.   
Angiographic methods for estimating the myocardial AAR 
 
Coronary angiography 
 
The use of coronary artery angiography and LV catheterisation is standard within cardiology. 
The need to be able to record the findings, standardise the report and explain the results to 
others led to the development of systems of scoring and describing abnormalities found such 
as that developed in 1977 at the Green Lane Hospital in Auckland
270
. Since that time a 
number of different coronary artery scoring systems have been described with their initial 
aim being to describe the total amount of myocardium at jeopardy from coronary artery 
disease and then to use this assessment to study and guide successful reperfusion strategies
271-
273
. Despite slightly different methodologies between the systems the basic tenets remain the 
same. A score is attributed to a diseased artery in proportion to the size of the myocardial area 
at jeopardy that it supplies; in general a higher score correlates with, a higher burden of 
coronary atherosclerosis
272
, a higher likelihood of ischaemic cardiomyopathy
271
  and a worse 
prognosis
274
. By expressing the score for the area in jeopardy as a percentage of the score for 
the whole left ventricle a value for the proportion of the LV at risk is obtained, and therefore 
it is possible to compare groups of patients by controlling for the initial percentage of AAR. 
(See chapter 4 for the method and use of two angiographic risk scores). 
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LV angiography 
 
Biplanar left ventriculography has been used for over 40 years as a method of measuring 
ventricular volumes
275
. By extending this method and assuming that any myocardium at risk 
during an acute MI does not contract normally then the LV myocardial area at risk can be 
estimated by assessing the proportion of abnormally contracting myocardium against that 
contracting normally. Whilst this technique has the advantages that it can be performed with 
the standard catheter laboratory equipment, is relatively quick and easy to do and the analysis 
can be done ‗off line‘ retrospectively, it has been overtaken as a standard technique mainly 
because it has fairly high inter and intra observer variability
276
 and performs poorly alongside 
newer techniques such as single photon emission computed tomography (SPECT) imaging
277
 
(see below). 
Echocardiographic techniques 
 
Echocardiography is an ultrasound technique which is well established for structural and 
functional imaging of the heart as it is safe, portable and can often be performed quickly. Its 
use in the clinical setting of acute MI to measure the myocardial AAR is less well 
established. Whilst it is possible to examine the regional wall motion of the LV, divide it in to 
segments and describe this to others, it does not really give a figure which is comparable 
between patients. The use of wall motion alone to evaluate AAR was found not to be 
particularly reliable as during acute MI, wall motion relies on other factors including volume 
and pressure loading conditions at the time
278
. However, the use of contrast agents to help 
examine perfusion of the myocardium has been much more promising. Initial animal 
experiments showed that in a canine model of coronary artery occlusion, contrast using 
hydrogen peroxide could allow echocardiography to delineate the non-perfused myocardium 
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and so the AAR at varying points through the heart could be assessed and that this correlated 
well with pathological comparison
279
. This technique has been extended to human use with 
the development of non-toxic contrast agents and has been well validated to a certain 
extent
280
. It has not however become a technique of choice because in the acute situation re-
establishing coronary artery patency is the priority and there is little time to spend trying to 
get optimal echocardiographic views that can be interpreted ‗offline‘ later and at present there 
is no echocardiographic technique to retrospectively establish the initial AAR. In this regard 
contrast echocardiography still has a role to play in evaluating myocardial microvascular 
perfusion but generally after the acute situation
280
. 
Nuclear Imaging Techniques 
 
Nuclear imaging is commonly used to identify perfusion defects in the myocardium. Similar 
techniques can delineate the AAR. By injecting the radioactive isotope intravenously 
(commonly technetium or thallium or both) prior to reperfusion the area of myocardium 
affected will not take up tracer. Thus, when imaged with single photon emission computed 
tomography (SPECT) following reperfusion the resultant defect correlates well to the 
AAR
281
. A subsequent pre-discharge perfusion scan shows the size of the resultant infarct and 
therefore myocardial salvage can be calculated. Although this technique has been used with 
success it is logistically difficult as the radioactive isotope has a half life of 6 hours and there 
must always be a supply on hand in order to inject acutely prior to reperfusion in acute MI. 
The perfusion imaging must be done within 8 hours of the acute infarct and the isotope 
handled within radiation safety guidelines. 
An alternative method which enables a longer time frame for imaging following MI is the use 
of 
123
I-labeled 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) which is an 
imaging radiopharmaceutical, which reflects fatty acid metabolism. BMIPP can be injected 
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even after reperfusion in acute MI, and it is possible to image the AAR, due to a lag in the 
recovery of fatty acid metabolism, up to 2 weeks following reperfusion
282
. This technique 
compares favourably with SPECT and does not have the disadvantages in terms of the short 
time frames needed but has yet to be adopted widely. One study has compared T2 MRI 
imaging (see later) to BMIPP for identification of acute myocardial injury and found greater 
accuracy with MRI
283
 although no comparison has been made in imaging the AAR as yet. 
Glucose metabolism is also deranged following acute MI and so the positron emission tracer, 
19
F-fluorodeoxyglucose has also been used to assess myocardial viability but has not been 
investigated in terms of AAR
284
. It has been suggested that further studies comparing 
metabolic imaging to MRI would be of interest
285
. 
Magnetic Resonance Imaging techniques 
 
Cardiac MRI is rapidly evolving and finding increasing application, particularly with 
myocardial tissue characterisation. Two techniques are currently used to measure the 
myocardial AAR; the ‗Endocardial Surface Area‘ measurement and T2 oedema imaging. 
These shall be described more fully in the next section. 
Cardiac magnetic resonance (CMR) imaging 
 
Theoretical Basis 
 
At its most basic, magnetic resonance imaging involves placing the patient within a 
homogenous magnetic field (currently 1.5T) and applying radiofrequency pulses. A signal is 
generated from the release of energy of excited protons which is measurable and 
subsequently transformable in to a recognisable image. Different tissues have different rates 
at which the protons ‗relax‘ or tend towards their original state, T1, T2 and T2*. By utilising 
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these different properties it is possible to use a variety of sequences which allow excellent 
tissue discrimination and tissue characterisation
286
. Application of MRI to the rapidly moving 
heart within the slowly moving chest was initially very challenging but advancements in 
technology and a number of techniques including ECG gating and repeated patient breath 
holding allows acquisition of optimal images. 
Assessment of cardiac function 
 
MRI is not constrained by anatomical ‗imaging windows‘ such as those needed for 
echocardiography and so images can be obtained in any desired plane or orientation. This 
gives a great flexibility to tailor the examination to the patient. However there are number of 
images which are acquired almost as standard in order to describe and if necessary quantify 
LV or RV function.  
Following initial ‗scout‘ images a sequence of transverse slices through the chest are made to 
evaluate gross anatomy and cardiac position/axis. Cine images can then be taken in long and 
short axis to allow the acquisition of a traditional ‗four chamber‘ view of the heart. Following 
this multiple cine image slices in short axis along the length of the ventricles from base (level 
of mitral and tricuspid valves) to apex allows a very accurate impression of LV/RV function 
to be made. A description of LV/RV function can not only be made in terms of broad overall 
ejection fraction but also in respect to individual regions, longitudinal function and the timing 
of contraction. 
One of the great advantages of MRI is that beyond a narrative description of the ventricular 
function it is possible to measure with great accuracy and limited variability, end-diastolic, 
end-systolic and myocardial volume and from these calculate stroke volume, ejection fraction 
and myocardial mass
287. In order to do this computer software is used to draw a ‗region of 
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interest‘ (ROI), either manually or by predetermined signalling threshold methods, around the 
endocardial border at end-diastole and end-systole and a further ROI is drawn around the 
epicardial border (either at end-systole or diastole). Knowing the slice thickness allows one to 
calculate the stroke volume from the difference between total end-diastolic volume and total 
end-systolic volume and similarly the myocardial volume (and subsequently mass, using a 
conversion factor) can be calculated. 
Thus accurate measurements can be made and importantly, because of the high 
reproducibility described above, changes over time can be reliably estimated. As there is no 
radiation involved, repeated scans do not pose a risk, which is particularly relevant in 
children with congenital heart disease who may require repeated scans over many years. 
Tissue characterisation 
 
By making use of the different behaviours of different tissues within the magnetic field 
judgements can be made about the composition and comparison to histological samples. By 
adding a contrast agent such as gadolinium which accumulates in the extra-cellular space and 
imaging at different time points post-administration, further information can be gleaned about 
myocardial perfusion, microvascular patency, extent of infarcted tissue and potential viability 
and the MRI data correlates well with known clinical parameters such as cardiac enzyme 
release
288
 (see below for more detailed description of contrast enhanced imaging). 
The use of cardiac MRI following acute myocardial infarction 
 
In the very acute stages of myocardial function MRI currently has a limited role because of 
the pressing time issues and concerns over prompt reperfusion and patient safety. Although in 
cases of diagnostic uncertainty MRI has been suggested as a superior method to ECG, 
Troponin and TIMI risk score in discriminating cases of acute coronary syndrome
289
. 
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However, in the days following acute MI valuable information can be gained which will 
guide clinical therapy and give researchers detailed information regarding cardioprotective 
techniques and whether these have provided a benefit or not. 
LV remodelling 
 
As described above accurate measurements of the LV/RV volumes and myocardial mass can 
be made. Following acute myocardial infarction, remodelling of the myocardium takes place 
to a greater or lesser extent in all people. Repeated scans enable these changes to be 
accurately mapped over time. 
Perfusion 
 
The rapid acquisition of images in the short axis plane, generally at 3 positions along the LV, 
whilst contrast is being injected, allows an assessment of myocardial perfusion. Normally this 
can be done at rest and stress (with exercise or pharmacological agent) to assess an inducible 
perfusion defect. In the short time following an acute MI it is inadvisable to subject the 
patient to a stress perfusion scan however rest images can easily be obtained. MRI can be 
used at an interval to assess the functional effect of any residual coronary stenosis noted on 
angiography. 
Microvascular Obstruction 
 
Imaging in the ‗early‘ period following contrast administration enables visualisation of any 
microvascular obstruction (MVO) present from the acute myocardial infarction and is the 
optimal method of detecting intraventricular thrombus.  
MVO is the result of injury sustained to the microvasculature during the period of ischaemia 
and reperfusion. MVO may occur despite adequate epicardial coronary artery 
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revascularisation and it is thought to result in the angiographic phenomenon of ‗slow‘ or ‗no 
reflow‘290. MVO is caused by a number of factors including distal embolisation, 
microvascular inflammation and disruption and the activation of vasoactive mediators
291
 and 
is thought to predominantly represent myocardial haemorrhage from red blood cell 
extravasation in to the extra-cellular space. The presence of MVO and myocardial 
haemorrhage has been shown to correlate to larger infarct size, increased adverse remodelling 
and reduced LV function over time following acute myocardial infarction
292 293
. Optimal 
reperfusion should aim to restore micro as well as macrovascular flow and as such is a target 
for improvements in therapy. Measurement with MRI allows accurate assessment of 
strategies aimed at reducing MVO. 
Infarct size 
 
Imaging in the ‗late‘ period (10-15 mins) following contrast administration allows images of 
the area of infarction to be obtained. Gadolinium is retained in the area of infarction for a 
longer period than either normal myocardium or blood. By adjusting the inversion time of the 
inversion recovery turbo fast low-angle shot (Turbo FLASH) MRI sequence the normal 
myocardium can be ‗nulled‘ to allow maximum discrimination between infarct, blood pool 
and normal myocardium
294
. This technique has been shown to accurately correlate to 
pathological specimens and offers excellent specificity
294 295
. It is as accurate as SPECT 
imaging but offers greater resolution and of course other information is obtained during the 
same scan
296
. Similarly to calculating other cardiac volumes, the ROI can be drawn around 
the infarct in each short axis slice and the total infarct volume/mass calculated. This can be 
expressed as a percentage either to the total LV volume/mass or to the AAR and can then be 
used as an end point in studies of cardioprotection. The extent of gadolinium enhancement 
correlates with functional recovery
297
 and long term outcomes
298
. 
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Measurement of the myocardial area at risk with cardiac MRI 
 
There are 2 methods currently in use which attempt to quantify the myocardial area at risk. 
MRI is an ideal imaging modality with which to attempt to image the AAR because of its 
high spatial resolution and a large amount of different information can be obtained at one 
sitting. The AAR can be imaged following the acute MI so avoiding the need to complicate 
the acute situation and allowing the patient to be stabilised prior to scanning. The images can 
be analysed, ‗offline‘ and blinded allowing detailed, unbiased evaluation- all attractive 
attributes for conducting studies of cardioprotection. 
Endocardial surface area 
 
This innovative technique described by Ortiz-Perez et al.
299
 is relatively easy to perform and 
follows on from the ‗wavefront‘ theory of infarct progression described by Reimer and 
Jennings
263
 and discussed earlier. The acute infarct is imaged as described above. The lateral 
extents of the infarct and AAR are set early on in the ischaemic period and are delineated by 
the lateral extent of the gadolinium enhancement. The length of the infarct on the endocardial 
border is measured, multiplied by the slice thickness to give surface area and this is 
proportional to the AAR. This is expressed as a percentage of the total endocardial surface 
area of normal myocardium (calculated in the same way) to give a percentage of LV 
myocardium at risk (see figure 6, chapter 4). This has been validated against the two most 
common angiographic jeopardy scores and performs well (r=0.9 and 0.87, p<0.001)
299
. 
T2 imaging 
 
Myocardial oedema has been recognised to develop following I/R injury for several decades 
and represents an increased water content both intra and extracellularly arising only in the 
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area of myocardium that was at jeopardy. Although it‘s exact cause remains uncertain it is 
thought to arise from an accumulation of osmotically active substances and a thermodynamic 
dysequalibrium contributing to the intercellular water influx
300
. Initial unsatisfactory 
sequences used to image myocardial oedema were improved greatly with the advent of T2 
weighted short inversion-time, inversion recovery (STIR) imaging
301
. 
In dogs the area of oedema imaged using the T2 sequence correlates excellently with the 
AAR as measured by microsphere injection
302
 and in pigs there is a similar excellent 
correlation with the fluroscein dye method (r=0.92)
303
. The extent of myocardial oedema in 
humans is greatest for up to a week following infarction and then gradually declines 
afterwards
304
 allowing enough time following the acute event to enable retrospective 
determination of the AAR. 
Although STIR imaging is able to provide fairly good tissue discrimination with reasonable 
signal-to-noise ratio there sometimes remains a problematic artefact with the blood pool 
remaining bright along the endocardial border. The development of a hybrid sequence called 
the Acquisition for Cardiac Unified T2 Edema Turbo Spin Echo Steady State Free Precession 
(ACUT2E TSE-SSFP) sequence has managed to rectify this artefact in dogs at least, giving 
even more precise delineation of the area of myocardial oedema and hence the AAR
305
. This 
improved technique has yet to be validated in humans. 
T2 STIR imaging has been compared against both BMIPP and SPECT imaging for the 
identification of acute myocardial injury and been found to be superior in identifying the 
culprit territory
283
. Very recently T2 STIR has been tested against the previous gold standard 
for AAR imaging, SPECT. 16 patients with acute MI received 
99m
Tc tetrofusmin prior to 
PPCI and underwent SPECT imaging within 4 hours. T2 STIR MRI imaging was performed 
on day 1, day 7, 6 weeks and 6 months following reperfusion. Measurement of AAR by T2 
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STIR was found to be equivalent for imaging of the AAR for up to one week following acute 
MI
306
. This will undoubtedly be tested in a larger cohort of patients but it suggests that the 
AAR can now reliably be estimated, retrospectively, within a week of acute MI without the 
need to administer radiolabelled tracers and perform nuclear imaging in the acute period. It 
also prevents the need to perform a further predischarge rest nuclear perfusion scan to 
measure the eventual infarct size. This can now all be done with one scan at a convenient 
point within a week of infarction, meaning that MRI is likely to become the imaging modality 
of choice in order to assess the effect of cardioprotective interventions on myocardial salvage. 
It has also been shown in a canine model of ischaemia that myocardial oedema may develop 
during periods of ischaemia that may not cause cell death and subsequent infarction. The 
human analogy would be episodes of unstable angina. T2 imaging is able to detect the 
oedema and help delineate not only the myocardial territory of ischaemia but can quantify the 
area of myocardium at risk of further ischaemia in this area
307
. 
However, a few issues remain regarding MRI and T2 imaging for assessment of 
cardioprotection. Despite its relative acceptability, claustrophobia remains a significant 
obstacle and lying stationary and flat for scan times towards 45mins is difficult for some 
patients following acute MI. Another factor to be considered is the impact of the 
cardioprotective intervention being assessed on the extent of myocardial oedema itself. Of 
course, if the intervention reduces or increases the area of oedema relative to the eventual 
infarct size the myocardial salvage may be under or overestimated respectively and the 
impact of myocardial oedema on cell death still merits further study
308
. These observations 
notwithstanding, cardiac MRI is likely to continue to play a leading role in the continuing 
search for improved cardioprotective strategies. 
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Conclusion 
 
We can see from the discussion above that both atorvastatin and erythropoietin have potential 
to limit myocardial injury in humans in the clinical setting. The assessment of 
cardioprotection in the heterogeneous clinical environment is not always easy with a number 
of different techniques needed. The next and subsequent chapters will discuss randomised 
trials of atorvastatin in cardiac surgery and erythropoietin in acute myocardial infarction 
performed in an attempt to reduce cardiac injury in these settings.  
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CHAPTER 2 
 
Elucidating the Mechanistic Pathways of Ischaemic Preconditioning and 
Postconditioning in the Clinical Setting 
 
The above title refers to a programme of studies investigating three pharmacological agents 
which target the Reperfusion Injury Salvage Kinase pathway. All three agents have been 
established in pre-clinical studies as able to limit lethal reperfusion injury and it is now 
important to investigate whether this is possible in the human clinical setting. Figure 1 below 
sets out the initial plan of investigating each agent in a variety of clinical scenarios. 
  
Figure 1: Schematic to show overall initial plan of the study titled ―elucidating the 
mechanistic pathways of ischaemic preconditioning and postconditioning in the clinical 
setting‖. 
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The highlighted sections in the figure above demonstrate the studies undertaken in this thesis; 
namely the use of atorvastatin in patients undergoing elective CABG and erythropoietin in 
patients with STEMI undergoing primary PCI. CABG- coronary artery bypass graft surgery, 
(N)STEMI- (non) ST elevation myocardial infarction, PCI-percutaneous coronary 
intervention, CsA- cycloporin, Epo- erythropoietin, TnT- Troponin T. 
 
This thesis has taken a portion of the above study programme rather than the whole and 
therefore addresses the potential role of atorvastatin in elective coronary artery bypass graft 
surgery (group 1 patients) and erythropoietin in patients with acute ST elevation myocardial 
infarction treated by primary percutaneous coronary intervention (group 4). The other groups 
of patients and investigational agents have been addressed by other investigators. 
As has been discussed, despite advances in revascularisation therapy in the elective and 
emergency setting, a considerable amount of myocardial injury may still occur and benefit 
can be gained if one can protect against this. Atorvastatin and erythropoietin are two agents 
which have been proven to act via a cell survival pathway (reperfusion injury salvage kinase 
pathway) to protect against IRI in preclinical animal studies. In order that this 
cardioprotective potential may be translated to the clinical setting, proof of concept studies 
are required to demonstrate safety and efficacy.  
During coronary artery bypass surgery the heart is subjected to periods of ischemia followed 
by reperfusion causing myocardial injury which has been correlated to outcome
158 159
. In 
preclinical studies the protective effect of statin use has been demonstrated to wane 
chronically but could be recaptured with an acute high dose prior to ischaemia
78
. Whether 
this phenomenon can be reproduced to protect against myocardial injury during CABG 
surgery has not been tested. 
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Erythropoeitin has demonstrated significant cardioprotective effects in preclinical studies (see 
table 7, chapter 1) and acute high dose treatment has been safe in human pilot studies
240 243
. 
Whether high dose erythropoietin, as an adjunctive treatment to primary percutaneous 
coronary intervention in patients presenting with STEMI, is protective has not previously 
been established. 
Hypotheses and Objectives 
 
This thesis aims to investigate the use of atorvastatin and erythropoietin as a novel means of 
reducing myocardial injury in the clinical setting. 
 
Hypothesis 1 
Acute high dose atorvastatin on a background of chronic statin use administered prior to 
elective coronary artery bypass surgery will significantly reduce peri-operative myocardial 
injury. 
 
Objectives 
a. 160mg additional atorvastatin 2 hours prior to surgery and 24 hours following 
will limit myocardial damage as measured by cardiac Troponin T release over 
72 hours following surgery. 
b. 160mg additional atorvastatin 12 hours prior to surgery and 24 hours 
following will limit myocardial damage as measured by cardiac Troponin T 
release over 72 hours following surgery. 
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Hypothesis 2 
High dose erythropoietin beta as an adjunct to primary percutaneous coronary intervention 
for ST elevation MI will reduce myocardial infarct size. 
 Objectives 
a. Erythropoietin (50,000units rhEpo-β) administered prior to reperfusion and 24 
hours after reperfusion to patients with ST elevation myocardial infarction 
(STEMI) as an adjunct to primary percutaneous coronary intervention (PPCI) will 
limit myocardial infarct size as measured by cardiac Troponin T release over 24 
hours following reperfusion. 
b. Erythropoietin as an adjunctive treatment in STEMI will provide beneficial 
effects as assessed by cardiac magnetic resonance imaging in the first week 
following reperfusion and at 4 months follow up: 
i. An increase in ejection fraction in the treated group. 
ii. Reduced adverse LV remodelling in the treated group, as evidenced by 
quantitative change in the LV end-diastolic and end-systolic volumes. 
iii. A reduction in myocardial infarction size as measured by 
quantification of the mass of delayed gadolinium contrast enhanced 
myocardium. 
iv. A reduction in the prevalence of microvascular obstruction in the 
treated group as assessed by early gadolinium contrast enhanced 
images. 
 
The hypotheses presented above will be examined in clinical studies discussed in chapters 3 
and 4. 
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CHAPTER 3 
 
The Effect Of Acute High Dose Atorvastatin On Myocardial Injury During Coronary 
Artery Bypass Graft Surgery 
Introduction 
Coronary artery disease remains the major cause of mortality and morbidity worldwide with 
more than 4 million deaths attributed to cardiovascular disease in the year 2000 in Europe 
alone
309
. Ischaemic heart disease is projected to be the leading cause of disability-adjusted 
life years by the year 2020 according to World Health Organisation estimates
1
. Although the 
mortality from routine adult elective coronary artery bypass graft (CABG) surgery is about 
1.5% in the United Kingdom, the changing risk profile of patients being operated in terms of 
the aging population, increased prevalence of diabetes, and more complex operations, have 
resulted in mortality rates in the region of 10-20% in some high-risk groups
310
. Therefore, 
novel cardioprotective strategies are required to improve clinical outcomes in this patient 
group. 
Mechanism of myocardial injury during CABG surgery 
 
Myocardial injury sustained during cardiac surgery can be attributed to several different 
mechanisms, with acute myocardial ischaemia—reperfusion injury being the most important. 
Other causes include the inflammatory response to the extraneous substances in the 
cardiopulmonary bypass circuit, left ventricular over-distension, coronary atheroembolism, 
increased cardiac workload during the intraoperative period and direct myocardial injury due 
to retraction and handling of the heart
162
. Myocardial injury can be minimised by cardiac 
decompression, careful management of blood pressure, heart rate and systemic vascular 
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resistance intra-operatively and by exercising caution during manipulation of the heart and 
aorta. 
 
Acute myocardial ischaemia—reperfusion injury during conventional on-pump CABG 
surgery results from the intermittent aortic cross-clamping required to undertake the 
attachment of each distal coronary anastomosis, resulting in cumulative episodes of global 
myocardial ischaemia. In patients undergoing a cardioplegic strategy, the cardioplegic 
solution is administered initially and repeated during each episode of aortic cross-clamping; 
or a continuous cardioplegia strategy may be used. In the technique of cross-clamp 
fibrillation an alternating current is applied to the myocardium to induce ventricular 
fibrillation. Ventricular fibrillation during perfusion results in an increase in the left 
ventricular end-diastolic pressure (LVEDP) causing subendocardial hypoperfusion
311
, 
however this rise in LVEDP does not occur during ischaemia
312
. Therefore aortic cross-
clamping and ventricular fibrillation appear to obviate the detrimental effects of each other. 
Overall however, the total time of aortic cross-clamping and fibrillation (approximately 30 
min) equates to a significant myocardial ischaemic insult
313
. Several studies have compared 
clinical outcomes and the extent of myocardial injury in cross-clamp fibrillation and 
cardioplegia
314-316
 and have found the two techniques to be comparable. 
The profile of patients undergoing CABG surgery is changing over the years with 
increasingly higher-risk patients being operated upon
317
. The favourable metabolic effects of 
cardioplegia have encouraged more surgeons to adopt this technique in their practice 
although comparable clinical outcomes have been achieved with cross-clamp fibrillation
318
. 
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Acute statin use as potential cardioprotective agent during CABG surgery 
 
Despite the current cardioprotective techniques discussed above, myocardial injury still 
occurs and has been associated with adverse outcomes
158 159
 and as such there is a need for 
novel cardioprotective strategies. It is clear that treatment with HMG Co enzyme A reductase 
inhibitors (‗statins‘) improves clinical outcomes in both patients at risk of coronary heart 
disease (CHD)
55
 and in patients with established CHD
319
. Beyond improving lipid profiles, 
statins have ‗pleiotropic effects‘ with actions, amongst others, on the vascular endothelium, 
platelet aggregation, oxidative stress, the stability of the atherosclerotic plaque and 
myocardial ischaemia-reperfusion (IR) injury
320
. Pre-clinical animal studies have 
demonstrated that the acute administration of ‗statins‘ reduces myocardial injury, 
independently of their cholesterol lowering effects, when given prior to the index ischaemia
64 
77 321
 as well as at the point of reperfusion
77 88 89 91
. With respect to its cardioprotective 
actions, the activation of the pro-survival kinases such as the PI3K-Akt and MEK1/2-Erk1/2, 
termed the Reperfusion Injury Salvage Kinase (RISK) pathway, is believed to underlie the 
protective action
53. Interestingly, however, the chronic administration of ‗atorvastatin‘ in 
animal studies failed to confer any cardio-protection, an effect which was attributed to the 
down-regulation of the PI3K-Akt component of the RISK pathway
78
. Of interest and 
potential clinical importance, the infarct-limiting effect of atorvastatin could be recaptured if 
a further high-dose of atorvastatin was administered acutely to these animals
78
. 
 
The objective of the current clinical study was to translate the above animal studies to the 
patient by determining whether the acute administration of high-dose atorvastatin was 
capable of reducing myocardial injury in patients, already on standard chronic ‗statin‘ 
therapy, undergoing elective CABG surgery.  
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Methods 
 
Study protocol 
 
This study is one part of a larger group of studies entitled, ―elucidating the mechanistic 
pathways of ischaemic preconditioning and postconditioning in the clinical setting‖ (see 
chapter 2). The full protocol was submitted for ethical approval to the joint University 
College London/University College London Hospitals Committee for ethical human research 
and sponsored by University College London Research and Development department. The 
trial was conducted according to University College of London Hospitals NHS Trust 
guidelines. In addition the patient information leaflet, consent form and general practitioner 
information leaflet were subject to ethical approval. Any amendments required to the study 
protocol were classed as minor or major according to criteria produced by the ethics 
committee. I made the amendments, and subject to the chief investigators approval, submitted 
the updated documents annotated with appropriate dates and version numbers for approval 
for each amendment. Any serious adverse event or reaction during the course of the study had 
to be reported to the R&D department as per adverse event guidelines. No serious adverse 
events or reactions occurred during the course of this study.  
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Patient population 
 
We obtained informed written consent from all patients entered into the trial. Patients were 
approached on admission to hospital 24 hours prior to surgery and sufficient time and 
information was allowed to enable fully informed consent. Between July 2007 and January 
2009 we recruited 45 consecutive adult patients to study 1 and 51 patients to study 2 who 
were due to undergo elective coronary artery bypass graft (CABG) surgery for severe 
coronary artery disease at our tertiary cardiac centre. The studies were performed sequentially 
with study 2 commenced following the results of study 1 and with a different dosing timing 
in order to explore whether a longer onset of action was required. 
Inclusion criteria 
 
All patients less than 80 years old undergoing elective ‗on-pump‘ CABG surgery who were 
already established on a statin medication (atorvastatin, simvastatin, pravastatin or 
rosuvastatin) for more than four weeks and were able to give informed consent. 
Exclusion criteria 
 
We excluded patients over 80 years old; with known intolerance to ‗statins‘; with renal 
impairment (serum creatinine > 120µmol/l) or hepatic impairment (any abnormality in liver 
enzymes); with unstable angina or an acute myocardial infarction within 3 months or with 
angina within 3 days. Patients were excluded if taking glibenclamide. 
Investigational Agent 
 
Consenting patients were randomly assigned to either receive 160mg Atorvastatin 2 hours 
prior to surgery (study 1) or 12 hours prior to surgery (study 2) (figure 2) and 24 hours post-
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operatively or their standard chronic ‗statin‘ therapy. The anaesthetist and surgical team were 
blinded to the treatment allocation.  
Surgical Procedure 
 
All patients received an anaesthetic premedication of 10-20 mg of Temazepam 1 hour prior to 
surgery. On arrival in the anaesthetic room a peripheral venous cannula was inserted and an 
infusion of Hartmann‘s solution commenced. A radial arterial line was also inserted. 
Anaesthesia was induced using midazolam with or without propofol, fentanyl and 
pancuronium. Anaesthesia was maintained without the use of isoflurane and using a propofol 
infusion. The trachea was intubated and mechanical ventilation initiated. A central venous 
catheter was inserted, as was a nasopharyngeal temperature probe, transoesphageal 
echocardiographic probe and urinary catheter. 
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Figure 2: Schematic to show study design and patient recruitment. 
68 Elective CABG 
patients screened
52 Patients 
randomised to 
160mg Atorvastatin 2 
hours prior to surgery 
or control
58 Patients 
randomised to 
160mg Atorvastatin 
12 hours prior to 
surgery or control
Study 1 Study 2
Elective ‘on-pump’ 
CABG with either 
cardioplegia or XC 
fibrillation
Troponin T assessed at 
0, 6, 12, 24, 48 and 72 
hours post operatively
65 Elective CABG 
patients screened
14 
ineligible
7
ineligible
7excluded prior 
to analysis (3 off 
pump, 3 protocol 
error, 1 raised 
initial troponin)
7excluded prior 
to analysis (2 
cancelled, 1 renal 
failure, 1 protocol 
error, 2 off-pump)
Analysis of 
45 patients
Analysis of 
51 patients
 
Cardiopulmonary bypass was standard, non-pulsatile with a membrane oxygenator and 
cardiotomy suction. All graft construction was done on cardiopulmonary bypass from aorta to 
target vessel or using the left internal mammary artery with either cold blood cardioplegia or 
intermittent cross-clamp fibrillation. Following construction of the grafts, cardiopulmonary 
bypass was discontinued and protamine used to reverse the heparinisation. 
Blood samples for Troponin-T were taken prior to surgery and at 6, 12, 24, 48 and 72 hours 
following surgery. Quantitative Troponin T measurement was performed using a one-step 
immunoassay based on electrochemiluminescence technology (Elecsys 2010, Roche, 
Switzerland). The lower detection concentration of the assay was 0.01µg/L, with a 
recommended diagnostic range of 0.05-0.09 µg/L indicating possible myocardial injury and a 
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threshold of 0.1 µg/L or more indicating myocardial infarction. Internal quality control was 
performed on a daily basis with external quality control performed every 4 weeks. 
Statistical Analysis 
 
Data are presented as mean ± SD. Descriptive statistics were used to summarise the relevant 
features of the groups. Data was checked for normal distribution by plotting histograms with 
a normal curve. Comparison between treatment groups was made using the unpaired student 
T test. Difference between categorical data were analysed using the Chi Squared test. A value 
of P<0.05 was considered significant. A sample size of at least 45 patients was determined 
based on the following assumptions: (a) that from our previous studies we would expect a 
difference in total serum troponin-T release over 72 hours of approximately 15 µg/L between 
treated and untreated patients
322
; (b) a power of least 80%; (c) a standard deviation of 25 
µg/L
322
; and (d) significance declared at the two-sided 5% level. After consent had been 
obtained for participation in the clinical trial, patients were randomly assigned to receive 
either atorvastatin treatment or control using a computer generated block randomisation 
sequence. The analysis was per-protocol, with this population defined by those patients who 
successfully received both doses of study medication, had a negative Troponin T at baseline, 
underwent CABG surgery with an ‗on-pump‘ method and had at least 5 of 6 blood test 
results. The area under the curve indicative of absolute troponin release over 72 hours was 
calculated as follows: 
AUCt1-t2 = [(TnT at t1 hours + TnT at t2 hours) / 2] x (t2 – t1). 
AUC72hours = AUC0-6 + AUC6-12 + AUC12-24 + AUC24-48 + AUC48-72 
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Results 
 
Study 1: 68 patients were assessed for eligibility and 52 patients fulfilled initial inclusion 
criteria and were recruited. 7 patients were excluded prior to analysis for not successfuly 
meeting study criteria for ongoing inclusion; 2 patients were cancelled at short notice after 
having had the first dose of study medication, 3 patients were operated using an ‗off-pump‘ 
method, 1 patient developed renal failure requiring CVVHF making Troponin measurement 
unreliable and 1 patient received only 1 dose of the study medication. Study 2: 65 patients 
were assessed for eligibility and 58 fulfilled initial inclusion criteria and were recruited. 7 
patients were excluded prior to analysis; 3 patients were operated using an ‗off pump‘ 
method, 1 patient was found to have a raised Troponin T at baseline, 1 received only one 
dose of study medication and 2 patients had missing blood samples. (Figure 2). 
There were no side effects from the atorvastatin noted either biochemically (peak CK over 72 
hours post-operatively, study 1: Control 630 U/L, Atorvastatin 687 U/L, p=0.5, study 2: 
Control 658 U/L, Atorvastatin 819 U/L, p=0.3) or symptomatically in the intervention group. 
There were no significant differences between patient characteristics (see table 1 and 2).  
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Table 1: Patient characteristics  
 Study 1 Study 2 
Control 
(n=22) 
Atorva 
(n=23) 
Control 
(n=23) 
Atorva 
(n=28) 
Demographics 
Age (years) 
 
61 ± 8.2 
 
64 ± 8.0 
 
63 ± 9.8 
 
61 ± 10.8 
Male 
Female  
20 (91) 
2 (9) 
19 (83) 
4 (17) 
21 (91) 
2 (9) 
25 (89) 
3 (11) 
Diabetes mellitus 7 (32) 4 (17) 6 (26) 6 (21) 
Hypercholesterolaemia 20 (91) 19 (83) 17 (74) 21 (75) 
Hypertension 14 (64) 18 (78) 17 (74) 16 (57) 
Previous myocardial infarction 6 (27) 7 (30) 9 (40) 7 (25) 
Previous stroke 0 (0) 0 (0) 0 (0) 0 (0) 
Peripheral vascular disease 2 (9) 0 (0) 2 (9) 1 (4) 
Current smokers 
Ex-smokers 
Never smoked 
4 (18) 
8 (36) 
10 (45) 
2 (9) 
6 (26) 
15 (65) 
1 (4) 
13 (57) 
9 (39) 
3 (11) 
15 (57) 
10 (36) 
Family history of IHD 7 (32) 13 (57) 12 (52) 14 (50) 
Body Mass Index 28 ± 4.2 29 ± 2.8 29 ± 4.6 30 ± 4.6 
NYHA class 1.8 ± 0.7 1.8 ± 0.8 1.5 ± 0.6 1.9 ± 0.6 
CCS class 1.6 ± 0.8 1.8 ± 0.9 1.5 ± 0.8 1.9 ± 0.7 
Ejection fraction 
                                 >55% 
                                 35-55% 
                                <35%                                  
 
20 (91) 
2 (9) 
0 (0)
 
20 (87) 
1 (4) 
2 (9) 
 
19 (83) 
3 (13) 
1 (4) 
 
25 (89) 
2 (7) 
1 (4) 
Euroscore 2.8 ± 1.7 2.9 ± 2.7 2.16 ± 1.7 1.85 ± 1.9 
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 Study 1 Study 2 
Control 
(n=22) 
Atorva 
(n=23) 
Control 
(n=23) 
Atorva 
(n=28) 
Drug history 
Aspirin 
 
0 (0) 
 
5 (22) 
 
2 
 
2 (7) 
Beta-blocker 14 (64) 20 (87) 17 (74) 27 (96) 
Statin 22 (100) 23 (100) 23 (100) 28 (100) 
ACE-inhibitor/ACE antagonist 13 (59) 18 (78) 15 (65) 16 (57) 
Long-acting nitrates 7 (32) 4 (17) 5 (22) 6 (21) 
Calcium Channel Antagonist 8 (36) 5 (22) 9 (39) 4 (14) 
Nicorandil 2 (9) 2 (9) 0 (0) 1 (3) 
Anti-diabetic drugs 
Insulin 
Sulphonylurea 
Metformin 
 
1 (5) 
1 (5) 
2 (9) 
 
2 (9) 
0 (0) 
3 (13) 
 
0 (0) 
5 (22) 
3 (13) 
 
1 (4) 
2 (7) 
4 (14) 
Values presented as mean ± SD or ‗N‘ (%) 
 
Page 124 of 236 
 
Table 2: Details of cardiac bypass surgery 
 Study 1 Study 2 
Control Atorva Control Atorva 
 
Bypass-time (min) 
 
80 ± 23 
 
84 ± 39 
 
83 ± 24 
 
80 ± 21 
Cross-clamp time (min) 45 ± 16 48 ± 25 49 ± 15 48 ± 13 
Intermittent cross-clamp 
fibrillation 
6 (27) 9 (39) 2 (9) 4 (14) 
Cardioplegia 16 (73) 14 (61) 21 (91) 24 (86) 
Number of grafts: 
                                   One  
                                   Two 
                                   Three 
                             Four 
                                   Five 
 
0 (0) 
6 (27) 
12 (55) 
3 (14) 
1 (5) 
 
1 (4) 
2 (9) 
12 (52) 
8 (35) 
0 (0) 
 
0 (0) 
0 (0) 
16 (70) 
6 (26) 
1 (4) 
 
0 (0) 
4 (14) 
18 (64) 
6 (21) 
0 (0) 
Values presented as mean ± SD or ‗N‘ (%) 
 
There was no significant difference in serum Troponin T at each time point and total 
Troponin release over 72 hours, calculated as the Area Under the Curve (AUC). Study 1: 
Atorvastatin 29.6±34.8 µg/L, Control 25.0±22.0 µg/L (95% CI -13.0 to 22.2, P=0.6). Study 
2: Atorvastatin 21.8±14.3 µg/L, Control 20.9±8. µg/L (95% CI -5.9 to 7.7, P=0.8) (See table 
3, figure 3 and figure 4).  
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Table 3: Serum troponin-T levels over the 72 hours following CABG surgery  
 Time after 
surgery 
(hrs) 
0 6 12 24 48 72 
Study1 
Control 0 
0.80 ± 
0.55 
0.61 ± 
0.42 
0.37 ± 
0.35 
0.31 ± 
0.29 
0.24 ± 
0.26 
Atorva 0 
0.82 ± 
0.51 
0.58 ± 
0.38 
0.39 ± 
0.38 
0.42 ± 
0.77 
0.30 ± 
0.41 
Mean 
Difference 
0 
0.20 ± 
0.16 
-0.32 ± 
0.12 
0.02 ± 
0.11 
0.11 ± 
0.18 
0.06 ± 
0.11 
Confidence 
Interval 
- 
-0.31 to 
0.35 
-0.28 to 
0.22 
-0.20 to 
0.24 
-0.26 to 
0.48 
-0.17 to 
0.29 
P value - P=0.9 P=0.8 P=0.9 P=0.5 P=0.6 
Study 2 
Control 0 
0.66 ± 
0.33 
0.50 ± 
0.23 
0.27 ± 
0.10 
0.22 ± 
0.10 
0.20 ± 
0.10 
Atorva 0 
0.64 ± 
0.39 
0.45 ± 
0.28 
0.29 ± 
0.22 
0.25 ± 
0.17 
0.27 ± 
0.22 
Mean 
Difference 
0 -0.17 ± 
0.10 
-0.04 ± 
0.07 
0.02 ± 
0.05 
0.02 ± 
0.04 
0.06 ± 
0.05 
Confidence 
Interval 
- -0.23 to 
0.19 
-0.19 to 
0.10 
-0.08 to 
0.12 
-0.06 to 
0.10 
-0.04 to 
0.17 
P value - P=0.87 P=0.56 P=0.66 P=0.58 P=0.23 
Values presented as mean ± SD (in µg/L) 
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Figure 3: Shows the mean cardiac Troponin T release over 72 hours following elective 
CABG surgery in control and atorvastatin treated groups in study 1 (treated 2 hours pre-
operatively) and study 2 (treated 12 hours pre-operatively). 
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Figure 4: The mean cardiac Troponin T AUC over 72 hours post-operatively in study 1 and 
study 2. 
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There was no significant difference in the number of patients with a Troponin-T ≥ 0.46 µg/L 
at 48 hours post-operatively, which is reported to correlate to a worse prognosis
158
, in either 
study (study 1: Control- 3 patients, Atorvastatin- 3 patients; study 2: Control- 0 patients, 
Atorvastatin- 4 patients).  
There was no significant difference in the relative distribution of size of Total Trop-T AUC 
over the 72 hours post-operatively (see table 4 and figure 5). 
 
Table 4: Distribution of Total Trop T AUC over 72 hours from studies 1 and 2 
 Percentage of study patients with Total Trop T AUC over 72 hours (µg/L) 
in the categories below 
 0 to 9.9 10 to 19.9 20 to 29.9 30 to 39.9 ≥40 
Study 1 Control(%) 13.6 36.3 27.3 9.1 13.6 
Atorva(%) 13.0 30.4 26.1 21.7 8.7 
Study 2 Control(%) 8.7 47.8 21.7 21.7 0 
Atorva(%) 10.7 35.7 35.7 7.1 10.7 
 
 
The current consensus guidelines on the definition of MI define a peri-operative MI 
following cardiac surgery as requiring elevation of cardiac enzymes greater than 5 times the 
ULN with new Q waves on ECG, angiographic evidence of new coronary artery occlusion or 
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non-invasive imaging suggesting newly non-viable myocardium
111
. Although in these studies 
ECG and imaging data was not obtained, an analysis of the incidence of patients in each 
group with a peak Troponin-T > 5 times the ULN showed no difference (Study 1: Atorva 
74% vs Control 73%; p=ns. Study 2: Atorva 57% vs Control 61%; p=ns). We do not have 
enough evidence to label these patients as having had a peri-operative myocardial infarction, 
a considerable number of patients do however have substantial measured Troponin release 
following their surgery although this is equal between the groups. 
An analysis of Trop-T AUC over 72 hours within studies 1 and 2 by intra-operative 
cardioprotective technique showed that patients operated with a cross-clamp fibrillation 
method displayed a non-significant trend towards less myocardial injury although the 
numbers of patients in the cross-clamp fibrillation group were relatively small. There was no 
significant difference between atorvastatin treated and control patients. (See figure 6). 
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Figure 5: Graph to show the percentage of patients against the relative size of the Total 
Troponin-T AUC over 72 hours in studies 1 and 2. 
 
 
 
Figure 6: Graph to show the Trop-T AUC over 72 hours by intra-operative cardioprotective 
technique. 
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Discussion 
 
From the results of these randomised controlled single blinded clinical studies this thesis 
reports that high-dose atorvastatin administered acutely to patients already on chronic 
standard ‗statin‘ therapy either 2 or 12 hours pre-operatively is safe but did not reduce 
myocardial injury during elective CABG surgery. This was evidenced by the lack of 
difference in cardiac enzyme release in patients randomised to receive the high-dose 
atorvastatin treatment when compared to standard ‗statin‘ therapy. On post-hoc sub-group 
analysis there was no difference in cardiac enzyme release between patients operated using 
cardioplegia or cross-clamp fibrillation cardioprotective techniques. There was no difference 
either in mean peak Troponin release, in number of patients with a peak Troponin greater 
than 5 times the upper limit of normal during the 72 hours post-operatively or in the 
incidence of patients with a Trop-T >0.46µg/l at 48 hours post-op which has been linked to 
adverse outcomes. 
In the clinical setting, ‗statins‘ have been demonstrated to exert beneficial effects beyond that 
expected from cholesterol lowering. In the MIRACL study, the early administration of high-
dose atorvastatin in the first few days following an acute coronary syndrome reduced 
recurrent symptomatic ischaemia and subsequent hospitalisation
138. In ‗statin‘ naïve patients, 
atorvastatin has been reported to reduce peri-procedural myocardial injury in both patients 
undergoing elective PCI
119
  and in NSTEMI patients undergoing PCI
128
 (for a comprehensive 
review see
323
). 
However, the beneficial effect of ‗statin‘ use prior to CABG surgery is somewhat less clear; a 
retrospective analysis of 5,439 patients undergoing elective CABG surgery found no effect of 
chronic administration of ‗statins‘ on clinical outcomes164. However a prospective 
observational study of 5,436 patients undergoing elective CABG surgery did show 
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significantly improved early all-cause mortality in patients taking chronic ‗statin‘ therapy, but 
there was no improvement in the incidence of peri-operative myocardial infarction
165
.  Statin 
medication commenced following CABG surgery has been associated with an improved 
mortality and reduced cardiac events at 6 months
324
. Recently a randomised study of 
rosuvastatin versus placebo in a selected population of patients undergoing CABG was 
performed. Patients treated for 7 days prior to CABG with rosuvastatin showed significantly 
less myocardial injury perioperatively
169
. However, in that particular study, patients already 
taking a statin were required to stop treatment 30 days prior to the study protocol and all 
patients were only treated for 7 days pre-operatively and for an unstated post-operative 
period; this therefore does not reflect common clinical practice. High doses of acute statins 
have not been shown to reduce the burden of atrial fibrillation following CABG surgery
325
. 
Experimental studies using mice have clearly demonstrated that the acute administration of 
‗statins‘ can reduce myocardial infarct size by approximately 50%. For example, treatment 
with acute atorvastatin at the onset of myocardial reperfusion following a period of lethal 
ischaemia reduced myocardial infarct size by approximately 50% in a manner dependent on 
PI3K, Akt and the upregulation of eNOS
88
. Crucially, the chronic administration of standard 
dose atorvastatin did not reduce myocardial infarct size. The failure to demonstrate 
cardioprotection was attributed to the upregulation of phosphatase tensin homolog deleted on 
chromosome ten (PTEN), a phosphatase which down-regulates the phosphorylation of Akt, a 
key mediator of cardioprotection. However, the re-activation of Akt using a high-dose of 
atorvastatin was able to recapture the cardioprotective effect of atorvastatin in these mice 
treated with chronic standard atorvastatin therapy
78
. The mechanism of action for the 
reactivation of the cardioprotective effect is not known. It has been speculated that this 
increased dose may activate other pathways which are cardioprotective such as the 
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extracellular signal-related kinase 1/2  (ERK 1/2)
46
 or whether it is just a matter of a higher 
dose being needed to overcome the upregulated PTEN in order to then activate the RISK 
pathway. The theory that cardioprotection can be ‗recaptured‘ has been tested in the setting of 
PCI in the ARMYDA-Recapture study. 352 patients already established on statin medication 
were randomised to a ‗reload‘ of 80mg atorvastatin 12 hours pre-PCI and 40mg immediately 
pre-PCI or placebo. Peri-procedural injury was significantly reduced
123
.  
In the current study, we were interested to determine whether the acute administration of a 
high-dose of atorvastatin could elicit cardioprotection in adult CABG patients already on 
standard dose ‗statin‘ therapy, however we did not observe any reduction in myocardial 
injury which is in contrast to the findings of the ARMYDA-Recapture study. The ARMYDA 
group have demonstrated that additional cardioprotection can be afforded by further acute 
dosing of atorvastatin. They report that this also reduces the incidence of 30 day MACE 
although all such events were peri-procedural. It is possible that the setting of PCI is more 
amenable to the study of this effect as there are less complicating factors not only in terms of 
causes of myocardial injury but also in regards to the much more invasive nature of surgery 
and the CPB required. Also, the translation of findings made in laboratory animal studies into 
the clinical environment may be hampered by several factors (reviewed in 
326
). The study of 
atorvastatin as a cardioprotective agent has for the most part been restricted to non-
atherosclerotic juvenile animal models of experimental myocardial infarction, in the absence 
of co-morbid illnesses and other medication. Patients undergoing CABG surgery are older, 
often have severe atherosclerotic coronary artery disease, are on various medications, have 
other co-morbidities and so on. Furthermore it has recently been shown that aspirin may 
abrogate the protective effect of atorvastatin in ischaemia-reperfusion injury
327
 and although 
the majority of patients had ceased their aspirin prior to surgery it is not known whether the 
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effect was still present. Work from the same group has also shown that a low dose of 
atorvastatin, which alone does not cardio-protect, can show protection when combined with 
other agents such as dipyridamole
82
 and sildenafil
328
 and future clinical work, potentially 
combining atorvastatin with these agents, may well yield more positive results. Furthermore, 
many of the experimental studies demonstrating cardioprotection with statin administration 
have used animal models of coronary artery occlusion, but pre-clinical investigation of statin 
therapy using an animal cardiac bypass model of ischaemia-reperfusion injury has been 
lacking. 
The myocardial injury encountered during CABG surgery comprises in addition to 
ischaemia-reperfusion, coronary microembolisation and direct myocardial injury from 
surgical handling. However, several clinical studies have reported that the myocardial injury 
sustained during CABG surgery is associated with worse clinical outcomes, and the release of 
cardiac-specific enzymes can be used to stratify patient outcome
157 158
. Indeed, using this 
clinical environment, we have recently been able to demonstrate the efficacy of remote 
ischaemic preconditioning using transient ischaemia of the arm in terms of a significant 
reduction in myocardial injury as measured by the 72 hour peri-operative release of serum 
troponin T
322 329
 although it must be appreciated that this has been replicated by some 
groups
330
 but not others
331
. We believe that this confirms that the setting of CABG surgery is 
indeed an appropriate one in which to investigate the cardioprotective potential of high-dose 
atorvastatin therapy. 
We chose 160mg of atorvastatin as the acute dose to be administered because this was 
almost certainly going to be significantly higher than any patient‘s current dose. This dose 
has previously been found to be safe
332
 and has been shown to produce comparable serum 
blood levels in humans to the doses used in animal experiments
333
. We found this dose to be 
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well tolerated with no recorded adverse effects. The acute dose of atorvastatin was given 2 
hours or 12 hours prior to surgery and then 24 hours following surgery. The peak plasma 
concentration of atorvastatin occurs between 1-2 hours after administration
334
 and although 
absorption can be affected by food
335
 all our patients were fasted prior to surgery. The first 
study administered atorvastatin 2 hours prior to surgery on the basis that peak serum levels 
occurred at this point. However once the results were analysed and discussed the possibility 
was raised that peak action may be somewhat later than peak serum levels. Hence the second 
study was performed with atorvastatin administered 12 hours prior to surgery. 
In summary, this thesis reports that the acute administration of high dose atorvastatin 
to adult, low risk patients already on a standard statin dose regimen was safe but did not 
reduce myocardial injury encountered during elective CABG surgery. It remains a possibility 
that patients at higher risk of intraoperative myocardial injury may have the potential to be 
protected and this warrants further investigation.  
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CHAPTER 4 
Effect of erythropoietin as an adjunct to primary percutaneous coronary 
intervention: a randomised controlled clinical trial 
 
Introduction 
 
Primary percutaneous coronary intervention (PPCI) is now established as the superior method 
of reperfusion in ST Elevation Myocardial Infarction (STEMI)
336
, however despite this recent 
advance the morbidity and mortality of STEMI remains significant. This may be due, in part, 
to myocardial reperfusion injury, a phenomenon in which the reperfusion of ischemic 
myocardium induces further cardiomyocyte death, thereby limiting the beneficial effects of 
PPCI
7
. Therefore, novel cardioprotective agents capable of reducing myocardial reperfusion 
injury, are required to realise the full benefits of reperfusion therapy, limit myocardial infarct 
size, preserve cardiac function and improve clinical outcomes in these patients.  
There is considerable evidence that the cytokine, erythropoietin (EPO), exerts 
pleiotropic effects beyond that of haematopoiesis, which include both neuroprotection and 
cardioprotection
337
. The acute administration of high-dose EPO at the time of reperfusion has 
been reported in animal models to reduce myocardial infarct size by approximately 50%
337
. 
Whether EPO is beneficial in STEMI patients when administered as an adjunct to PPCI is 
unknown and is investigated in this proof-of-concept randomised clinical trial. 
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Methods 
Study Protocol 
 
This study is one part of a larger group of studies titled, ―elucidating the mechanistic 
pathways of ischaemic preconditioning and postconditioning in the clinical setting‖ (see 
chapter 3, figure 1). The full protocol was submitted for ethical approval to the joint 
University College London/University College London Hospitals Committee for ethical 
human research and sponsored by University College London Research and Development 
department. The trial was conducted according to University College of London Hospitals 
NHS Trust guidelines. In addition the patient information leaflet, consent form and general 
practitioner information leaflet were subject to ethical approval. Any amendments required to 
the study protocol were classed as minor or major according to criteria produced by the ethics 
committee. I made the amendments, and subject to the chief investigators approval, submitted 
the updated documents annotated with appropriate dates and version numbers for approval 
for each amendment. Any serious adverse event or reaction during the course of the study had 
to be reported to the R&D department as per adverse event guidelines. The study was 
registered with the United Kingdom Clinical Research Network (Study ID 4058). 
Patient selection 
 
Between July 2007 and August 2009 we conducted a randomised double-blind placebo-
controlled trial of STEMI patients referred to a single tertiary cardiac centre for PPCI (see 
figure 1). We obtained written informed consent from all patients who entered the study (for 
a discussion on informed consent in research in STEMI see appendix 2).  
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Inclusion criteria 
 
Patients were included if they presented for PPCI within 12 hours of onset of symptoms and 
had the following ECG criteria (≥2mm ST-elevation in chest ECG leads, ≥1mm ST-elevation 
in contiguous limb leads or new onset left bundle branch block), were under 80 years old 
with a single vessel culprit lesion, and had Thrombolysis in Myocardial Infarction (TIMI)
338
 
grade 0 and Rentrop
339
 collateral grade 0 on coronary angiography.  
 
Figure 1: Schematic to show patient recruitment and study flow. 
110 patients screened
90 patients consented
20 patients not eligible
51 patients eligible
39 patients excluded
(19 TIMI flow> 0 , 1 Rentrop grade 
>0, 3 incomplete reperfusion, 6 
normal coros, 1 missed dose, 3 VF, 
1 renal failure, 2 >12hrs pain, 3 
multivessel infarct
26 assigned EPO
Cardiac enzymes measured 
over 24 hours
25 assigned Placebo
Cardiac enzymes measured 
over 24 hours
22 with cardiac MRI 
within 6 days
19 with cardiac MRI 
within 6 days
16 with CMR at 4 months18 with CMR at 4 months
No CMR
2 Claustrophobia
2 Declined
No CMR
2 Claustrophobia
4 Declined
No CMR
2 Abroad
1 Claustrophobia
1 Declined
No CMR
1 Abroad
1 Claustrophobia
1 Death
 
Exclusion Criteria 
 
Exclusion criteria included abnormal renal function (serum creatinine >120 µmol/L), known 
thromboembolic disorder, malignant disease, multi-vessel disease, failure to achieve TIMI 3 
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flow at the end of the PCI procedure, cardiogenic shock and cardiac arrest. Patients were 
excluded from CMR if they had any metal implants which rendered CMR unsafe or if they 
were claustrophobic.  
Procedures 
 
Potentially eligible patients were approached at their acute admission with their STEMI. Due 
to the time pressures involved of this emergency treatment a rapid assessment of preliminary 
eligibility was made and consent taken. However entry in to the trial was not confirmed until 
following the PPCI and the patient had fulfilled the pre-specified inclusion criteria and did 
not meet any excludion criteria, as above. Patients were randomly allocated to receive either 
EPO treatment or placebo prior to PPCI. A computer-generated blocked randomisation list 
was prepared in advance of the trial. Treatment allocation was undertaken by a Clinical 
Research Fellow (not involved with assessing clinical outcomes or the PPCI procedure) using 
sealed opaque envelopes. The patient, the PPCI operator, and the assessor of clinical 
outcomes were blinded to the treatment allocation.  
Investigational agent 
 
The EPO treatment arm comprised 50,000 IU of rhEPOβ (Neorecormon, Roche Ltd., 
Welwyn Garden City, UK) in 10 mls 0.9% saline, whereas the placebo comprised 10 mls 
0.9% saline. Either was administered via a peripheral intravenous cannula over 2 minutes 
prior to PPCI, with an additional rhEPOβ dose or placebo administered via the same route 24 
hours following PPCI. Once reconstituted the solutions were identical. This dose of rhEPOβ 
was obtained from a previously published proof-of-concept clinical study which suggested 
that rhEPOβ (33,000 IU) administered daily for 3 days (total dose 99,000 IU) may be 
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beneficial in stroke patients
240
. We used this total dose but over 24 hours to ensure no barrier 
to early discharge if indicated on day 2.  
Percutaneous Coronary Intervention 
 
PPCI was undertaken according to the Cardiologists‘ preference with no restriction placed on 
vascular access route, type of stent or method of stenting (predilatation or direct). Bystander 
PCI was permitted as long as this was not a second culprit vessel. However, thrombolytics 
and adenosine were not used.  
Study end-points 
 
Blood samples for Troponin-T and CK-MB were taken prior to PPCI and 6, 12, 24 hours 
post-procedure. Blood samples for haemoglobin, haematocrit, platelet count, prothrombin 
time, and renal function were taken at baseline and at 2 days post-PPCI.  
 
The primary end-point was myocardial infarct size, determined by the 24 hour area-under-
curve (AUC) serum Troponin-T. Secondary end-points included 24 hour AUC serum CK-
MB, and CMR-determined myocardial infarct size, myocardial salvage index, LV volumes, 
mass and ejection fraction, and the presence of MVO. All in-hospital major adverse cardiac 
and cerebrovascular events (MACCE) were recorded and patients undergoing CMR at 4 
months were interviewed for any MACCE during the follow up period. 
CMR imaging 
 
CMR imaging was performed at a median of 2 days from PPCI (range 1 to 6 days) and 
repeated at 4 months using a 1.5-T scanner (Avanto-Siemens, Erlangen, Germany). Patients 
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were transferred (using a critical care ambulance service with medical escort) to Great 
Ormond Street Hospital for CMR to take place as at the time of the study there was no CMR 
scanner on site at The Heart Hospital.  Left ventricular (LV) function and volumes were 
assessed by standard steady-state free precession technique. Consecutive short-axis views 
were obtained by encompassing the LV from base to apex; vertical and horizontal long-axis 
views were acquired. Typical image parameters were as follows: TE 1.16ms, TR 2.73ms, 
flip-angle 65°, matrix 144x192, slice-thickness 7mm, gap 3mm. A velocity encoded aortic 
flow map was acquired to confirm LV volumes. Rest myocardial perfusion images were 
evaluated with a first-pass technique using a T1-weighted multi-shot gradient echo-planar 
inversion-recovery sequence (TR 2.6ms, TE 1.1ms, TI 200ms, flip-angle 12°, slice-thickness 
10mm). Three short-axis slices (basal, mid-cavity, and apex) were obtained injecting 
0.2mmol/kg gadolinium (Dotarem®; Guerbet SA, Paris, France) at 2ml/s followed by a 20ml 
saline flush into an antecubital vein. Early gadolinium enhancement (EGE) images were 
acquired 1-2 minutes after gadolinium injection with a fixed inversion time (TI) of 440ms. 
Two-dimensional slices in LV short axis were imaged with no inter-slice gap. (TR 7.0ms, TE 
4.9ms, flip-angle 23°). Late gadolinium enhancement (LGE) images were acquired in long- 
and short-axis views with a segmented inversion-recovery fast gradient echo sequence 10 
minutes after the contrast injection. Sequence parameters were as follows: TR 8.9ms, TE 
4.9ms, flip-angle 25°, slice-thickness 7mm, gap 3mm. The inversion time was optimised to 
null normal myocardium. 
CMR analysis  
 
All CMR images were analysed by an experienced CMR reader (A.L. or J.H.). All LV 
volume data were independently and blindly analysed by both readers. LV ejection fraction, 
end-systolic and end-diastolic volumes and mass were calculated from segmentation of the 
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LV and indexed to body-surface-area (see figure 2). The EGE images were assessed 
qualitatively for the presence or absence of microvascular obstruction (MVO) (see figure 3). 
Myocardial infarct mass was measured by manual segmentation of areas of LGE and 
analysed by concordance between the two readers. In case of discordance, blinded review by 
a level III accredited CMR reader (J.M. or D.J.H.) was performed. Analysis was performed 
using Osirix (version 3.5.1) software. Inter-observer variability was calculated (table 4).
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Figure 2: Example of LV segmentation analysis. 
 
The figure shows one slice in short axis through the left ventricle at end diastole (left panel) 
and end systole (right panel) with manual traces around the endocardial and epicardial 
borders. This is repeated throughout the ventricle allowing total cavity and myocardial 
volumes to be calculated 
 
Figure 3: Representative images of gadolinium enhancement from an initial CMR scan. 
* *
  
The left panel displays early gadolinium enhancement revealing evidence of microvascular 
obstruction (*) and the right panel, late gadolinium enhancement depicting a transmural 
myocardial infarct (arrow) with a core of microvascular obstruction (*). 
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Determining the myocardial salvage index  
 
When assessing the efficacy of a reperfusion treatment strategy, it is essential to express 
myocardial infarct size (IS) as a percentage of the area-at-risk (AAR). In this study, the AAR 
was quantified using both coronary angiography (modified Bypass Angioplasty 
Revascularisation Investigation [BARI]
273
 (figure 4) and modified Alberta Provincial Project 
for Outcome Assessment in Coronary Heart Disease [APPROACH] (figure 5) jeopardy 
scores)
299
 and the acute CMR scan (infarct endocardial-surface-area [Infarct-ESA](figure 
6))
299
. As a measure of the AAR, infarct-ESA has been validated against the BARI and 
modified APPROACH scores
299
 and T2-weighted imaging of myocardial oedema
340
. 
Myocardial salvage index was calculated as follows (AAR-IS)/AAR. 
 
Figure 4: Diagram to show the BARI angiographic myocardial risk score
273
 and how it may 
be applied to a right coronary artery occlusion. 
RCA
LCx
LAD
2
2
2
2
3
3
1
1 1
2
RCA = 4
LCx = 6
LAD = 9
Total LV = 19
RCA infarct = 4/19 x 100
 
RCA- right coronary artery, LCx- left circumflex artery, LAD- left anterior descending, LV- 
left ventricle. 
 
Page 144 of 236 
 
Figure 5: The modified- Alberta Provincial Project for Outcome Assessment in Coronary 
Heart Disease (APPROACH) angiographic myocardial risk score.
299
 
Culprit lesion 
location 
Infarct related artery side 
branches 
Diagonal for LAD occlusion only 
Or 
Posterolateral for all others 
Small or 
absent 
Medium Large 
LAD (RD or 
LD) 
 Distal 13.75 14.8 15.9 
Mid 27.5 29.7 31.8 
Proximal 41.25 44.5 47.75 
Proximal 
LCx (RD) 
OM Small or 
absent 
9.25 12.5 15.75 
Medium 15.25 18.5 21.75 
Large 21.25 24.5 27.75 
Proximal 
LCx (LD) 
PDA Small or 
absent 
23.5 28 32.5 
Medium 29.5 34 38.5 
Large 35.5 40 44.5 
Mid LCx 
(LD) or RCA 
(RD) 
PDA Small or 
absent 
9.25 12.5 15.75 
Medium 15.25 18.5 21.75 
Large 21.25 24.5 27.75 
Mid LCx 
(RD) 
 3.25 6.5 9.75 
LAD-left anterior descending, RCA- right coronary artery, LCx- left circumflex artery, PDA- 
posterior descending artery, LD- left dominance, RD- right dominance. 
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Figure 6: The infarct- endocardial surface area (infarct-ESA) method of measuring 
myocardial area at risk.
299
 
 
The endocardial surface area of the infarct (red) is traced on each slice through the left 
ventricle in short axis and expressed as a percentage of the total LV endocardial surface area 
(red and green) which gives a percentage of LV myocardium at risk. 
 
Statistical analysis 
 
The patient cohort was made up of those patients who fulfilled all study entry criteria at the 
end of their PPCI procedure and successfully received the correct study protocol. Descriptive 
statistics were computed to summarise the relevant features of the data. An unpaired t-test 
was used to test the differences in means in the EPO versus placebo groups for continuous 
data and 95% confidence intervals were calculated for the difference of the means between 
the EPO and placebo groups. The assumptions of the t-test were examined using residuals 
analysis. A sensitivity analysis was performed where individual patients had Studentised 
residuals greater than two standard deviations by omitting these patients from the analysis 
and examining the impact to the mean difference and 95% confidence intervals. A Bland-
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Altman
341
 plot was used to calculate the difference and limits of agreement between the two 
observers for each continuous clinical measurement. The number of measurements falling 
outside the limits of agreement was used as a heuristic guide to agreement. A paired t-test of 
the measurements was used to formally test that the difference of the means of the two 
measurements was zero. In addition, the reliability (intra-class correlation) was computed for 
each continuous clinical measurement. A kappa statistic was calculated to measure the 
observer agreement for categorical clinical measurements. For categorical data a Z-test of 
proportions was used to test the equality of the proportion of patients in the EPO group versus 
the control group. An approximate 95% confidence interval for the difference in the 
proportions in the two groups was also calculated.  
At study inception there were no similar studies that had used Troponin-T as an end point or 
reduction in myocardial infarct size as measured by cardiac MRI and therefore gauging 
treatment effect in order to estimate sample size was based on the successful study of 
ischaemic post-conditioning in acute myocardial infarction
30
. The sample size was therefore 
calculated from the effect on total CK from this study with the presumption that Troponin 
release would be similarly affected. A sample size of at least 44 patients in total was 
determined based on the following assumptions: (a) A 36% reduction in total Troponin T 
release (b) power of at least 80%; (c) a standard deviation of 40%; and (d) significance 
declared at the two-sided 5% level. All analyses were done with Stata version 11 or SPSS 
statistical software version 15.0. 
Results 
 
110 patients were screened for inclusion in the study with 20 patients immediately recognised 
as ineligible. At this stage 90 patients were consented for the study prior to coronary 
angiography. Following angiography a further 39 patients were excluded as more criteria for 
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exclusion were identified. Therefore 51 patients were successfully randomised, to receive 
either placebo (n=25) or rhEPOβ (n=26) (figure 1). The treatment groups were well balanced, 
apart from a non-statistically significant predominance of LAD infarcts in the placebo group, 
and the characteristics are summarised in tables 1 and 2. There was good agreement using the 
three different scores to measure the area-at-risk. Table 3 summarises the AAR scores and the 
main results. Myocardial infarct size assessed by 24 hour AUC serum Troponin T and CK-
MB (figure 7) and by the initial and follow-up CMR scan showed a non-significant increase 
in the EPO-treated group compared to placebo. Unexpectedly, at the initial CMR scan, the 
presence of microvascular obstruction was almost doubled in the EPO-treated group when 
compared to placebo. Furthermore, there was an increase in indexed LV end-systolic and 
end-diastolic volumes and mass in the EPO-treated group compared to placebo (figure 8 and 
9). There were no significant differences between the groups in terms of the LV stroke 
volume index and LV ejection fraction and the myocardial salvage index.  There were no 
significant differences in the CMR end-points on the 4 month follow-up scan, although there 
 
Table 1. Patient characteristics 
 EPO 
(n=26 ) 
Placebo 
(n=25 ) 
 
Age, mean yrs  
 
55.5 (12.8) 
 
61 (10.0) 
Men  23 (88) 21 (84) 
Hypercholesterolemia  7 (30) 13 (50) 
Diabetes Mellitus  3 (12) 2 (8) 
Hypertension  10 (39) 13 (50) 
Family History of IHD  4 (17) 5 (21) 
Previous MI  2 (9) 1 (4) 
Previous Angina  1 (4) 1 (4) 
Respiratory Disease 2 (9) 1 (4) 
Smoking status  
Never 
Ex-smoker 
Current 
 
10 (38) 
5 (19) 
11 (43) 
 
9 (36) 
4 (16) 
12 (48) 
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 EPO 
(n=26 ) 
Placebo 
(n=25 ) 
Medication at presentation (%) 
Aspirin 
Clopidogrel 
ACE-I/ARB 
Beta-blocker 
CCB 
Statin 
Nitrate 
Sulphonylurea 
Metformin 
PPI 
 
5 (19) 
0 
4 (15) 
1 (4) 
3 (12) 
4 (15) 
1 (4) 
1 (4) 
2 (8) 
1 (4) 
 
5 (20) 
0 
6 (24) 
2 (8) 
1 (4) 
6 (24) 
0 
2 (8) 
2 (8) 
1 (4) 
 
Blood result at presentation 
Hb (g/dl)  
Haematocrit  
Platelet count (10
9
/L) 
Prothrombin Time (secs) 
Creatinine (µmol/l)  
 
 
14.7 (1.2) 
0.42 (0.03) 
256 (53) 
10.7 (0.7) 
83 (15) 
 
14.2 (1.1) 
0.41 (0.03) 
254 (76) 
10.5 (0.5) 
79 (14) 
Blood Result Day 2 
Hb (g/dl)  
Haematocrit  
Platelet count (10
9
/L) 
Creatinine (µmol/l)  
 
 
13.6 (1.6) 
0.40 (0.04) 
217 (53) 
83 (14) 
 
13.6 (1.6) 
0.39 (0.04) 
234 (83) 
82 (15) 
Data are number (%) or mean (SD). ARB- Angiotensin receptor blocker. CCB- calcium 
channel blocker. PPI- proton pump inhibitor. 
 
Table 2. Details of PPCI procedure 
 EPO Placebo 
Culprit vessel  
LAD  
LCx 
RCA 
 
 
10 (38) 
7 (27) 
9 (35) 
 
13 (52) 
4 (16) 
8 (32) 
Symptom to PPCI time, mean (mins) 
 
224 (104) 257 (156) 
Door to balloon time, mean (mins)  
 
56 (24) 39 (16) 
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 EPO Placebo 
Medication during PPCI  
Asprin 
Clopidogrel 
Heparin 
Opiate 
Nitrate 
Abciximab 
Metoclopramide 
Atropine 
 
26 (100) 
26 (100) 
26 (100) 
15 (58) 
13 (50) 
25 (96) 
7 (27) 
4 (15) 
 
 
25 (100) 
25 (100) 
25 (100) 
13 (52) 
16 (64) 
23 (92) 
10 (40) 
7 (28) 
Mean TIMI flow before PPCI (grade) 0 0 
Mean TIMI flow after PPCI (grade) 3 3 
Rentrop Grade (Collateralisation) 0 0 
Lesion predilated 25 (96) 23 (92) 
Direct stent to lesion  1 (4) 2 (8) 
Bare Metal Stent  17 (65) 16 (64)* 
Drug Eluting Stent  9 (35) 10 (40)* 
Mean arterial pressure, mmHg  
Pre-PCI 
Post PCI 
Day 2 
Follow up 
 
110 (14) 
97 (16) 
93 (14) 
102 (15) 
 
111 (22) 
95 (22) 
95 (11) 
103 (17) 
Median length of hospital stay, days (range) 
 
3.0 (2 to 6) 3.5 (2 to 10) 
Medication on discharge (%) 
Aspirin 
Clopidogrel 
ACE-I/ARB 
Beta-blocker 
Statin 
PPI 
 
25 (96) 
26 (100) 
25 (96) 
23 (88) 
26 (100) 
3 (13) 
 
25 (100) 
25 (100) 
25 (100) 
20 (80) 
25 (100) 
1 (5) 
Medication at follow-up (%) 
Aspirin 
Clopidogrel 
ACE-I/ARB 
Beta-blocker 
Statin 
PPI 
 
16 (89) 
12 (67) 
17 (94) 
14 (78) 
15 (83) 
1 (6) 
 
14 (88) 
12 (75) 
13 (81) 
12 (75) 
13 (81) 
1 (6) 
Median time to acute CMR scan (range) 2 (1 to 4) 2 (1 to 6) 
Median time to follow-up CMR scan (range) 126 (116 to 
160) 
131 (106 to 
163) 
Data are number (%) or mean (SD). LAD- left anterior descending artery. LCx- left 
circumflex artery. RCA- right coronary artery. ARB- Angiotensin receptor blocker. PPI- 
proton pump inhibitor. *One patient received both bare metal and drug eluting stent. 
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Table 3. Clinical outcomes 
 EPO Placebo Difference (95% CI) P-value 
Initial blood results, myocardial area-at-risk and CMR scan 
24 hr Troponin-T AUC (µg/l) 114.6 100.8  13.81( -29.69, 57.31) 0.526 
24 hr CK-MB AUC (U/l) 4682.3 3649.1 1033.2(-562.7, 2629.1) 0.199 
BARI score (%) 29 33 -3.8 (-8.6, 1.0) 0.12 
APPROACH score (%) 30 31 -0.8(-6.8,5.2) 0.8 
Infarct-ESA by CMR (%) 28 27 0.8(-5.4, 7.0) 0.8 
Myocardial infarct mass (g)  32.8 25.4 7.46 (-2.76, 17.69) 0.148 
Myocardial salvage Index 0.38 0.47 -0.09 (-0.28, 0.10) 0.333 
Microvascular obstruction (%) 81.8 47.4 34.4 (6.8, 62.1) 0.020 
LVEDVi (mL/m
2
) 84.4 73.0 11.40 (4.05, 18.75) 0.003 
LVESVi (mL/m
2
) 41.3 34.6 6.77 (0.45, 13.09) 0.036 
LVSVi (mL/m
2
)  43.1 38.4 4.63 (-0.44, 9.70) 0.072 
LVMi (g/m
2
)  89.2 79.4 9.78 (0.94, 18.63) 0.031 
LVEF (%)  51.3 53.2 -1.87 (-7.40, 3.66) 0.499 
4 month follow-up CMR endpoints 
LVEDVi (mL/m
2
)  88.1 84.4 3.74 (-10.11, 17.58) 0.586 
LVESVi (mL/m
2
)  42.7 36.4 6.30 (-6.60, 19.21) 0.327 
LVSVi (mL/m
2
)  45.4 48.0 -2.56 (-8.24, 3.11) 0.364 
LVMi (g/m
2
)  82.4 75.0 7.33 (-5.00, 19.56) 0.235 
LVEF(%)  52.6 59.1 -6.46 (-13.94, 1.01) 0.088 
Myocardial infarct mass (g) 17.7 12.4 5.31 (-0.57, 11.19) 0.075 
Page 151 of 236 
 
Values are mean (SD). AUC- area-under-curve. LVEDVi- Indexed left ventricle end-diastolic 
volume. LVESVi- Indexed left ventricle end-systolic volume. LVSVi- Indexed left ventricle 
stroke volume. LVMi- Indexed left ventricle mass. LVEF- left ventricle ejection fraction.  
 
Figure 7: Graphs to show cardiac enzyme release following PPCI. 
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Mean serum Troponin-T (left panel) and CK-MB (right panel) concentrations over 24 hours 
in patients treated with PPCI. Error bars show SEM. 
Figure 8 and 9: Cardiac magnetic resonance imaging results. 
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Graphs to show the indexed left ventricular end diastolic volume (LVEDVi), end systolic 
volume (LVESVi), stroke volume (LVESVi) and mass (LVMi) in EPO and placebo groups at 
the acute scan and follow up. * indicates significant result with p<0.05. Error bars are SEM. 
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was a trend to increased infarct size and reduced LV ejection fraction in the EPO-treated 
group compared to placebo.  
There was good to excellent agreement between observers with the intra class 
correlation (ICC) ranging between 0.7 and 0.95 (table 4). Due to the trial size there was some 
sensitivity in the mean differences due to observations identified as outliers but there were no 
substantive changes in the conclusions drawn. 
 
Table 4: Calculated inter-observer agreement for analysis of left ventricular volumes and 
microvascular obstruction from the magnetic resonance imaging results. 
 
 
 
 
N Reliability 
(ICC) 
Difference (95% 
Limits of agreement) 
MVO (%) 41  82.6%  N/A 
LVEDV  (ml/m
2
) (scan 1) 41 93.7% 2.70 (-16.58, 21.97) 
LVESV (ml/m
2
) (scan 1) 41 87.9% 1.61 (-17.16, 20.51) 
Myocardial mass (g) (scan 1)  41 77.3% -13.03 (-44.91, 18.85) 
LVSV (ml/m
2
) (scan 1) 41 90.5% 1.02 (-15.72, 17.76) 
LVEDV  (ml/m
2
) (scan 2) 34 95.2% -0.69 (-24.74, 23.36) 
LVESV (ml/m
2
) (scan 2) 34 95.2% -0.17 (-21.01, 20.67) 
Myocardial mass (g) (scan 2)  34 65.8% -17.66 (-45.87, 10.54) 
LVSV (ml/m
2
) (scan 2) 34 85.8% -0.52 (-19.09, 18.05) 
LVEDV- Left ventricle end-diastolic volume. LVESV- Left ventricle end-systolic volume. 
LVSV- Left ventricle stroke volume. LVM- Left ventricle mass. MVO- microvascular 
obstruction. 
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Adverse Events 
 
Due to the high risk nature of STEMI adverse events (see table 5) are to be expected but of 
course must be monitored and each reported. 
Three serious adverse events were reported to the trial sponsor and ethics committee. The 
first was a patient (RM) who was initially deemed eligible for the study but was eventually 
excluded as it was discovered he had had a ventricular fibrillation cardiac arrest en route to 
The Heart hospital. RM was recruited to the study, allocated to the erythropoietin group and 
successfully completed all initial aspects. Whilst making contact to arrange the follow up 
scan it was discovered that he had died from a spontaneous intracranial haemorrhage. An 
investigation with independent review was conducted which concluded that the trial was 
unlikely to have played a role in this death. 
The second was a patient (MA) who was recruited to the placebo arm of the study.  On day 1 
post-MI the patient developed an ischaemic lower limb which required vascular surgery. 
Post-operatively myocardial ischaemia was noted and repeat PCI planned to treat residual 
disease noted at the index coronary intervention. Unfortunately during this procedure the 
patient suffered a cardiac arrest and died. Following an independent review, the trial was 
found to have no role in the causation of this incident. This patient had undergone the acute 
CMR scan and so accounts for 1 drop out from the follow up scan. 
The third patient (RN) was consented and randomised in to the EPO arm of the study. His 
blood pressure at the start of the cardiac catheterisation, at the same time as receiving the first 
dose of EPO, fulfilled criteria for cardiogenic shock. During the PPCI treatment for his 
inferior STEMI he sustained a cardiac arrest and subsequently died. Once again the case was 
reviewed with the clinical consultant and an independent reviewer who acknowledged that 
the onset of cardiogenic shock was prior to EPO administration and the trial was not thought 
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to have played any role. Due to the pre-existing cardiogenic shock and cardiac arrest, both 
exclusion criteria for this study, the patient was excluded. Also due to the development of 
cardiogenic shock and death no meaningful results were obtained from this patient.  
 
During the initial PCI 1 patient in the EPO group and 2 in the placebo group underwent non-
culprit vessel PCI. In the group eligible for analysis there was one death in the placebo group 
(as above). Over the follow up period 5 patients in the EPO group were admitted unplanned 
to hospital for investigation of chest pain versus 1 from the placebo group. 1 patient from the 
EPO group underwent unplanned CABG surgery and 2 patients from each group underwent 
PCI planned at the index admission. At follow up 1 patient was found to have a left 
ventricular thrombus which was brought to the attention of the clinical team. The unplanned 
CABG and hospital admissions in the EPO group made up a MACCE rate in the analysis 
group of 23% (6/26) and 8% (2/25) in the placebo group (p=NS). (Table 5). 
 
Table 5: In-hospital adverse events rate and up to 4 months in those with a follow-up CMR 
scan. 
 
 EPO Placebo P 
Bystander PCI, n (%) 1 (4) 2 (8)  
All cause mortality, n 
(%) 
0 1 (4)  
Cardiac Death, n (%) 0 1 (4)  
MI/Unstable Angina, 
n (%) 
0 0  
Hospital Admission, n 
(%) 
5 (19) 1 (4)  
Unplanned PCI or 1 (4) 0  
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 EPO Placebo P 
CABG, n (%) 
Planned PCI, n (%) 2 (8) 2 (8)  
LV Thrombus 1 (4) 0  
Total MACE, n (%) 6 (23) 2 (8) 0.2 
 
Study Limitations 
 
This clinical study was conducted in a group of patients who are seriously unwell and where 
there is a considerable pressure to achieve treatment within a target ‗door to balloon time‘. As 
such all patients were approached for consideration and consented provisionally pending the 
identification of exclusion criteria. In order to replicate the conditions of the pre-clinical 
studies the study entry criteria are necessarily strict. The basic science would suggest that the 
most benefit is achieved in this group and hence in order to demonstrate efficacy these 
criteria were chosen. This does have the effect however of limiting the real world 
applicability of the intervention. This is not necessarily a problem as some existing treatments 
are only efficacious in certain patient groups, but it is a matter of identifying the correct 
group. Subsequently although a large number of patients were consented, exclusion criteria 
were often identified and these patients took no further part in the study. If this study had 
been successful it would have potentially been necessary to look at the effect of EPO in a 
larger group of ‗all-comers‘ to address efficacy in a less homogenous population. As such the 
data analysis is conducted on a per-protocol basis although the patients were all selected on 
pre-specified criteria. Clearly, whilst adequately powered, the study is of small numbers and 
as such the generalisability of the findings is limited. The mechanism of protection of EPO in 
this setting is still uncertain and we did not attempt to elucidate this any further. The numbers 
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of patients undergoing cardiac MRI was less than anticipated and related to a number of 
issues, largely patient choice but also difficulties in faciliting transfer across London within 
48 hours of an acute MI to the CMR unit. A CMR scanner on site (as is now the case) would 
have been considerably easier. Further drop out was observed between first and second scans 
and reflected the difficulties of ensuring 100 percent follow up in such studies. 
 
Discussion 
 
The major findings of this proof-of-concept randomised clinical trial are that the 
administration of high-dose rhEPOβ as an adjunct to PPCI had no beneficial effects in terms 
of myocardial infarct size, myocardial salvage index, or LV ejection fraction. In fact, the 
findings suggest that rhEPOβ may actually be detrimental in this setting, as it almost doubled 
the incidence of microvascular obstruction (MVO). Furthermore, it was associated with acute 
LV dilatation and an acute increase in calculated myocardial mass. On the 4 month follow-up 
CMR scan there were no significant differences between the treatment groups although there 
is a noticeable trend to increased infarct size and reduced LV ejection fraction in the EPO 
group. Adverse events were increased in the EPO group but not significantly so. 
It is well-established that in STEMI patients successfully treated with PPCI, the 
presence of MVO is associated with worse clinical outcomes
342 343
. MVO can be detected in 
about 30-40% of PPCI patients using echocardiography
344
 or CMR
292 343
, even in the 
presence of Thrombolysis in Myocardial Infarction (TIMI) 3 coronary artery flow post-PPCI. 
In our study, in patients treated with rhEPOβ the incidence of MVO detected by the initial 
CMR scan was dramatically increased from 47% in placebo to 82%, a finding which might 
be expected to be associated with worse clinical outcomes. Importantly, factors which are 
known to impact on the development of MVO such as the presence of co-morbid conditions, 
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anti-platelet and anticoagulant therapy, and myocardial infarct size were not significantly 
different between the two treatment groups. MVO results in poor myocardial perfusion 
despite epicardial coronary artery revascularisation and its development has been attributed to 
a variety of factors including distal embolisation, endothelial dysfunction, leucocyte 
migration and plugging and platelet aggregation
345
. The mechanism underlying the increased 
incidence of MVO following PPCI in the rhEPOβ-treated group in our study is unknown but 
may be attributed to the increased platelet reactivity and the pro-thrombotic effects which 
have been described with rhEPO therapy in healthy subjects
346
, in critically ill patients
347
, and 
in patients with chronic kidney disease
254 348
, cancer
349
 and stroke
350
. Interestingly, high-dose 
rhEPO (intravenous 400 IU/kg given daily for 3 days) significantly blunted the aspirin-
mediated increase in bleeding time when compared with placebo in healthy volunteers, 
although no effect was observed on the clopidogrel-mediated increase in bleeding time
255
.  
The explanation for the increased myocardial mass (calculated from the myocardial 
volume) observed on the initial CMR scan, in patients treated with rhEPOβ is unknown. It 
may have been due to enhanced myocardial oedema associated with increased myocardial 
injury, as suggested by the greater incidence of MVO in the rhEPOβ-treated patients. In this 
respect, an increased indexed myocardial mass has been noted by CMR one week following 
an acute myocardial infarction in a previous study
351
.  As for the mechanism underlying the 
acute LV dilatation noted in patients treated with rhEPOβ, this may well be a compensatory 
response to greater myocardial injury, where an increase in preload provokes LV dilatation in 
an attempt to maintain the LV stroke volume.  
Interestingly, the effect of high-dose rhEPO as a novel cytoprotective agent in a 
variety of other clinical settings of ischemia-reperfusion injury including coronary artery 
bypass graft (CABG) surgery
343
, non-ST elevation myocardial infarction (NSTEMI)
345
, and 
stroke
350
, has also been negative. In a large phase II multicentre German study
350
, the 
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administration of rhEPOα (40,000 IU per day for 3 days), initiated within 6 hours of stroke 
onset, to 223 stroke patients had no beneficial effects in terms of cerebral infarct size and 
functional recovery, when compared to 237 stroke patients given placebo. Importantly, 
rhEPOα treatment was associated with a significant increase in death rate of 16.4% compared 
to 9.0% in patients administered placebo at 90 days (OR, 1.98; 95% CI, 1.16 to 3.38;P<0.01), 
a significant proportion (15.2%) of which were due to thromboembolic complications
350
.  
In a preliminary study comprising 22 patients receiving PPCI the administration of an 
intravenous bolus of darbepoetin alpha (300µg equivalent to about 60,000 IU rhEPOα) did 
not report any safety concerns
243
. The administration of rhEPOβ (30,000 IU) prior to 
tenecteplase thrombolysis in STEMI patients failed to find any difference in cardiac enzyme 
release or any difference in major adverse cardiac events
245
. A small clinical study has 
reported that the administration of rhEPOα (33,000 IU daily for 3 days) to PPCI patients 
reduced CK-MB release but failed to limit myocardial infarct size on a CMR scan performed 
within 3 days of PPCI
248
. In that study, the effect of rhEPO on CMR-detected MVO was not 
reported. 
There are several ongoing multi-centre studies investigating the effects of high-dose 
rhEPO in PPCI patients (including HEBE-III
352
, EPAMINONDAS
353
, and REVIVAL-3
354
), 
of which the preliminary findings from the REVIVAL-3 study were presented at last year‘s 
American College of Cardiology Scientific Sessions
354
. In that study comprising 138 PPCI 
patients, it was reported that treatment with rhEPOβ (33,333 IU daily for 3 days) had no 
difference on LV ejection fraction measured at 6 months by CMR, and that there was a trend 
to adverse cardiovascular outcomes (death, recurrent myocardial infarction, infarct-related 
artery revascularisation and stroke)
354
.  
In our study, the failure of rhEPOβ to reduce myocardial infarct size in PPCI patients 
is in conflict with the pre-clinical data reporting 50% reductions in myocardial infarct size in 
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rat, rabbit and dog models of ischemia-reperfusion injury, with EPO administered at time of 
reperfusion
337
. Interestingly, the infarct-limiting effects of EPO as reperfusion therapy in 
larger animal studies of ischemia-reperfusion injury such as sheep
214
 and porcine
208
 have 
been negative. Discordant findings between pre-clinical animal studies and the clinical 
translation of novel cardioprotective strategies has been a recurring issue, the causes of which 
have been highlighted in several recent articles
7 326 355
. Specifically, the pro-inflammatory and 
pro-thrombotic conditions associated with an acute myocardial infarction in a middle-aged 
patient with co-morbidities such as diabetes, dyslipidaemia and hypertension are not 
reproduced by experimental coronary artery occlusion in disease-free juvenile small to 
medium-size animal models. 
In summary, we have demonstrated that the administration of high-dose rhEPOβ as an 
adjunct to PPCI failed to reduce myocardial infarct size or improve cardiac function. In fact, 
its use may actually be detrimental in that it was associated with a doubling in the incidence 
of MVO, acute LV dilatation and increased myocardial mass. This study highlights the 
importance of CMR as a technique for assessing the safety and efficacy of novel reperfusion 
therapies. The findings from the current study should be considered in the design of future 
studies investigating the use of high-dose rhEPO in patients with acute myocardial infarction. 
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CHAPTER 5 
Targeting the reperfusion injury salvage kinase pathway in the clinical 
setting: Lost in translation 
 
Introduction 
 
This thesis has examined the use of atorvastatin and erythropoietin as pharmacological 
mimetics of ischaemic preconditioning in two different clinical settings of myocardial 
ischaemia-reperfusion injury. Neither agent was shown to have beneficial effects despite 
significant pre-clinical data which suggested that they would and as such this effect could be 
regarded as ‗lost in translation‘. This is not a novel issue, as since ischaemic preconditioning 
was first described there is yet to be a successfully translated technique which has been 
adopted to routine clinical practice and replicates the extraordinary protection seen in the 
animal setting.  Coronary heart disease still represents a huge burden of morbidity and 
mortality (see chapter 1) and it is not doubted that further improvement in treatment is 
needed. Novel cardioprotective strategies are required and ‗cardioprotection‘ has long been 
regarded as one method which may be successful in accomplishing this.  
This chapter aims to examine the reasons behind why the two agents studied were not 
protective and to look at the wider issues surrounding this which have become apparent to the 
author during the conduct of this research degree.  
Inparticular the shortcomings of the current animal experimental disease models which are 
used in this area of research will be examined, areas highlighted where more representative 
animal disease models exist, the relevance to the studies reported in this thesis will be 
emphasised and finally the design of clinical cardioprotection studies will be discussed in 
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order to increase the overall success in translating cardioprotective treatment strategies from 
‗bench to bedside‘. 
Background 
Since the realisation that cardiomyocyte death was not inevitable following coronary artery 
occlusion the search has been on for techniques or pharmacological agents capable of 
limiting myocardial infarct size. A major conceptual leap forward was the discovery that 
restoring coronary artery blood flow following an acute occlusion could limit ischaemic 
myocardial injury
356
, a finding which is still currently the optimal therapeutic strategy for an 
acute coronary artery occlusion. However, the process of reperfusing ischaemic myocardium 
is a ‗double-edged sword‘357, and can in itself induce cardiomyocyte death (a concept termed 
lethal reperfusion injury and reviewed in
7
). The concept of cardioprotection was first 
conceived in the late 1960s, and has evolved to include the endogenous cardioprotective 
phenomenon of ‗Ischaemic Conditioning‘, a concept in which the heart can be protected from 
an episode of acute ischaemia-reperfusion injury by applying brief non-lethal episodes of 
ischaemia and reperfusion either to the heart itself or an organ or tissue remote from the 
heart. The advent of interventional strategies and pharmacological agents capable of limiting 
myocardial injury when applied either before or during myocardial ischaemia or at the onset 
of myocardial reperfusion has demonstrated the potential application for cardioprotection. 
The development of novel treatment strategies for protecting the myocardium against the 
detrimental effects of acute ischaemia-reperfusion injury and improving clinical outcomes in 
patients with CHD requires the use of appropriate animal disease models. Despite the ability 
to demonstrate this enhanced cardioprotection in a wealth of experimental animal disease 
models, the translation to the human clinical setting has been largely disappointing
355 358
.  
 
Page 162 of 236 
 
Current animal models used to investigate myocardial ischaemia-reperfusion injury 
 
Applying one or more brief non-lethal episodes of ischaemia and reperfusion to the heart 
itself (‗ischaemic conditioning‘) or to an organ or tissue away from the heart (‗remote 
ischaemic conditioning‘), has been widely reported to dramatically reduce the size of a 
myocardial infarct by 40-50% in a variety of different animal disease models. The 
‗conditioning‘ non-lethal episodes of ischaemia and reperfusion are able to elicit 
cardioprotection when applied prior to the index myocardial ischaemia
18 359
, or after the onset 
of index myocardial ischaemia (perconditioning)
360
 or even at the onset of myocardial 
reperfusion (postconditioning)
361 362 
.  
Isolated in vitro buffer-perfused animal hearts subjected to regional or global 
ischaemia and reperfusion at the end of which cardiac enzyme release, infarct size or cardiac 
function are determined have been the mainstay for investigating potentially new treatment 
strategies for protecting the heart against acute ischaemia-reperfusion injury. This model is 
the one used in the pre-clinical study
78
 upon which the clinical atorvastatin studies in this 
thesis are based.  This animal disease model provides a robust, reproducible, and efficient 
infarct model in which treatment strategies can be administered prior to infarction, during 
myocardial ischaemia or at the time of myocardial reperfusion. In vivo animal disease models 
of acute myocardial infarction which may be technically more demanding, take into account 
the effects of an intact nervous system and circulation.  However, on a number of different 
levels these animal disease models cannot be expected to be representative of the complex 
human clinical setting of an acute myocardial infarction.  
The response of the heart to acute myocardial ischaemia-reperfusion injury varies 
depending on the animal disease model of myocardial infarction used. For example, in rodent 
models of myocardial infarction, 30-40 minutes of either regional or global myocardial 
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ischaemia is sufficient to induce an infarct size, 50% of the area at risk. However, in the 
porcine heart, longer durations (60-90 minutes) of myocardial ischaemia are required to 
achieve equivalent levels of infarction. Human myocardial infarcts generally require 90 
minutes to establish, with maximum salvage possible before 6 hours and little benefit derived 
from reperfusion beyond 12 hours. Primate models can be used (principally macaque 
monkeys) which, although more representative of the human physiology, are prohibitively 
expensive.  In addition, in these experimental models short periods of myocardial reperfusion 
are used ranging from 1 to 2 hours for the in vitro studies and 2 hours to 72 hours for the in 
vivo infarct studies. The long-term effects of the cardioprotective treatment strategy in terms 
of long-term infarct size reduction, cardiac remodelling, and mortality remains undetermined. 
However, the availability of echocardiography and small animal cardiac MRI has been used 
recently to delineate the effects of cardioprotective strategies on these cardiac indices, 
thereby making the studies more clinically relevant.  
Experimental coronary artery occlusion in animal models of infarction is often 
mediated by external compression of a healthy coronary artery, whereas in the AMI patient 
the rupture of an unstable atherosclerotic plaque and the formation of thrombus are 
responsible for the acute coronary occlusion. In addition, an AMI generates an acute 
inflammatory state not easily emulated in experimental animal disease models of infarction. 
Some animal disease models have attempted to mimic the scenario of an acute myocardial 
infarct in both rodents and larger animals. Endothelial irritants such as ferric chloride applied 
within a coronary artery
363 364
 in order to activate the clotting cascade, thrombotic promotion 
with agents such as rose bengal and green light laser agitation
365
 and in the carotid artery 
partial surgical ligation and a hypercholesterolaemic diet
366
 all go some way to replicate the 
human scenario but these techniques are challenging to perform, are not widely used and are 
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unable to fully mirror the complex interplay of events occurring in acute myocardial 
infarction. Closed chest, catheter and balloon coronary artery occlusion has been used 
successfully, such as those used to investigate erythropoietin
213 214
, but requires greater 
operator ability and is easiest in large animals. This is not possible in all laboratories given 
the facilities needed and using smaller animals is even more technically challenging.  
Impact of co-morbid illnesses on cardioprotection 
 
The phenotypic patient suffering an AMI is male, aged 65 years old, has a combination of co-
morbid illnesses which can include hypertension, diabetes, metabolic syndrome, 
hyperlipidaemia and so forth. However, the majority of animal disease models are performed 
on young, healthy, male animals in the absence of any co-morbid illnesses. It is well-
established that age, gender and the presence of disease states such as hypertension, diabetes, 
the metabolic syndrome, atherosclerosis, and hyperlipidaemia can impact on how the heart 
responds to cardioprotective treatment strategies (reviewed in
367
). In general, the presence of 
such a co-morbid illness renders the myocardium resistant to cardioprotection against 
infarction by physical or pharmacological stimuli, however in some cases cardioprotection 
may still be possible but a stronger cardioprotective stimulus is required to achieve an 
effect
368
. Therefore, the development of novel cardioprotective treatment strategies should 
involve rigorous pre-clinical testing in animal disease models which take these factors into 
account. However, these animals are often significantly more expensive, and to investigate an 
agent in each disease setting would be difficult, although it would be easier to achieve using a 
collaborative strategy between different research groups. However, deficits in these 
individual models are evident as the combination of risk factors normally present in a CHD 
patient is difficult to replicate in one animal disease model. 
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Translational experimental models 
 
The testing of a cardioprotective agent in human heart tissue or controlled human in-vivo 
studies is a crucial translational step between bench and bedside. In this respect using isolated 
human cells is an obvious advance from animal cardiac cells, although obtaining human 
cardiomyocytes is not easy. A further advance is the human atrial trabeculae model pioneered 
by our laboratory
369
, in which human atrial trabeculae are isolated from right atrial appendage 
tissue harvested from patients undergoing cardiac surgery, and are subjected to simulated 
ischaemia-reperfusion injury. This in vitro model provides a method for investigating a 
variety of cardioprotective strategies in human cardiac tissue which has been exposed to all 
the risk factors contributing to CHD, although of course ventricular muscle would be 
preferable and the end point of developed contractile force is a surrogate for myocardial 
injury. This is the pre-clinical model upon which our group had shown significant benefit of 
Epo
215 
 prior to commencing the clinical study undertaken in this thesis. There exists a variety 
of surrogate models for investigating signalling mechanisms underlying ischaemic 
conditioning in human volunteers and patients, and these include models of endothelial 
function, exercise testing, coronary angioplasty and so on (reviewed in
370
). 
Designing appropriate clinical cardioprotection trials 
 
In designing the studies which are investigated in this thesis cognisance was taken of the 
significant pre-clinical data in these areas and we attempted to perform proof-of-concept 
studies which replicated as far as possible the study conditions which had previously been 
successful. Whilst this is difficult and not possible to recreate conditions 100 percent 
successfully we feel it is important to approach studies of this sort in this manner.  Too often 
in the past, in the enthusiasm to demonstrate cardioprotection in the clinical setting, many 
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interventions are rushed in to the clinical environment with conflicting or at worst no 
consistent evidence of benefit in animal studies. A working group convened by the US 
National Heart Lung and Blood Institute (NHLBI) concluded that animal studies should be 
conducted more akin to their clinical counterparts with convincing benefit shown in multi-
centre, randomised, blinded, controlled studies prior to undertaking large expensive studies in 
humans
355
.  
Furthermore, choosing the appropriate clinical setting and treatment strategy is crucial 
and it is imperative to take heed of the pre-clinical animal data in this respect. For example, 
overwhelming pre-clinical animal data suggested that cariporide (a sodium-hydrogen ion 
exchange inhibitor) was beneficial if administered prior to the index myocardial ischaemia as 
opposed to prior to myocardial reperfusion (reviewed in
371
). Therefore, it was no surprise 
then that the clinical studies demonstrated that this agent was cardioprotective in the setting 
of cardiac surgery but not in ST-elevation patients undergoing primary PCI
372
. Similarly, if 
the pre-clinical data suggests that a treatment strategy is effective only if administered either 
prior to or at the onset of myocardial reperfusion, there is little rationale for designing a study 
in which the drug is administered several hours following myocardial reperfusion. EPO was 
shown to be maximally protective in animals when administered prior to reperfusion, hence 
our clinical study aimed to ensure that patients still had an occluded coronary artery prior to 
receiving their first dose of EPO. 
Patient selection is crucial when designing clinical trials of cardioprotection strategies 
as adjuncts to myocardial reperfusion in ST-elevation MI (STEMI) patients such as the EPO 
study in this thesis. Furthermore, it has been suggested that 75% of STEMI patients obtain 
maximum benefit with prompt myocardial reperfusion alone, leaving only 25% who may 
actually benefit from an adjunct to myocardial reperfusion
373
. The current challenge is to 
Page 167 of 236 
 
identify and target this high-risk group of patients, with adjunctive reperfusion therapy in 
order to enhance myocardial salvage. In terms of myocardial salvage, STEMI patients 
presenting for myocardial reperfusion within 0 to 6 hours of chest pain accrue the most 
benefit. Whether the same applies to a cardioprotective strategy designed to attenuate lethal 
reperfusion injury is currently unclear. However, the current clinical evidence does suggest 
that those patients most likely to benefit from a cardioprotective treatment strategy 
administered at the onset of myocardial reperfusion are those sustaining a large myocardial 
infarct (usually anterior infarct), in which the infarct size is greater than 40% of the left 
ventricular volume. Presumably, in this group of patients the contribution of lethal 
reperfusion injury is significant, and so administering an adjunct to myocardial reperfusion is 
beneficial. Therefore in our Epo study we may have seen more benefit if we had restricted 
further the study cohort, perhaps to those patients presenting greater than 3 hours but less 
than approximately 9 hours in to their infarction. This of course further limits the 
applicability of the intervention. 
If the cardioprotective strategy needs to be administered prior to or at the immediate 
onset of myocardial reperfusion, there is little rationale for recruiting patients which do not 
have a fully occluded coronary artery (TIMI <1) at presentation, although it is appreciated 
that the infarct-related coronary artery may spontaneously occlude or open prior to PPCI, and 
this can be monitored by continuous in-ambulance ECG monitoring. Other determinants of 
myocardial infarct size which need to be excluded include the area at risk (which can be 
estimated using coronary angiography, nuclear myocardial scanning or more recently cardiac 
MRI), the presence of significant collateralisation to the area at risk (which can be excluded 
by Rentrop grading at time of coronary angiography), and the presence of chest pain within 3 
days (which may inadvertently precondition the patient prior to their MI).  
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The end-points of cardioprotection have to be carefully chosen in these clinical 
cardioprotection studies, and for proof-of-concept studies these have often been restricted to 
the measurement of cardiac enzymes. However, more robust endpoints of clinical 
cardioprotection are required as surrogate markers of clinical outcome, given the large 
numbers of patients which are required for the definitive mortality studies. In this respect, 
cardiac MRI is emerging as a powerful imaging strategy capable of quantifying left 
ventricular dimensions and function, myocardial infarct size, the area at risk, microvascular 
obstruction, myocardial haemorrhage, indices which have been linked to clinical outcomes 
following an AMI
374
. The improved spatial resolution of MRI over and above nuclear 
imaging enables greater reproducibility and allows smaller sample sizes in clinical trials to be 
used, and a number of different measures of cardioprotection can be made within one 
imaging modality, increasingly making it the modality of choice in assessing surrogate 
outcomes of cardioprotection. Without cardiac MRI it is unlikely that in our Epo study we 
would have been able to document the increased incidence of microvascular obstruction, 
other techniques are not particularly sensitive in this regard. 
Cardioprotection not lost in translation 
 
There have been a couple of recent examples in which the transition from ‗bench to bedside‘ 
has been successful. Interrupting myocardial reperfusion with several short-lived episodes (5 
to 60 seconds) of myocardial ischaemia and reperfusion has been demonstrated in a variety of 
animal infarct models to reduce myocardial infarct size by 40-50%- a phenomenon termed 
ischaemic postconditioning
29 375 376
. In the clinical setting this has been achieved by 3-6 
cycles of inflation and deflation of a coronary angioplasty balloon following deployment of 
the stent within the infarct-related coronary artery, a protocol which has been reported to 
reduce myocardial infarct size at 6 months and preserve LV ejection fraction at one year
33
. 
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Similarly, pre-clinical animal infarct data has established that pharmacologically inhibiting 
the mitochondrial permeability transition pore (mPTP), a non-selective channel of the inner 
mitochondrial membrane which mediates cell death by opening at the onset of myocardial 
reperfusion, reduces myocardial infarct size by 30-40%
377 378
 and preserves LV ejection 
fraction, and improves survival
379
. A recent proof-of-concept clinical study has demonstrated 
that as an adjunct to PPCI, cyclosporine-A is capable of reducing myocardial infarct size in 
STEMI patients
380
. Clearly, for both these treatment interventions, large multicentre studies 
are required to determine their effect on clinical outcomes. One could hypothesise that 
physical methods of preconditioning are able to act on several end-effectors of 
preconditioning and as such have a ‗stronger‘ protective stimulus; as opposed to 
pharmacological agents such as atorvastatin and erythropoietin which would appear to target 
a limited range of cellular protective pathways which perhaps have a limited effect when put 
in the complex clinical context. 
The effect of acute high dose atorvastatin on myocardial injury during coronary artery 
bypass graft surgery 
The above study described in Chapter 3 of this thesis unfortunately failed to translate the 
expected benefit seen in pre-clinical animal and human tissue experiments in to the human 
clinical setting. As discussed in chapter 3 there are a number of possible reasons as to why 
the study results did not show cardioprotection however the basis for the study was sound 
given the animal evidence available. However there are perhaps one or two key areas that 
bear highlighting. The first is that the basis for the study was the ability to ‗recapture‘ the 
waning cardioprotective effect of ‗statins‘ based on Mensah‘s report78. The ability to add an 
acute ‗statin‘ dose and recapture cardioprotection has not been validated in other animal 
studies. However the waning of cardioprotection with chronic statin use has been replicated
87
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and then in the human setting of percutaneous coronary intervention an acute dose of 
atorvastatin demonstrated benefit
123
, although the benefit was largely driven by patients who 
had recently experienced an acute coronary syndrome. So it would seem that the principles of 
the study hold out- the cardioprotection of ‗statins‘ wanes, and the ability to ‗recapture‘ the 
cardioprotection is possible- but unfortunately there is a lack of a directly comparable animal 
study. If it were undertaken this study it would ideally use a model of bypass surgery in an 
elderly large mammal with a metabolic syndrome phenotype and clearly this would provide 
significant insights. However as discussed above the expertise and costs involved in complex 
large animal models often make them prohibitive.  
The second issue to highlight is that the ARMYDA Recapture study
123
 which demonstrated a 
benefit from acute statin use on a background of chronic use in PCI did so largely in those 
patients who had recently presented with an acute coronary syndrome. Clearly there are likely 
to be significant differences in elective versus urgent/emergency patients in inflammatory 
state, atherosclerotic plaque stability, platelet reactivity etc and so the elective group will be 
less likely to sustain myocardial injury making demonstrating protection difficult. The study 
reported in chapter 3 recruited only elective patients in order to maintain homogeneity and to 
prevent the wide differences in ACS presentation making interpretation of data difficult. This 
may well have been a significant limitation of the study and in-retrospect recruiting all 
patients, elective and urgent, but then adjusting for confounding factors may well have 
provided a wider view of the effects of acute atorvastatin.  
The third factor is the remaining uncertainty of the whole mechanism of ischaemic 
preconditioning and pharmacological mimetics of this. Although thought to be fairly well 
elucidated (discussed in chapter 1) the cell survival pathways attributed to IPC are multitude 
and it is not clear which may play a dominant role in which setting. The RISK pathway, 
thought to be central to the protective effect of ‗statins‘ has a great deal of supporting 
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evidence and yet this is not always consistent
381 382
 and so questions still exist as to the exact 
mechanism. There have been an increasing number of small clinical trials that have 
demonstrated the cardioprotective benefit of physical interventions such as remote ischaemic 
preconditioning
322 329
 
383 384
 and post-conditioning
30 33
. It is possible that at present 
pharmacological agents (possibly cyclosporine excepted
380
) are not able to activate the 
breadth of survival pathways, that perhaps a more intense physical stimuli is able to do, in 
order to demonstrate significant protection.  
 
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention 
 
The above study (chapter 4) also failed to demonstrate cardioprotective benefit and 
surprisingly erythropoietin in the setting of acute STEMI was associated with detrimental 
effects, an increase in the incidence of MVO and acute LV dilatation in the treated group. 
Once again there is a wealth of animal data supporting beneficial effects of Epo in the setting 
of reperfusion injury (see chapters 1 and 3) and there are pilot studies in brain
240
 and cardiac 
injury
243
 which have demonstrated safety and suggested the potential for benefit however, 
once again, a pharmacological preconditioning mimetic has failed to translate to the human 
clinical setting. Importantly a number of other recently published studies also appear to be 
demonstrating similar results, with a large study in stroke showing a worse outcome in the 
Epo treated group
350
, and in a recently reported study in acute STEMI (REVIVAL-3
354
). Of 
note it may be significant that the large mammal experiments performed with Epo failed to 
show any significant myocardial infarct size reduction
213 214
. It remains possible that any 
beneficial effect of Epo is small in the majority of cases where reperfusion alone provides 
maximal benefit. As discussed above, treating those patients with large AAR, beyond 3 hours 
but within 6-9 hours of symptom onset may demonstrate that further protection is possible. 
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However if adverse effects of Epo use in this setting remain a concern then any benefit may 
be outweighed by the detrimental effects and ethically further study would be difficult until 
the details were clearer. 
Furthermore there has been a recent paper challenging the pleiotropic abilities of Epo and the 
presence of biologically active Epo R in tissues not involved in erythropoeisis
385
 however this 
paper has been criticised by a large body of researchers for overstating its conclusions
386
 and 
not providing enough evidence for which to discount the work of a large body of other 
investigators. Thus, the debate as to the exact abilities of Epo continues.  
Conclusion 
 
Both atorvastatin and erythropoietin have shown significant potential for cardioprotection in 
the pre-clinical setting and it was hoped that considerable benefit from their acute use in 
preventing reperfusion injury would be realised. This thesis has examined both these agents 
in two different clinical settings of ischaemia-reperfusion injury and as has been discussed 
neither was demonstrated to show cardioprotection. This is unfortunately characteristic of this 
field of research, where huge strides have been made in clarifying mechanistic pathways but 
no real translation has occurred to routine clinical use. Therefore in order to advance the 
research field of cardioprotection and harness the huge potential of ischaemic conditioning, 
cardiovascular scientists and cardiologists will have to work side by side to ensure (1) the 
design of suitable pre-clinical animal disease models more accurately reflect the clinical 
setting under scrutiny and (2) that the design of clinical cardioprotection trials take into 
account the major findings of the laboratory studies. Through this integrated and co-ordinated 
approach, the carefully selected cardioprotective interventions should be investigated in the 
clinical arena using rigorously designed proof-of-concept clinical studies followed by larger 
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studies using surrogate markers of clinical endpoints (such as cardiac MRI) before multi-
centre clinical evaluation of clinical outcomes.   
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APPENDIX 1 
Research in the setting of acute myocardial infarction 
 
The ongoing mortality and morbidity arising from acute MI necessitates the innovation and 
testing of new techniques, devices or pharmacological agents which will improve the current 
standard of care. Although animal and human tissue experiments in the laboratory are able to 
provide detailed mechanistic insight and suggest that a new innovation will be beneficial 
there will always come a time where experiments in humans must be conducted. The ethical 
conduct of research is not always straightforward and throughout history the trial subject has 
not always been safeguarded. Currently standards of trial conduct are carefully regulated to 
ensure that the participants are protected as much as possible. The setting of acute myocardial 
infarction is however an interesting and sometimes difficult area in which to conduct research 
because time to treatment is of the essence. In the following section the difficulties involved 
in gaining informed patient consent and methods of how trials may be conducted in this 
setting are briefly discussed.  
Conduct of research 
 
Physicians have always been pioneers and have led attempts to improve the possibility of a 
cure for their patient. However, not all physicians have been altruistic in their ambitions and 
sometimes (whether deliberately or not) the interests of the individual have been overridden 
in the quest for greater knowledge
387
. Following research atrocities which occurred during the 
second world war, the Nuremberg code was drawn up to guide human research and attempt to 
prevent similar events, although was never enshrined as law in most countries. The 
Declaration of Helsinki was drawn up and accepted in 1964 by the World Medical 
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Association
388
, and exists today in updated form
389
, as a guide to the ethical conduct of 
human research trials in the modern environment. In the United Kingdom the conduct of 
research is very tightly regulated in legislative law and overseen by the National Research 
Ethics Service (NRES) and the Medicines and Healthcare products Regulatory Agency 
(MHRA). Depending on the type of investigation, whether a clinical trial of investigational 
medicinal product (CTIMP) or not (non-CTIMP) decides as to whether the study is regulated 
by the MHRA or NRES respectively. The studies conducted within this thesis were deemed 
of a mechanistic nature by the MHRA and therefore did not need their approval and oversight 
was provided by the local research and development (R&D) department and local ethics 
committee. 
Consent 
 
One of the basic principles protecting participants in research is the need to gain informed 
consent (usually written) prior to their inclusion in the study. In a planned situation such as 
elective CABG surgery (see chapter 3) this is relatively straightforward and enables the 
patient to fully consider whether or not they wish to take part. In the setting of acute 
myocardial infarction the situation is more difficult. The time to reperfusion therapy is crucial 
and research studies cannot be allowed to delay treatments that are known to be beneficial. 
Often the patient is alert and able to comprehend their situation and take in information given 
to them, however the spectrum is wide and many patients may be in too much discomfort, 
have received opiate medication or may even have suffered cardiac arrest rendering them 
lacking the capacity to make an informed decision about their immediate treatment let alone 
taking part in research. The study detailed in this thesis investigating the cardioprotective 
benefits of Epo in STEMI (chapter 4) was conducted along the traditional lines of gaining 
written consent during the acute situation for the patients‘ inclusion in the study. This method 
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was relatively successful however it is debatable exactly how much information each patient 
was able to retain in the acute situation and the investigators took great care to fully explain 
and in effect re-consent the patient after they had been stabilised. Along similar lines 
treatment by PPCI for STEMI currently requires written consent but again this would appear 
to be very difficult to achieve properly in the acute situation and it has been suggested that in 
fact verbal consent, adjusted to the situation would be less stressful for the patient and would 
expedite treatment at this critical time
390
. It is worth remembering that it is the consent 
process which is important and not just the patients‘ signature on a form.  
Patients who lack capacity 
 
Patients suffering from a STEMI may temporarily lack capacity to make informed decisions 
regarding their treatment or their participation in clinical research. Recent legislation for non-
CTIMPs has helped researchers clarify this difficult area. The Mental Capacity Act 2005
391
 
has acknowledged that research may sometimes need to be conducted in patients lacking 
capacity and as such, subject to safeguards, has made provision for this. Sections 30 to 34 of 
the Mental Capacity Act 2005 deal very well with issues of diminished capacity and 
enrolment in to clinical studies. Far from being too restrictive to those wishing to study 
groups of patients with diminished capacity the Act is supportive as long as the patient group 
being studied must necessarily be recruited at a time when capacity is diminished and time is 
of the essence e.g. studies in acute myocardial infarction. Section 31, paragraph 5a, highlights 
that the research study must have, ‗...the potential to benefit the patient (P) without imposing 
on P a burden that is disproportionate to the potential benefit to P...‘ 
For researchers it is important to note that the act does not apply necessarily to trials which 
fall under the Medicines for Human Use Regulations 2004, as separate legislation and 
guidance exists. 
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Researchers must work closely with their local ethics committee to ensure that the consent 
process is appropriate to the situation and that the stipulations of the Act are followed but it is 
also important to realise that research in patient groups with diminished capacity is essential 
in some circumstances and that the Act clearly allows for this
392
.  
In the setting of acute MI following careful ethical committee approval it may be possible to 
include patients in research studies by adjusting the consent process to their capacity at the 
time and then allowing further informed consent at a later time point. This would have the 
additional benefit of not selecting out from studies the most ill patients who are unable to 
consent but who may have much to gain from further innovation
393
. 
This is the approach that was formulated and agreed with the local ethics committee for the 
running of the PREP-MI study (Pre-hospital REmote Ischaemic Postconditioning in Myocardial 
Infarction) which I have subsequently commenced and although the study is in the early stages 
this method of consent appears successful. 
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APPENDIX 2 
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a 
randomised controlled clinical trial. 
 
In order to further examine the effect of erythropoietin in STEMI a further exploratory post-
hoc analysis of group characteristics and outcomes has been performed by culprit vessel. As a 
sub-group analysis patient numbers are small and so the ability to form further conclusions is 
limited. 
 
Table 1: Patient characteristics by culprit artery 
 Epo 
(n=26 ) 
Placebo 
(n=25 ) 
P value 
LAD RCA LCx LAD RCA LCx 
N 10 9 7 13 8 4  
Age, mean yrs (SD)       >0.05 
Men (%) 80 89 100 92 75 75 >0.05 
Hypercholesterolaemia (%) 40 11 29 46 63 50 >0.05 
Diabetes Mellitus (%) 20 11 0 15 0 0 >0.05 
Hypertension (%) 70 11 29 54 50 50 >0.05 
Family History of IHD (%) 0 22 29 15 38 0 >0.05 
Previous MI (%) 10 0 14 0 13 0 >0.05 
Previous Angina (%) 0 11 0 0 13 0 >0.05 
Respiratory Disease (%) 0 22 0 0 13 0 >0.05 
Smoking status (%) 
Never 
Ex 
Current 
 
60 
20 
20 
 
33 
22 
55 
 
29 
14 
57 
 
23 
23 
54 
 
49 
13 
38 
 
50 
0 
50 
>0.05 
Medication at presentation 
(%) 
Aspirin 
Clopidogrel 
ACEI/ARB 
Beta-blocker 
CCB 
Statin 
Nitrate 
Sulphonylurea 
Metformin 
PPI 
 
 
20 
0 
30 
0 
10 
30 
0 
10 
20 
10 
 
 
22 
0 
11 
0 
11 
11 
11 
22 
22 
0 
 
 
14 
0 
0 
14 
14 
14 
0 
0 
0 
0 
 
 
15 
0 
15 
8 
8 
23 
0 
0 
0 
0 
 
 
25 
0 
38 
13 
0 
13 
0 
0 
0 
13 
 
 
25 
0 
25 
0 
0 
50 
0 
0 
0 
0 
>0.05 
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Table 2: Interventional Details 
 EPO 
(n=26) 
Placebo 
(n=25) 
 LAD RCA LCx LAD RCA LCx 
Culprit vessel, N (%) 10 
(38) 
9 
(35) 
7 
(27) 
13 
(52) 
8 
(32) 
4 
(16) 
Symptom to reperfusion 
time, mins (SD) 
229 
(120) 
208 
(96) 
237 
(102) 
260 
(165) 
289 
(175) 
182 
(54) 
Medication peri-PCI (%) 
Asprin 
Clopidogrel 
Heparin 
Opiate 
Nitrate 
Abciximab 
Metoclopramide 
Atropine 
 
100 
100 
100 
50 
40 
90 
20 
0 
 
100 
100 
100 
66 
33 
100 
33 
33 
 
100 
100 
100 
57 
86 
100 
29 
14 
 
100 
100 
100 
69 
77 
92 
54 
8 
 
100 
100 
100 
38 
63 
100 
25 
63 
 
100 
100 
100 
25 
25 
75 
25 
25 
Mean TIMI flow before 
PCI,  (grade) 
0 0 0 0 0 0 
Mean TIMI flow after PCI 
(grade) 
2.92 2.9 3 2.9 3 3 
Predilated (%) 90 100 100 92 88 100 
Direct stent (%) 10 0 0 8 12 0 
Bare Metal Stent (%) 50 100 43 54* 75 75 
Drug Eluting Stent (%) 50 0 57 54* 25 25 
Mean arterial pressure, 
(mmHg) 
Pre-PCI 
Post PCI 
Day2 
Follow up 
 
 
111 
99 
93 
104 
 
 
108  
95 
89 
106 
 
 
113 
98 
99 
97 
 
 
109 
94 
96 
94 
 
 
112 
88 
94 
106 
 
 
115 
111 
97 
133 
Mean length of hospital 
stay, days (SD) 
4.1 
(1.5) 
3 
(0.9) 
3.6 
(1.4) 
3.7 
(2.1) 
4.6 
(1.6) 
5 
(2.1) 
*One patient received both bare metal and drug eluting stents. 
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Table 3: Cardiac enzyme release by culprit vessel 
Troponin T (µg/l ± SD) 
 Vessel 0 hrs 6 hrs 12 hrs 24 hrs AUC 
EPO LAD 0.04 ± 0.06 9.69 ± 6.12 7.30 ± 4.17 4.09 ± 2.82 131±94 
RCA 0.15 ± 0.34 6.14 ± 4.74 5.54 ± 4.14 3.51 ± 2.34 108±80 
LCx 0.35 ± 0.78 5.57 ± 3.16 4.77 ± 2.68 3.67 ± 2.29 99±55 
Placebo LAD 0.17 ± 0.44 8.79 ± 5.19 6.3 ± 5.96 4.44 ± 3.53 110±93 
RCA 0.12 ± 0.19 3.44 ± 1.84 4.27 ± 1.5 2.64 ± 0.96 75±76 
LCx 0.04 ± 0.04 4.67 ± 2.25 6.64 ± 5.94 6.41 ± 7.07 119±84 
P 
Value 
 NS NS NS NS NS 
 
 
Table 4: Imaging DATA by Culprit Artery 
 EPO Placebo P 
LAD RCA LCx LAD RCA LCx 
Patients with acute 
MRI % 
38 23 23 40 32 8 >0.05 
Patients with acute 
and follow up MRI 
% 
27 23 19 32 28 4 >0.05 
Days post MI of 
first MRI, mean 
(SD) 
2.1 1.5 2 2.1 2.1 5.5 >0.05 
Days between MRI 
scans, mean (SD) 
130 
(18) 
133 
(16) 
123 
(5) 
136 
(14) 
130 
(15) 
152  
(-) 
>0.05 
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Table 5: Area At Risk by culprit vessel 
 EPO Placebo P 
LAD RCA LCx LAD RCA LCx 
BARI (%) 33 25 27 39 27 23 NS 
APPROACH (%) 38 24 25 38 25 17 NS 
MRI ESA (%) 31 29 22 32 22 22 NS 
 
Table 6: Acute Scan CMR results by culprit vessel 
 
  
Trial 
intervention Vessel Mean Std. Deviation 
MRI ESA Mass 
(g) 
EPO LAD 49 17 
RCA 43 9 
LCx 39 18 
  Control LAD 48 24 
RCA 29 6 
LCx 30 2 
EDV (ml) EPO LAD 162 24 
RCA 163 19 
LCx 170 18 
  Control LAD 147 23 
RCA 138 30 
LCx 117 48 
ESV (ml) EPO LAD 80 18 
RCA 81 16 
LCx 79 18 
  Control LAD 74 18 
RCA 56 12 
LCx 48 24 
SV (ml) EPO LAD 82 19 
RCA 81 6 
LCx 91 15 
  Control LAD 73 13 
RCA 82 25 
LCx 69 24 
EF (%) EPO LAD 51 8 
RCA 50 7 
LCx 54 9 
  Control LAD 50 8 
RCA 59 8 
LCx 60 4 
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Trial 
intervention Vessel Mean Std. Deviation 
CO (L/min) EPO LAD 6.2 1.4 
RCA 6.1 0.68 
LCx 5.8 1.4 
  Control LAD 5.4 1.3 
RCA 6.0 1.5 
LCx 4.4 1.7 
Myocardial Mass 
(g) 
EPO LAD 157 34 
RCA 149 25 
LCx 167 40 
  Control LAD 146 29 
RCA 139 26 
LCx 136 14 
Infarct Volume 
(ml) 
EPO LAD 33 16 
RCA 31 10 
LCx 29 18 
  Control LAD 29 21 
RCA 20 5 
LCx 16 12 
Infarct Mass (g) EPO LAD 35 17 
RCA 32 11 
LCx 30 19 
  Control LAD 30 22 
RCA 22 6 
LCx 17 12 
Infarct Size (% 
of LV 
myocardium) 
  
EPO 
 
LAD 22 10 
RCA 22 5 
LCx 17 8 
Control LAD 20 12 
RCA 16 5 
LCx 12 8 
MVO (%) EPO LAD 70 - 
RCA 100 - 
LCx 83 - 
  Control LAD 56 - 
RCA 57 - 
LCx 0 - 
LVEDVi (ml/m
2
) EPO LAD 83 12 
RCA 83 9 
LCx 87 8 
  Control LAD 76 11 
RCA 72 15 
LCx 60 19 
LVESVi (ml/m
2
) EPO LAD 42 10 
RCA 41 9 
LCx 41 10 
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Trial 
intervention Vessel Mean Std. Deviation 
  Control LAD 38 10 
RCA 29 6 
LCx 24 10 
LVSVi (ml/m
2
) EPO LAD 42 8 
RCA 42 5 
LCx 46 5 
  Control LAD 38 6 
RCA 43 12 
LCx 36 9 
CI (l/min/m
2
) EPO LAD 3.2 0.5 
RCA 3.1 0.5 
LCx 2.9 0.4 
  Control LAD 2.8 0.6 
RCA 3.1 0.7 
LCx 2.2 0.7 
LVMi (g/m
2
) EPO LAD 80 13 
RCA 76 8 
LCx 85 13 
  Control LAD 75 13 
RCA 72 11 
LCx 71 0.1 
 
LVEDV(i)- Left ventricle end-diastolic volume (indexed). LVESV(i)- Left ventricle end-
systolic volume (indexed). LVSVi- Left ventricle stroke volume (indexed). LVMi- Left 
ventricle mass (indexed). LVEF- left ventricular ejection fraction. CI- cardiac index. MVO- 
microvascular obstruction. LAD- left anterior descending artery, RCA- right coronary artery, 
LCx- left circumflex artery. 
 
Table 7: Follow-up Scan CMR results by culprit vessel 
 
Trial 
intervention Vessel Mean Std. Deviation 
EDV (ml) Control LAD 165 50 
RCA 152 25 
LCx 212 - 
  EPO LAD 165 14 
RCA 180 52 
LCx 162 49 
ESV (ml) Control LAD 72 47 
RCA 59 12 
LCx 144 - 
  EPO LAD 82 13 
RCA 86 44 
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LCx 68 26 
 
Trial 
intervention Vessel Mean Std. Deviation 
SV (ml) Control LAD 93 11 
RCA 93 21 
LCx 69 - 
  EPO LAD 83 12 
RCA 95 15 
LCx 94 28 
EF (%) Control LAD 59 14 
RCA 61 7 
LCx 32 - 
  EPO LAD 50 6 
RCA 55 10 
LCx 58 5 
CO (L/min) Control LAD 5.9 0.7 
RCA 5.8 1.4 
LCx 3.8 - 
  EPO LAD 5.3 0.6 
RCA 6.5 0.7 
LCx 5 1.4 
Myocardial Mass 
(g) 
Control LAD 119 29 
RCA 119 30 
LCx 141 - 
  EPO LAD 134 24 
RCA 150 38 
LCx 131 32 
Infarct Volume 
(ml) 
Control LAD 11.8 10.8 
RCA 10.4 4 
LCx 7 - 
  EPO LAD 19.7 8.1 
RCA 17.2 5.5 
LCx 9.4 6.6 
Infarct Mass (g) Control LAD 12.4 11.3 
RCA 10.9 4.2 
LCx 7.3 - 
  EPO LAD 20.7 8.5 
RCA 18 5.8 
LCx 9.9 7 
Infarct (% of LV 
myocardium) 
Control LAD 10.1 9.2 
RCA 10.2 6.2 
LCx 5.5 - 
  EPO LAD 15.6 6.1 
RCA 12 2 
LCx 6.9 3.5 
MVO Control LAD 0 - 
RCA 0 - 
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LCx 0 - 
 
Trial 
intervention Vessel Mean Std. Deviation 
  EPO LAD 0 - 
RCA 0 - 
LCx 25 - 
LVEDVi (ml/m
2
) Control LAD 82 23 
RCA 80 12 
LCx 110 - 
  EPO LAD 85 8 
RCA 93 30 
LCx 82 14 
LVESVi (ml/m
2
) Control LAD 36 23 
RCA 31 7 
LCx 75 - 
  EPO LAD 42 7 
RCA 44 25 
LCx 34 9 
LVSVi (ml/m
2
) Control LAD 46 4 
RCA 49 10 
LCx 36 - 
  EPO LAD 43 7 
RCA 49 9 
LCx 48 9 
CI (l/min/m
2
) Control LAD 2.9 0.4 
RCA 3.0 0.7 
LCx 2.0 - 
  EPO LAD 2.7 0.2 
RCA 3.4 0.4 
LCx 2.6 0.7 
LVMi (g/m
2
) Control LAD 59 12 
RCA 63 15 
LCx 73 - 
  EPO LAD 69 12 
RCA 78 22 
LCx 67 8 
LVEDV(i)- Left ventricle end-diastolic volume (indexed). LVESV(i)- Left ventricle end-
systolic volume (indexed). LVSVi- Left ventricle stroke volume (indexed). LVMi- Left 
ventricle mass (indexed). LVEF- left ventricular ejection fraction. CI- cardiac index. MVO- 
microvascular obstruction. LAD- left anterior descending artery, RCA- right coronary artery, 
LCx- left circumflex 
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